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Foodborne enteric diseases cause millions of illness and thousands of deaths annually 
in the United States. Major enteric bacterial pathogens include Salmonella, 
enterohemorrhagic Escherichia coli O157:H7 (EHEC), Campylobacter, Listeria, 
Shigella, Vibrio, and Yersinia which account for more than 90% cases of culture-
confirmed infections. Among these causative agents, Salmonella enterica is 
responsible for the highest rate of hospitalization and EHEC has the lowest infectious 
dose. Their pathogenesis involves numerous virulent factors whereas their colonization 
and invasion on host gut intestine mainly depend on the type III secretion system. The 
prevention of foodborne enteric diseases is of great concern to public health 
  
professionals, farmers, and food producers. Due to the increased public health concern 
about antibiotic-resistance dissemination, alternative strategies such as pro-commensal 
approach by applying probiotics, prebiotics, and combination of both (synbiotics) are 
of interests for prevention and therapy of foodborne enteric diseases. In this study, we 
both in vitro and in vivo evaluated the preventive capabilities of Lactobacillus against 
enteric pathogenic bacterial colonization and infection. Functional food cocoa and 
peanut containing prebiotic-like ingredients selectively promoted the growth of 
beneficial bacteria and stimulated the production of bio-active metabolites especially 
conjugated linoleic acids in Lactobacillus. We also detected the synergistic effects of 
Lactobacillus and cocoa/peanut on competitive exclusion of S. Typhimurium and 
EHEC, alteration on physicochemical properties, disruption of host-pathogen 
interactions, and down-regulation on virulence gene expressions. Furthermore, with 
homologous recombination, we overexpressed myosin cross-reactive antigen gene 
encoding linoleate isomerase in L. casei and improved the efficiency in their linoleic 
acids production as well as the gut intestinal adherence and colonization. By applying 
genetically engineered LC-CLA, S. Typhimurium and EHEC were much effectively 
controlled and restricted from all aspects in vitro mentioned before. Additionally, the 
in vivo pre-administration of LC-CLA reduced S. Typhimurium gut intestinal 
colonization/infection in a significant level and induced anti-inflammatory effects, 
which benefitted the overall mice gut health. Our findings established a baseline upon 
which self-promoting probiotic independent from prebiotic in prevention or treatment 
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Chapter 1: Literature review 
 
Foodborne enteric bacterial pathogens and diseases 
Foodborne enteric diseases are estimated to be responsible for 47.8 million 
people cases of illness, 127,839 hospitalizations, 3,037 deaths, and $77.7 billion 
economic burden each year (Hoffmann, Batz, & Morris, 2012) in the United States 
(US). Prevention of foodborne diseases is of great concern to public health 
professionals, farmers, as well as food producers. However, to further deteriorate the 
current situation, the commonly used antibiotics for control and treatment of zoonotic 
bacterial pathogen infections have been recorded to worsen the niche of beneficial gut 
microflora (Andersson & Hughes, 2010), and the efficacy of these antibiotics is 
compromised since numerous bacterial pathogens are evolving into multi-drug-
resistant strains (DeWaal, Roberts, & Plunkett, 2013). 
Major foodborne bacterial pathogens in the US include Salmonella, 
enterohemorrhagic Escherichia coli O157:H7 (EHEC), Campylobacter, Listeria 
monocytogenes, Shigella, Vibrio, and Yersinia (D. Adams et al., 2015, 2017; D. A. 
Adams et al., 2016). Common diseases caused by these foodborne bacterial pathogens 
are summarized in Table 1-1. Most of the foodborne pathogens inhabit at gastro-





and processing environment, which allows them contaminate meat and milk products 
during slaughter and milking or contaminate produce vegetables if the soil was 
fertilized with improperly composted animal manure (McEwen and Fedorka-Cray, 
2002). From both the pre-harvest (farm level) food safety and transmission through 
food products in the US, Salmonella especially Salmonella enterica serovars 
Typhimurium and Enteritidis, EHEC, Campylobacter jejuni, and L. monocytogenes are 
the most important foodborne pathogens with severe public health concerns (Bryan, 
2002; Oliver, Patel, Callaway, & Torrence, 2009; Mengfei Peng et al., 2016; S. 
Salaheen, Peng, & Biswas, 2016). Farm animals including chickens, turkeys, swine, 
cattle, and sheep as well as wild birds around farm environments are the principle 
reservoirs and sources of these foodborne bacterial pathogens (Oliver et al., 2009). 
Further specifically, EHEC usually shed and harbor in dairy and beef cattle (Meng, 
LeJeune, Zhao, & Doyle, 2013) which animals can remain asymptomatically due to the 
lack of vascular expression of Gb3 (Pruimboom-Brees et al., 2000). S. Typhimurium, 
C. jejuni, and L. monocytogenes, are normally carried by poultry and swine as well as 








Salmonella (Gram-negative) is a genus of rod-shaped bacteria belongs to 
Enterobacteriaceae family which is responsible for nearly half of all foodborne 
infections annually in the US (K. J. Cummings et al., 2012). Salmonella has two species 
- Salmonella bongori and Salmonella enterica, but over 2500 serovars have been 
isolated worldwide, in which S. Typhimurium and S. Enteritidis are the most frequently 
isolated strains associated with human diseases. According to the report from Scallan 
et al. (2011), Salmonella enterica alone is responsible for approximate 1.2 million 
illnesses, 20 thousand hospitalizations, and 400 deaths each year in the US. Moreover, 
it was estimated that annual Salmonella infections cause $4.4 billion economic lose 
including medical costs and productivity lost (Scharff, 2012). Factors including 
virulence plasmids, flagella, fimbriae, endotoxins (lipopolysaccharide), and exotoxins 
all contribute to Salmonella infections (Van Asten & Van Dijk, 2005) which induce 
salmonellosis with manifestations including diarrhea, abdominal cramps, vomiting, 
dehydration, fever, anorexia, and malaise after 12 to 72 hours of infection, while its 
invasive infections might induce meningitis, osteitis, osteomyelitis, hypovolemic shock, 
septic shock, and even death for infants, elderly, and immunocompromised individuals 
(Arshad et al., 2008; T. F. Jones et al., 2008). Post-infectious irritable bowel syndrome 





constipation and diarrhea alteration and accompanied by abdominal pain (Mearin et al., 
2005). IBS could further induce chronic mucosal immunological dysregulation 
accompanied with intestinal permeability and motility alterations leading to persistent 
intestinal symptoms (DuPont, 2008). Reiter’s syndrome is another post-infection 
sequelae of Salmonella, in which, a certain percentage of infected individuals could 
develop reactive and even chronic arthritis as a result of attacking on cartilaginous 
tissues in the joints by immune system in response to Salmonella bacteria in short or 
long term period (Townes, 2010). 
 
Enterohemorrhagic Escherichia coli O157:H7 
EHEC (Gram-negative) is an emerging foodborne pathogen associated with 
severe form of human diseases including enterohemorrhagic diarrhea and hemolytic 
uremic syndrome (HUS) (Nguyen & Sperandio, 2012). According to Teunis et al. 
(2008), EHEC has an extremely low infectious dose of fewer than 100 colony forming 
units (CFUs), some cases ingesting as few as 10 of this pathogen could cause individual 
illness. As a result of infection by a prophage containing the structural coding for shiga 
toxin, the non-producing strain evolved and obtained the ability to express shiga-like 
toxins which induce antibiotic treatment in EHEC-induced diarrheal illness has been 





membrane injury which favors the acute release of shiga-like toxins (Safdar, Said, 
Gangnon, & Maki, 2002). Other factors such as acid resistance gene systems, 
lipopolysaccharides, enterotoxins, fimbriae, and flagella also play important roles in 
EHEC infection (Nguyen & Sperandio, 2012). Except for symptoms such as abdominal 
pain, diarrhea, vomiting, and fever, in some cases particularly young children and 
elderly, EHEC infection can lead to life-threatening HUS. Characterized by acute 
kidney failure, hemolytic anemia, and thrombocytopenia, HUS was estimated to have 
a fatality rate ranging from 3 to 5%, and neurological complications like seizure, stroke, 
and coma caused by HUS can also happen in 25% of the HUS patients (Nguyen & 
Sperandio, 2012). Even though recovering from HUS, long-term renal complications 
including hypertension, renal insufficiency, and end-stage renal failure can occur in 
approximately 50% of the previous patients (Oliver et al., 2009). Furthermore, EHEC 
is also the predominant causative agent for ulcerative colitis (UC), which is the chronic 
inflammation in human large intestine (Jess et al., 2011; Ternhag, Törner, Svensson, 
Ekdahl, & Giesecke, 2008). UC is characterized by severe abdominal cramps, bloody 
diarrhea, immune abnormality, and intestinal barrier functional defection (Sasaki & 
Klapproth, 2012), and is also considered as the pre-condition of colorectal cancer 






Major virulence factors and pathogenesis of foodborne pathogen infections 
Foodborne bacterial pathogens once ingested with food or water manages to 
survive and pass through the acidic stomach environment and move to intestine. They 
usually colonize the gut intestine especially large intestine and cross the mucosal 
barrier through active invasion process or translocation with phagocytic M cells (A. J. 
Müller et al., 2012). Eventually, some of them randomly taken up by different 
phagocytes (macrophages, dendritic cells, and poly-morphonuclear cells) could 
disseminate to extra-intestinal sites such as lymph nodes, liver, kidney, spleen, and 
brain, causing inflammation and local tissue damage (Bhunia, 2008). The host cell 
invasion pathway for invasive bacterial pathogen acts as the essential role in foodborne 
infections and the design of therapeutic agents for preventing/blocking invasion ability 
is one of major considerations. Type III secretion system (T3SS) is the most common 
system play important role in several invasive bacterial pathogens especially 
Salmonella and EHEC for bacterial invasion of host cells. 
Pathogenicity islands, conferring a virulence phenotype, are genetic elements 
within the core bacterial genome (Shames, Auweter, & Finlay, 2009) involve in 
invasiveness. The Salmonella pathogenicity islands 1 carries critical genes required for 
the biosynthesis of functional T3SS apparatus, including multiple regulatory proteins, 





lumen of small intestine and sensing the gut environment, T3SS-1 (encoded by SPI-1) 
genes could be expressed and subsequent secretion apparatus could be assembled on 
the surface of bacterial membrane (Lara-Tejero & Galán, 2009). The host cell invasion 
is initiated by pathogen binding which activates the assembly and insertion of 
translocons (molecular syringe) into the host cell membrane through its affinity for 
cholesterol (Hayward et al., 2005). The needle complex is regulated by more than 20 
virulence genes including prgI (needle), invG (outer rings), prgK (neck), prgH (inner 
rings), and invA/invC/spaP/spaQ/spaR/spaS (inner membrane components). The 
molecular syringe complex is precisely coordinated to ensure the secretion is in a 
coherent order with translocases (SipB and SipD) secreted earlier to assist in 
translocation of other effector proteins (Lara-Tejero, Kato, Wagner, Liu, & Galán, 
2011). At least 15 effector proteins were found in Salmonella to be translocated into 
host cells by T3SS-1 and result in followed bacterial entry (McGhie, Brawn, Hume, 
Humphreys, & Koronakis, 2009). Among these effector proteins, 5 major effectors 
(SopB, SopE, SopE2, SipA, and SipC) in Salmonella, each with the capability in 
manipulation of the cytoskeletal machinery within the host cells, are known to drive 
bacterial engulfment. SopB (inositol phosphatase), SopE (guanine exchange factors), 
and SopE2 (guanine exchange factors) target the RhoGTPase and activate Rho family 





Arp2/3 complexes whose function is triggering the actin remodeling/polymerization (J. 
C. Patel & Galán, 2006; Zhou, Chen, Hernandez, Shears, & Galán, 2001). SipA and 
SipC engage in actin and control/localize actin polymerization at the bacterial 
attachment site. SipC with distinct N- and C- domains is able to nucleate F-actin and 
promote its bundling (Myeni & Zhou, 2010). SipA on the other hand, could induce 
invasion-competent ruffles either indirectly by stimulating SipC activities or directly 
by antagonizing depolymerizing factors and stabilizing F-actin (McGhie, Hayward, & 
Koronakis, 2004; Zhou, Mooseker, & Galán, 1999). It is noteworthy that these effectors 
mentioned above functioning in T3SS-1-dependent Salmonella entry also have 
profound effects on later infection processes, which include membrane trafficking, 
disruption of tight junctions and intestinal barrier integrity, host cell apoptosis, antigen 
presentation cytokine, and chemokine production (Boyle, Brown, & Finlay, 2006; 
Santos et al., 2009). After bacterial entry, effector protein SopB also plays a role in 
Salmonella-containing vacuole biogenesis and packaging, which prevents Salmonella 
from directly fusing with lysosomes (Dove et al., 2002; Knodler, Winfree, Drecktrah, 
Ireland, & Steele-Mortimer, 2009; J. C. Patel, Hueffer, Lam, & Galán, 2009). As the 
infection progresses, Salmonella also takes use of T3SS-2 encoded by the SPI-2 in 





through the Salmonella-containing vacuole membrane to ensure intracellular bacterial 
survival and replication (Figueira & Holden, 2012; Malik-Kale et al., 2011). 
T3SS also assist EHEC in forming attaching and effacing (A/E) lesions on the 
mucosal epithelium once passing through the acidic barrier and allows its colonization 
on gut intestine. The virulence genes required for T3SS, regulators, chaperones, and 
effector proteins related to A/E lesions formation are encoded within the chromosomal 
pathogenicity island known as the locus for enterocyte effacement (LEE) (Elliott et al., 
1998). The LEE-encoded regulator protein (Ler) acts as the master transcription factor 
of the entire pathogenicity island and regulates the expression of the LEE (D. Müller 
et al., 2009). Following the initial attachment of EHEC to intestinal cell, several LEE 
encoded proteins including EspA, EspB, and EspD are secreted into the host cells by 
T3SS. EspA forms filamentous appendages between EHEC and host cell which acts as 
the translocation machinery. EspB and EspD once translocated into host cell rapidly 
alter the host cell’s signal transduction pathways (Nguyen & Sperandio, 2012). In order 
to move on to the next stage of attachment and effacement, intimate attachment 
between EHEC and host cell is required. To accomplish the intimate attachment, EHEC 
manage to translocate its own receptor protein translocated intimin receptor (Tir), 
encoded by tir gene, to the host cell and express on the host cell membrane. While 





membrane protein for tightly binding with the expressed Tir on host cell surface (Deibel, 
Krämer, Chakraborty, & Ebel, 1998). Following this tight binding, E. coli secreted 
protein F-like protein from prophage U, a non-LEE coded effector protein, is secreted 
and cooperates with Tir in recruiting actin nucleation/cytoskeleton reorganization-
promoting factors and regulators, and eventually forms actin pedestals in host cell 
beneath the attached EHEC for disruption the overall mucosal barrier and intestinal cell 
functions (Campellone, Robbins, & Leong, 2004; Weiss et al., 2009). 
 
Antibiotic treatment and the development of antibiotic resistance in bacterial pathogens 
Since the mid-twentieth century when broad-spectrum antibiotics were first 
introduced in treatment of human bacterial and fungal diseases, they have reduced the 
morbidity and mortality in human by a dramatic level (M Peng, Salaheen, Biswas, & 
Park, 2014; Serajus Salaheen, Peng, & Biswas, 2015). The application of antibiotics 
have been considered as the most vitally important medical event in human history, 
and the use of them was boosted worldwide for both human medication and agricultural 
farm animal production (Andersson & Hughes, 2010; Wise, 2002). Broad-spectrum 
antibiotics are also used to control GI pathogens specifically foodborne pathogens in 
severe situations. For example, erythromycin and ciprofloxacin are used for 





by Clostridium difficile, ciprofloxacin and co-trimoxazole are used for enterocolitis 
caused by Salmonella (Lund & O’Brien, 2011; Traa, Fischer Walker, Munos, & Black, 
2010). However, antibiotic treatment and therapy could disrupt the intestinal microbial 
ecosystem resulting in colonic microbiota imbalance and cause antibiotic-associated 
diarrhea (AAD), which is usually induced by opportunistic pathogenic microorganisms 
especially C. difficile. In addition, early aged antibiotic treatments could also induce 
permanent disruption on gut microbiome development and functions in infants and 
young children and even cause disorders in adipose and hepatic cell metabolism which 
ultimately develops into type-2 diabetes and obesity (Esteve, Ricart, & Fernández-Real, 
2011; Kootte et al., 2012). 
 Furthermore, the intensive and improper use of antibiotics in both human 
medicine and agriculture has induced the widespread dissemination of antibiotic-
resistance genes and altered the resistant frequency among human bacterial and fungal 
pathogens (Salyers & Shoemaker, 2006). Bacteria developed numerous complex 
mechanisms to resist antibiotics such as by reducing antibiotic uptake into bacterial 
cells, eliminating target receptors binding with antibiotics, enzymatic cleavage or 
modification of antibiotic molecule, overproduction of antibiotic targets, etc. (Todar, 
2008), and these resistance could spread from animal to human through either direct 





out that the antibiotic-resistant human pathogens evolved to be more virulent and 
aggressive in respect to disease occurrence (Guay, 2008; Lew, Pai, Oxlade, Martin, & 
Menzies, 2008; Woodford & Livermore, 2009), which complicate the original 
situations by raising fatality as well as economic burden on health care (Depuydt et al., 
2008; Roberts et al., 2009; Sipahi, 2008). According to Saga and Yamaguchi (2009), 
Penicillin resistance in several strains of staphylococcus was recognized immediately 
after the introduction of the drug in the late 1940s. Likewise, the resistance to 
chloramphenicol, streptomycin, and tetracycline was also noted soon. Then the strain 
of Shigella dysenteriae also exhibited resistance to chloramphenicol, streptomycin, 
tetracycline, and sulfonamides. Over the years, the use of all antibiotics selected 
bacterial resistance, and almost every known bacterial pathogens have developed at 
least single or multi-resistance to antibiotics for clinical use (Todar, 2008). Some drug-
resistant foodborne bacterial pathogens include EHEC, S. aureus, Salmonella enterica, 
Campylobacter, L. monocytogenes, Streptococcus pneumonia, Vibrio, Shigella etc. 
Nowadays, more than 70% of the infections-causing bacterial pathogens in hospitals 
are single or multi drug-resistance and some bacteria are even resistant to all approved 






Alternative strategies in prevention and therapy of foodborne illness 
Because of the increased concern about antibiotic resistance, several non-
antibiotic antimicrobials have been developed and introduced to prevent and inhibit 
foodborne bacterial pathogens. The major potential agents include plant- or animal-
derived products, bacteriophages, and vaccines (M Peng et al., 2014). 
 Various products with plant origin can be served as antimicrobial agents and 
the antimicrobial properties of different plant products like spices/herbs and 
vegetable/fruit extracts are well documented. For example, a significant number of 
scientific research have been conducted on the antimicrobial properties of different 
spices and herbs like mustard, garlic, cinnamon, cumin, bay, clove, thyme, pepper, 
rosemary, basil, and turmeric (Lai & Roy, 2004; Skrinjar & Nemet, 2009; Vallverdú-
Queralt et al., 2014; Yanishlieva, Marinova, & Pokorný, 2006). These spices, herbs, 
and their extracted products have been recommended to be used in food to reduce 
microbial contamination and increase overall shelf life of food products at a more 
natural and healthy way (Skrinjar & Nemet, 2009). Antimicrobials from spices and 
herbs are collected at different ways, from volatile or oily liquids, seeds, leaves, barks, 
and sometimes roots of plants (Tajkarimi, Ibrahim, & Cliver, 2010). It has been 
concluded that the presence of alkaloids, glycosides, steroids, phenols, coumarins, and 





oils, are the main factors responsible for their antimicrobial properties (Ebana, 
Madunagu, Ekpe, & Otung, 1991). Additionally, different fruits and vegetables such as 
pomegranate, raspberry, cranberry, grapes, olive (Olea europaea), and their extracts 
are rich in bio-active compounds, which have antimicrobial activity. These compounds 
are broadly grouped into phenolic compounds, essential oils, terpenoids, alkaloids, 
polypeptides, lectins, etc. Different compounds have different roles and different 
modes of action on pathogenic and spoiling microorganisms (Serajus Salaheen et al., 
2015). 
 Multiple animal-derived products have also been documented as being effective 
in foodborne-pathogen inhibition. Chitosan, isolated from the exoskeletons of 
crustaceans and arthropods (insects, spiders, millipedes, and centipedes), has been 
shown to inhibit the growth and reduce trans-shell penetration of mold and several 
foodborne pathogens including S. Enteritidis, E. coli, and L. monocytogenes (Leleu et 
al., 2011). A heat-stable and salt-tolerant peptide, pleurocidin, could be isolated from 
myeloid cells and mucosal tissue of both vertebrates and invertebrates, whose 
inhibitory effect against different foodborne pathogens such as L. monocytogenes and 
EHEC has already been documented (H. J. Jung et al., 2007). Other products such as 
defensin, lactoferrin, lactoperoxidase, lysozyme, and ovotransferrin have all shown 





foodborne pathogens, but their application in pre-harvest control of foodborne 
pathogens in farm animals needs to be studied further. 
 Bacteriophages can be active against specific bacterial strains because of their 
high specificity in recognizing and injecting ‘disrupting DNA’ into a host bacterium. 
Specificity allows bacteriophages to be used against targeted foodborne pathogens in a 
mixed population without disturbing the composition of normal gut microflora. Owing 
to their rapid replication and high level of specificity, bacteriophages can serve as a 
potential treatment against foodborne pathogens. However, the efficacy of 
bacteriophages against infecting bacteria needs to be tested in the lab before application. 
The specificity of bacteriophages is also a disadvantage when a need to target multiple 
pathogens or causative agents of disease is not confirmed (Inal, 2003). In addition, 
compared to antibiotics, bacteriophages are more complex organisms that are able to 
transfer genes between bacteria and induce pathogenic mutation. Only by careful 
selection of strictly lytic bacteriophages and sequencing their hereditary materials can 
cross-gene transfer be prevented (Inal, 2003). 
 Vaccination is the method of inhibiting pathogens by inducing the defense 
mechanisms of host’s immune systems. Some live-attenuated specific vaccination has 
already shown great efficacy in reducing the levels of foodborne pathogens in mice. 





organizations for the purpose of developing vaccines against the most well-known 
foodborne bacteria Shigella and EHEC. However, vaccines made from any one bacteria 
serovar cannot confer cross-protection against another serovar, no matter how much 
antigenic similarity there is between them, whereas more than 2500 serovars of 
Salmonella and various Campylobacter species are found in animals and humans 
(Singh, 2009). As a consequence, the super-high specificity as well as additional costs 
prevents vaccination from being commonly used in prevention and control of 
foodborne illness. 
 Competitive exclusion is a strategy with the presentation of non-pathogenic 
single or mixed bacterial cultures for colonizing the GI tract and providing pathogen-
exclusion effects (Steer, Carpenter, Tuohy, & Gibson, 2000). Depending on the 
purpose and diseases, competitive exclusion can be the exclusion of pathogens from 
the native gut intestine or the displacement of invading pathogenic populations 
(Kamada, Chen, Inohara, & Núñez, 2013; Woo & Ahn, 2013). Several potential 
proposed modes of action for competitive exclusion in eliminating pathogenic bacteria 
include direct and indirect competition for limiting nutrients, competition for 
attachment sites on the host intestinal cells, and the production of antimicrobial 
compounds such as bacteriocins and other antimicrobial polypeptides (Kamada et al., 





‘procommensal strategies’ by establishing non-pathogenic native or introduced 
microbial intestinal ecosystem to reduce and exclude foodborne bacterial pathogens. 
Procommensal strategies at one hand promote the growth of target groups of beneficial 
bacteria that are competitive with or antagonistic to the pathogens of interest, and on 
the other hand prevent the opportunistic pathogens from remaining in the gut intestine. 
Current procommensal strategies applied in both human and farm animals include 
probiotics, prebiotics (as well as foods with prebiotic-like effects), and synbiotics 
(functional foods containing both probiotics and nutrients with prebiotic-like effects). 
 
The active role of human gut microbes and their metabolites production in gut intestine 
Human gut epithelial cells and mucus-containing surfaces are colonized by 
enormous microorganisms commonly known as normal gut microflora, and they 
comprise a crucial and complex ecosystem with considerable microbial diversity 
(Tlaskalová-Hogenová et al., 2011). These commensal microorganisms protect the 
human intestinal tract from pathogenic bacterial colonization and infection, either 
directly, through competitive exclusion, or indirectly by producing antimicrobial 
byproducts/metabolites or modulating gut immunity (Mengfei Peng, Reichmann, & 
Biswas, 2015). Several genera, in particular Bifidobacteria and Lactobacillus, produce 





2014; Marcobal et al., 2013); however, the quantity and composition of bio-active 
metabolites in the gut are mediated by bacterial spatial distribution as well as host 
dietary intake (Pédron et al., 2012; Walter & Ley, 2011). 
 
The importance of human gut microbiome homeostasis 
The human gut microbiome is composed of bacteria, viruses (mainly phages), 
fungi, and protozoans. Together, these microorganisms entail a microbial genetic 
repertoire that is approximately 100 times greater than that of their human host 
(Fujimura, Slusher, & Cabana, 2010). The human distal GI microbiome possesses 1000 
distinct bacterial species and the number was estimated to be at least 1014 CFU/g, ten 
times more than all the human cells in the body. Bacteroidetes, Firmicutes, 
Proteobacteria, and Actinobacteria are the dominant phyla in the gut microbiome, 
among which Bacteroides, which alone constitutes approximately 30% of all bacteria 
therein, along with Bifidobacterium, Clostridium, Eubacterium, Escherichia, 
Fusobacterium, Lactobacillus, Peptococcus, Peptostreptococcus, and Ruminococcus 
form the majority genera (Guarner & Malagelada, 2003; Khanna & Tosh, 2014; 
Vedantam & Hecht, 2003). 
 The human gut microbiome is integral to the natural defense mechanisms of the 





incoming pathogenic attackers (Mengfei Peng, Reichmann, et al., 2015). By either 
directly interfering with pathogenic bacteria through competition for niches and 
nutrients, or by modulating/enhancing host immune defense mechanisms, the 
microbiota prevent the attachment and proliferation of pathogenic microorganisms on 
intestinal surfaces as well as their invasion and circulation into intestinal cells 
(Tlaskalová-Hogenová et al., 2011; Turner, 2009). Indirect evidence points to the 
complex microbiome-host interactions and the microflora’s role in controlling the 
outgrowth and infections of pathogenic bacteria; e.g., alteration in the composition of 
the gut microbiome following antibiotic treatment was associated with an over-
shedding of Clostridium difficile in the stool of infected mice (Lawley et al., 2008; 
Rupnik, M.; Wilcox, M.H.; Gerding, 2009). Moreover, germ-free and antibiotic-treated 
mice are more susceptible to infection by numerous enteric pathogenic bacteria, 
including S. Typhimurium (S. Fukuda et al., 2011; Lawley et al., 2009). 
 As the first line of defense, the intestinal mucosal barrier has evolved complex 
protective mechanisms in order to resist xenobiotic pathogen adherence and invasion, 
and more than 80% of immune cells act through the mucosal-associated lymphatic 
tissue (Tlaskalová-Hogenová et al., 2004). The healthy gut microbiome is the key of 
protection against colonization and infection of enteric bacterial pathogens through 





barrier and associated immune tissue functions (Peterson & Artis, 2014; Round & 
Mazmanian, 2009). It has been reported that germ-free mice have impaired Paneth cells 
which is responsible for producing antimicrobial peptides in small intestine, as well as 
deficient intestinal mucosal barriers and fragile in pathogenic bacterial translocation (K. 
S. Kobayashi et al., 2005; Vaishnava, Behrendt, Ismail, Eckmann, & Hooper, 2008). 
Moreover, commensal gut bacterial signaling mechanism also promotes the mucosal 
barrier functions by stimulating IgA production; these antibodies bind with and 
neutralize pathogenic antigens, thus protecting against bacterial infection (Fagarasan, 
Kawamoto, Kanagawa, & Suzuki, 2010; Frantz et al., 2012; Strugnell & Wijburg, 2010; 
Suzuki et al., 2010). Recent studies have also revealed that commensal gut anaerobes 
can induce the production of T helper (Th) 17 cytokines (IL-17 and IL-22) by CD4
+ Th 
cells (Ivanov et al., 2009), whereas aberrant Th17 populations are associated with 
certain GI-dysbiosis-associated chronic disorders such as rheumatoid arthritis, lupus, 
and inflammatory bowel disease (Chow & Mazmanian, 2009; T. Kobayashi et al., 
2008). In addition, another protective mechanism is through stimulation of the host 
innate immunity (Kamada et al., 2013). This important microbial immune-modulation 
is amplified by IL-1β, the cytokine critical for neutrophil recruitment in response to 





macrophages which are able to quickly respond to enteric infections by rapid 
conversion of pro-IL-1β to active IL-1β (Franchi et al., 2012). 
 Both commensal and pathogenic bacteria require similar ecological niches to 
colonize host epithelial cells and proliferate throughout the intestine. A healthy gut 
microbiota is able to competitively exclude incoming pathogens (Hammami, 
Fernandez, Lacroix, & Fliss, 2013). Commensal bacteria produce certain 
antimicrobials which inhibit the adhesion, multiplication, survival and colonization of 
neighbor bacterial species, including pathogens. For example, intestinal bacteriocins 
produced by E. coli and enterotoxins secreted by Bacillus cereus can directly block the 
colonization space of pathogenic E. coli and foodborne pathogenic Bacillus (Ceuppens 
et al., 2012; Schamberger & Diez-Gonzalez, 2002). Moreover, Bifidobacterium and 
Lactobacillus inhibit the growth of several intestinal pathogens including EHEC by 
generating and secreting bio-active fatty acids and acidifying the local gut environment 
(Cherrington, Hinton, Pearson, & Chopra, 1991; R. Shin, Suzuki, & Morishita, 2002). 
Furthermore, commensal gut bacterial flora and enteric bacterial pathogens share 
certain nutritional requirements, and as such, the indigenous microbial community 
plays a critical role in limiting pathogen colonization and infection through competing 
nutrients. For example, commensal E. coli consumes the lion’s share of necessary 





resources, which leads to starvation and death of the foreign pathogen (Fabich et al., 
2008; Leatham et al., 2009; Momose, Hirayama, & Itoh, 2008a, 2008b). In addition, 
interactions between gut microbiota and their host cells can suppress and compromise 
the virulent properties of pathogens. Production of certain metabolites such as butyrate 
by commensal bacteria can down-regulate the expression of virulent genes involved in 
T3SS of S. Enteritidis and S. Typhimurium (Gantois et al., 2006). Interactions between 
Bacteroides thetaiotaomicron and host-produced mucins induce the production of 
fucose by the fucosidase-bearing commensal bacteria; the secreted fucose then down-
regulates expression of the master regulator ler for EHEC LEE genes (Pacheco, Munera, 
Waldor, Sperandio, & Ritchie, 2012). Finally, disruption of the ambient conditions 
essential for virulence activity can also inhibit pathogenesis. Enterobacteriaceae can 
consume residual oxygen, restricting the virulence of bacterial pathogens like Shigella 
flexneri, which requires an oxygen-rich environment for growth in the intestine 
(Marteyn et al., 2010). 
 
Probiotics and their beneficial effects 
Probiotics are live non-pathogenic microorganisms that are administered in 
order to improve gut intestinal microbial balance as well as protect the host from 





fermented dairy products and probiotic strains fortified foods, whereas freeze dried 
probiotics are also commercial available in the form of tablets, capsules, powders, or 
sachets. Several documented probiotic strains include Bifidobacterium, Bacillus 
coagulans, Streptococcus thermophilus, Saccharomyces cerevisiae, and most 
importantly multiple Lactobacillus spp. (L. acidophilus, L. boulardii, L. bulgaricus, L. 
casei, L. johnsonii, L. paracasei, L. plantarum, L. rhamnosus, L. reuteri) (Hutkins et 
al., 2016; M E Sanders, Gibson, Gill, & Guarner, 2007; Mary Ellen Sanders, 2008). 
However, presence of bacteriophage of these probiotic strains play an important role in 
production of fermented common in dairy and other products. They are responsible for 
most of the incomplete and slow fermentation (Marcó, Moineau, & Quiberoni, 2012). 
As a consequence, minimizing the contamination by bacteriophage and developing 
phage-resistant starter strains are of major concern for both researchers and industrial 
technologists. General characteristics of probiotic strains especially Lactobacillus 
include the abilities to modulate gut innate and acquired immunity, maintain the 
epithelial gut barrier, and the antimicrobial properties against enteric pathogens by 
secreting hydrogen peroxide, organic acids, antimicrobial polypeptides, etc. 
(Monachese et al., 2011). These special characteristics are all associated with their 
functions in prevention and therapy of (chronic) enteric infections and diarrhea 





gut niches with beneficial bacteria so as to block and exclude the establishment of 
pathogenic bacteria (Doyle & Erickson, 2006; Gaggìa, Mattarelli, & Biavati, 2010). 
 Various beneficial attributes associated with combatting foodborne illness by 
probiotics (Table 1-2) include production of antimicrobial agents such as lactic acids, 
hydrogen peroxide, and bacteriocins, production of short chain fatty acid (SCFA), 
immunologic enhancement, colonization/adhesion resistance, and modulation of 
mucosal barrier functions. Besides these, other benefits on human beings are connected 
with their properties in improving digestion, anti-inflammation, anti-carcinogenesis, 
and assimilation and lowering cholesterol (Amalaradjou & Bhunia, 2012; Dicks & 
Botes, 2010; Nagpal et al., 2012; Salminen et al., 2010; Thomas & Ockhuizen, 2012). 
 Evidences for using wild type probiotics in prevention and control of enteric 
infections have been recorded recently. Both Lactobacillus and Bifidobacterium are 
found to enhance colonization resistance which contributes in their competition with 
enteric bacterial pathogens (Wagner, Johnson, & Rubin, 2009). Probiotic 
bifidobacteria, Enterococcus faecium and non-pathogenic probiotic E. coli strains 
inhibited EHEC growth, protected mice against EHEC infection, and caused reduction 
in Shiga toxin production (Takashi Asahara et al., 2004; Lema, Williams, & Rao, 2001; 
Reissbrodt et al., 2009). Multiple Lactobacillus strains including L. acidophilus, L. 





to host intestinal cells and diminish the intestinal and extra-intestinal dissemination of 
EHEC, Salmonella, C. jejuni, and V. parahemolyticus by competitive exclusion and 
displacement (Lema et al., 2001; Satish Kumar et al., 2011). Administration of several 
combined probiotic strains could synergistically reduce Proteus mirabilis, 
Pseudomonas aeruginosa, Salmonella, S. aureus, and Shigella sonnei (Higgins et al., 
2008; Zschüttig et al., 2012). In addition, Probiotics like L. paracasei were also shown 
to up-regulate dendritic cells, activate Th cells and antibody production, as well as 
down-regulate pro-inflammatory cytokines, which resulted in a reversed/enhanced gut 
intestinal integrity and protection against enteric bacterial pathogens especially 
Salmonella (Tsai, Cheng, & Pan, 2010; Wagner et al., 2009). 
 Over the last decade, scientists have been working on development of novel and 
innovative genetically-recombinant probiotics with enhanced advantages such as 
higher ability in mucosal and intestinal colonization, higher tolerance to bacteriophage, 
gastric acid, and bile salts for survival in GI tract, prolonged colonization as well as 
competition with enteric pathogens, and higher expression of target antimicrobial 
molecules against pathogens (Sleator & Hill, 2008; J. Wells, 2011; J. M. Wells & 
Mercenier, 2008). To achieve these purposes, various bioengineering actions could be 
applied. First, toxin-specific host cell receptors could be expressed on probiotics strain 





(Paton, Morona, & Paton, 2006). Adhesins and other key factors in secretory systems 
of enteric pathogens could be cloned and expressed on probiotic strains to create 
competitive environment for specific pathogen colonization (Jagadeesan et al., 2011). 
Furthermore, by mimicking expression of virulence genes from enteric bacteria, 
probiotic strains could interrupt pathogenic quorum sensing pathway and suppress the 
associated virulence gene expression in the target pathogen (Waters & Bassler, 2005). 
Finally, the development and administration of probiotic strains with heterologous 
antigen expression could stimulate immune responses (cytokine production) and assist 
in suppressing intestinal inflammation and providing cyto-protection (J. M. Wells & 
Mercenier, 2008). 
 
Prebiotics and prebiotic-like foods in gut microbiome modulation 
 Gibson and Roberfroid (1995) first defined the terminology ‘prebiotics’ as 
‘non-digestible food ingredients which improve the host health by selectively 
stimulating the growth and activity of limited numbers of bacteria in the colon’. Nine 
years after at 2004, they redefined the term as ‘selectively fermented ingredients that 
allow specific changes both in the composition and/or activity in the GI microflora that 
confer benefits upon host well-being and health’ (Glenn R. Gibson, Probert, Loo, 





oligosaccharides, and their major characteristics are colonic microflora fermentable 
while resistant to digestive enzymes in human gut (Bielecka, Biedrzycka, & 
Majkowska, 2002a; Kolida, Tuohy, & Gibson, 2002a). Moreover, multiple preliminary 
studies have revealed that several bifidogenic prebiotics could provide native 
microflora limiting nutrients and energy for fermentation, either producing vitamins, 
SCFAs, and antioxidants for modulation of intestinal microflora composition or 
releasing antimicrobial byproducts as competitive advantages for exclusion of 
pathogenic bacteria (J. H. Cummings & Macfarlane, 2002; M. Fukuda et al., 2002; 
Videla et al., 2001). Besides all of these mentioned above, research has also 
demonstrated the potential effects of prebiotics on stimulating mineral absorption (such 
as calcium), enhancing immune system effectiveness, and reduction of colorectal 
cancer risk (Geier, Butler, & Howarth, 2006; Lohner, Küllenberg, Antes, Decsi, & 
Meerpohl, 2014; Lomax & Calder, 2009; Scholz-Ahrens & Schrezenmeir, 2007). 
 Prebiotics are generally coming from food sources. The top-10 prebiotic-
containing foods, their prebiotic fiber content, and recommended daily serving are 
summarized in Table 1-3. Chicory root is considered the richest natural source of inulin 
and oligosaccharides. Beans, raw oats, Whole wheat, banana, et al. are believed to be 
other traditional dietary sources of prebiotics. Certain oligosaccharides naturally exist 





immune system in infants (Seifert & Watzl, 2007). Except for inulin, lactulose, and 
oligosaccharides, several other compounds such as flavanols and polyunsaturated fatty 
acid (PUFA) especially conjugated linoleic acids (CLA) are also found to possess 
similar prebiotic-like effects (Andoh, Tsujikawa, & Fujiyama, 2003; Tzounis et al., 
2011). 
 In 2003, the Food and Drug Administration (FDA) approved a qualified health 
claim that suggest consuming 1.5 ounces (42 g) of most nuts, including peanuts 
(approximately 15 to 20 g of peanut), as part of a diet low in saturated fat and 
cholesterol may reduce the risk of heart disease. Per 20 g peanut contains 5 g dietary 
fibers, 10 g proteins, 5 g total fat, and multiple other bio-active compounds. The 
benefits on reducing cardiovascular diseases (Bao et al., 2013; Isanga & Zhang, 2007; 
J. B. Jones et al., 2014; Ozcan, 2010) with daily intake of peanut or other nut products 
has been suggested to associate with their dietary fibers (prebiotics) as well as the 
phenolic compound Resveratrol (3,4,5-trihydroxystilbene) (Bubonja-Sonje, 
Giacometti, & Abram, 2011; Wang, Yan, Li, Jiang, & Liu, 2011). Additionally, the 
prebiotic-like benefits of multiple compounds from peanut in large intestine can 
promote the growth of selective beneficial gut microflora, especially Bifidobacteria 





 Cocoa is also a rich source of dietary fibers and various polyphenols including 
flavanols and procyanidins, which are free radical cleaning molecules with strongly 
antioxidant activity and anti-inflammatory potential (Bubonja-Sonje et al., 2011; Cai, 
Luo, Sun, & Corke, 2004; Gu, House, Wu, Ou, & Prior, 2006; Pérez-Berezo, Franch, 
Castellote, Castell, & Pérez-Cano, 2012). The compounds from cocoa also have been 
shown to have numerous health-promoting properties such as reducing blood pressure, 
increasing the formation of endothelial nitric oxide, and promoting vasodilation (Ried, 
Fakler, & Stocks, 2012). Previous reports found that Lactobacillus strains were one of 
the predominating bacterial species of cocoa bean fermentations (Lefeber, Janssens, 
Camu, & De Vuyst, 2010; Papalexandratou, Camu, Falony, & De Vuyst, 2011), and 
there is also evidence that cocoa components like flavanols, multiple carbohydrates, 
and dietary fibers that reach the large intestine may have prebiotic-like benefits by 
promoting the growth of select beneficial gut microflora (Massot-Cladera, Pérez-
Berezo, Franch, Castell, & Pérez-Cano, 2012; Tzounis et al., 2011). 
 
Synbiotics and synergistic effects 
The concept ‘synbiotic’ was first introduced by Gibson and Roberfroid (1995) 
as ‘mixtures of probiotics and prebiotics that beneficially affect the host by improving 





selectively stimulating the growth and/or by activating the metabolism of one or a 
limited number of health-promoting bacteria, thus improving host welfare’. Briefly, 
several related studies have revealed the co-administration of probiotics and prebiotics 
could possibly yield a synergistic effect in the limitation of foodborne pathogenic 
bacterial populations in the hosts. The symbiotic combination of inulin/oligofructose 
with B. bifidum and L. plantarum could promote the growth of bifidobacteria whereas 
reduce the growth of EHEC, C. jejuni, and S. Enteritidis in vitro (Fooks & Gibson, 
2002). Likewise, bifidobacteria in together with trans-galacto-oligosaccharides could 
protect mice from S. Typhimurium and following lethal infections (T. Asahara et al., 
2011). Moreover, synbiotics with L. paracasei and oligo-fructose significantly 
increased the amount of Lactobacillus spp., Bifidobacterium spp., total anaerobes, and 
total aerobes in weanling piglets’ feces, while significantly reduced fecal 
concentrations of Clostridium spp. and Enterobacterium spp. in vivo study (Bomba et 
al., 2002). More recently, synbiotics have been suggested to be more effective than 
either probiotics or prebiotics alone in improving the gut health by modulation of gut 
microbiota (Adebola, Corcoran, & Morgan, 2014; Saulnier, Gibson, & Kolida, 2008) 
as well as the quality of life in patients suffering from foodborne illness and UC 






Intestinal production of beneficial metabolites by probiotics 
Undigested dietary components from consumed food that reach the large 
intestine are fermented and/or metabolized by the gut microbial community, resulting 
in the generation of a diverse bank of beneficial metabolites (Flint, Scott, Louis, & 
Duncan, 2012; Marcobal et al., 2013). During fermentation, beneficial bacteria 
(probiotics), particularly the lactic acid bacteria Lactobacillus, produce a wide range of 
secondary metabolites (byproducts) that are associated with health-promoting benefits 
to the host. Major byproducts include lipid molecules of various chemical structures 
such as SCFAs and PUFAs (Louis et al., 2014; Serini, Piccioni, Merendino, & Calviello, 
2009). The combined concentration of lipid byproducts in the human colon is 
approximately 50-150 mM, and these beneficial molecules assist in modulation of host 
immune responses and regulation of cell apoptosis (Louis et al., 2014). Other bio-
functional metabolites from probiotics include bio-active proteins or polypeptides with 
antimicrobial and immune-modulatory properties and vitamin B, essential for human 







Antimicrobial polypeptides (bacteriocins) 
Bacteriocins are proteins or polypeptides with antimicrobial activities produced 
by certain bacteria especially probiotics for the purpose of inhibiting the growth of their 
competitive bacterial strains in the environment. Such antimicrobial proteins are able 
to inhibit the growth of major foodborne bacterial pathogens like Salmonella, Listeria, 
and Campylobacter (Patton, Dickson, Lonergan, Cutler, & Stahl, 2007; Stahl, Callaway, 
Lincoln, Lonergan, & Genovese, 2004). For example nisin, produced by L. lactis, has 
already been found to be effective in spoilage bacteria reduction in meat and milk, and 
encapsulated nisin is able to inhibit the growth of L. monocytogenes (da Silva 
Malheiros, Daroit, & Brandelli, 2010). Reaching or secreting in the lower gut, nisin 
exerts it antimicrobial activities by disrupting the cell membranes of target foodborne 
pathogens. Likewise, the mixture of related cyclic polypeptides called ‘bacitracin’ 
produced mainly by Bacillus subtilis also has antimicrobial properties by interfering 
with bacterial cell wall and peptidoglycan bio-synthesis in both Gram-positive and 
Gram-negative bacteria (Weston, Wahab, Roberts, & Mason, 2001). Furthermore, 
reuterin, a broad-spectrum antimicrobial substance produced by L. reuteri, can inhibit 
the growth of L. monocytogenes, C. jejuni, Yersinia enterocolitica, S. aureus, and 
EHEC, and it has been used as bio-preservative in different food products like beef 






Essential vitamin B 
The B-group vitamins including thiamine (B1), riboflavin (B2), niacin (B3), 
pantothenic acid (B5), pyridoxine (B6), biotin (B7), folate (B11), and cobalamin (B12) 
act synergistically to maintain the body’s homeostasis by regulating cell metabolic 
processes such as energy production, red blood cell formation, and nucleic acids 
synthesis (LeBlanc et al., 2011). Most of these vitamins cannot be synthesized by 
humans and animals, but they could be produced by LAB fermentation (A. Patel, Shah, 
& Prajapati, 2013). For instance, folic acid as an essential cofactor for bacterial 
metabolism could be used by L. lactis for biosynthesis of folate which is essential for 
reproduction and reducing coronary heart disease as well as cancer risks (Sybesma et 
al., 2003). Similarly, multivitamin production such as riboflavin and cobalamin has 
recently been achieved by single strain of L. lactis (Sybesma, Burgess, Starrenburg, 
Van Sinderen, & Hugenholtz, 2004). These two B-group vitamins are essential co-
factors in fatty acids, amino acids, carbohydrates and nucleic acids metabolism 






Intestinal production of PUFAs/ SCFAs and their major contributors 
The common PUFAs are summarized in Table 1-4. The major bio-function of 
PUFA linoleic acid conjugation in bacteria is to detoxify the inhibitory effects of fatty 
acids on growth (Coakley et al., 2003; Jiang, Björck, & Fondén, 1998). The rumen 
anaerobic bacteria Butyrivibrio fibrisolvens was the first to be recognized as a CLA 
producer (Kepler, Hirons, McNeill, & Tove, 1966). In 1998, it was found that 
Propionibacterium freudenreichii could also convert linoleic acid to CLA (Jiang et al., 
1998). It has since been shown that numerous genera of dairy and human/animal 
intestinal bacteria, including lactic acid bacteria Lactobacillus and Bifidobacterium, are 
able to produce CLA during normal metabolic activities (Alonso, Cuesta, & Gilliland, 
2003a; Y. J. Kim & Liu, 2002; Tung Y. Lin, 2000; Ogawa, Matsumura, Kishino, Omura, 
& Shimizu, 2001; Soo et al., 2008). Among these bacteria, Bifidobacterium bifidum, 
Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus, 
Lactobacillus casei, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactococcus 
lactis, and Streptococcus thermophilus, most of which are known to be common gut 
microflora, have been revealed as CLA producers (Farooq, Mohsin, Liu, & Zhang, 
2013; Van Nieuwenhove, Cano, Pérez-Chaia, & González, 2011), however the levels 
of CLA produced varies. Moreover, isomers of PUFAs formed are also strain-





paracasei and S. thermophilus, each only produce a single isomer, whereas two or more 
CLA isomers are generated by other strains such as L. acidophilus, L. casei, and L. 
plantarum. 
 Linoleate isomerase (LI) is the enzyme responsible for linoleic acid 
isomerization and CLA production in several bacteria, especially Lactobacillus and 
Bifidobacterium (Martin Macouzet, Robert, & Lee, 2010). The mechanisms for 
Lactobacillus production of CLA were found to involve hydroxyl fatty acids as 
intermediates (Kishino, Ogawa, Yokozeki, & Shimizu, 2011); later analysis revealed 
that CLA formation is composed of three distinct steps: linoleic acid hydration into 10-
hydroxy-octadecenoic acid, followed by isomerization and subsequent dehydration 
into CLA (B. Yang et al., 2014). The LI is a myosin cross-reactive antigen (MCRA) 
originally discovered in Streptococcus pyogenes as a 67 kD protein (Kil, Cunningham, 
& Barnett, 1994). Previously, Peng et al., (2007) showed that MCRA-like proteins 
contain more than 50% sequence similarity with LI from L. acidophilus and 
Lactobacillus reuteri. Recently, it was reported that MCRAs comprise a family of 
proteins present in a wide range of bacteria, especially lactic acid bacteria. MCRAs 
from multiple species of LAB were confirmed as fatty acid hydratase (B. Yang et al., 
2014). A BLAST search using the MCRA protein sequence revealed more than 148 





species (Volkov et al., 2010). In 2011, Kishino et al. reported that the linoleic acid 
isomerase in L. plantarum, as a multi-component enzyme system, was associated with 
both membrane and soluble fractions, and a hydration step from linoleic acid to 10-
hydroxy-12-octadecenoic acid was also involved in the isomerization reaction. 
Thereafter, Rosberg-Cody et al., (2007) reported that the recombinant Lactococcus and 
Corynebacterium with heterologous gene of MCRA (mcra) from B. breve are more 
resistant to heat and stress compared to wild-type strains. Moreover, O’connell et al., 
(2013) demonstrated that MCRA enzyme in B. breve was an oleate hydratase and it 
might provide detoxification activities on bacteria by catalyzing hydration of multiple 
unsaturated fatty acids. Additionally, MCRAs found across a wide range of taxa 
including LAB have been shown to promote blood survival and cell adherence 
(O’Flaherty & Klaenhammer, 2010; Volkov et al., 2010). 
 SCFAs are released in the anaerobic gut lumen as fermentation byproducts of 
human intestinal microflora when indigestible carbohydrates are incompletely oxidized. 
The type and structures of available complex carbohydrates play a critical role in 
determining the complement of fermented products produced by the microbiota. 
Therefore, the level and composition of intestinal SCFAs are heavily influenced by diet 
and the endogenous microbial community structure (Harrison, Balan, & Babu, 2013). 





fermenting microbes such as the Bacteroidetes, to be subsequently utilized for 
generation of SCFAs by secondary fermenting microbes such as Clostridium and other 
butyrate-producing gut microorganisms (Nava, Friedrichsen, & Stappenbeck, 2011). 
The resultant hydrogenous byproducts are taken up by acetogens for the production of 
acetate, the dominant type of SCFA in the human gut (Rey et al., 2010). Another major 
intestinal SCFA, butyrate, is thought to be produced via one of two transformation 
pathways, acetyl-CoA condensation and butyryl-CoA formation; it has been proposed 
based on previous research which led to the development of metabolic enzyme 
molecular markers for use in revealing the functional dynamics of microbial intestinal 
ecology (Hosseini, Grootaert, Verstraete, & Van de Wiele, 2011). In the proposed 
pathway, catalyzed by butyrate kinase and phosphotransbutyrylase from Clostridium 
acetobutylicum, butyryl-phosphate was surmised to be an intermediate in conversion 
of butyryl-CoA to the final product butyrate (Hartmanis & Gatenbeck, 1984). In the 
recent molecular and enzymatic in vitro studies on major intestinal butyrate sources, 
butyryl-CoA-acetate-CoA transferase is recognized as an alternative butyrate-
producing pathway, in which the coenzyme itself catalyzes the transformation from 






 Quantity and composition of intestinal SCFAs can also be determined by spatial 
organization of the human endogenous microbial community (Table 1-5) (Pédron et al., 
2012; Roy, Kien, Bouthillier, & Levy, 2006; Topping & Clifton, 2001). For example, 
large spatial variation has been found in the relative ratio of different SCFAs, resulting 
in different pH environments between the small and large intestine, as the small 
intestine contains a relatively lower microbial distribution (Walter & Ley, 2011). 
However, diet also plays a critical role in SCFA production, since the type of SCFAs 
produced by fermenting gut microbiota is dictated by the structural complexity of the 
carbohydrate substrates available. Some examples are summarized in Table 1-6. 
 
Beneficial effects of CLA on human health 
CLA is the generic term to describe a mixture of positional and geometric 
isomers of linoleic acid (C18:2, c9, c12). These isomers contain double bond system in 
either cis or trans configuration at several different possible positions (Banni, 2002), 
among which c9, t11-CLA and t10, c12-CLA are the most common and mainly found 
isomers, and they are also associated with multiple health and nutritional benefits on 
human beings (Alonso et al., 2003a). Structures of linoleic acid and its common 
isomers are listed in Table 1-7. Dietary sources of linoleic acid and CLA include dairy 





butter (Kris-Etherton et al., 2000; Sonwai, Kaphueakngam, & Flood, 2012), whereas 
the major source for human is through milk consuming. Therefore, CLA especially c9, 
t11-CLA (represents 80-90%) as the intermediate during dietary linoleic acid bio-
hydrogenation is accumulated predominantly in milk fat (Jensen, 2002). Due to their 
biological benefits, CLA has received great attention in recent years, and most research 
was conducted for the purpose to evaluate the health effects of mixed isomers of CLA 
(Kelley, Hubbard, & Erickson, 2007). 
 A number of biological functions and health benefits of CLA have been 
established, and certain CLA-producer probiotic strains including Lactobacillus have 
also been associated with a variety of systemic health promoting effects (O’Shea, Cotter, 
Stanton, Ross, & Hill, 2012). CLA produced during fermentation by probiotic bacteria 
possess potential beneficial roles including anti-cancer, anti-inflammatory, and anti-
pathogenic activities (Ewaschuk, Walker, Diaz, & Madsen, 2006; Bo Yang et al., 2015). 
 CLA is well documented in numerous studies as an efficient inhibitor for all 
stages of carcinogenesis including initiation, promotion, and metastasis (Belury, 2002a; 
B. Q. Chen et al., 2003; Kelley et al., 2007; Lau & Archer, 2010; Soel, Choi, Bang, 
Park, & Kim, 2007). In vitro studies suggested that both c9, t11-CLA and t10, c12-CLA 
as well as their mixture have anti-proliferative effects against multiple cancer cell lines, 





2006; Flowers & Thompson, 2009; Lau & Archer, 2010; Ochoa et al., 2004; Rakib et 
al., 2013). In vivo animal researches revealed that 0.05-1% (w/w) mixture of CLA 
isomers c9, t11-CLA and t10, c12-CLA could significantly inhibit chemically-induced 
colon, forestomach, and mammary gland tumors (Bassaganya-Riera, Viladomiu, 
Pedragosa, De Simone, & Hontecillas, 2012; McGowan et al., 2013; Rosberg-Cody et 
al., 2007). By preferentially affecting arachidonic acid metabolism and down-
regulating cyclooxygenase and 5-lipoxygenase expression, c9, t11-CLA reduces the 
level of prostaglandin E2 and thromboxane B2 (Ochoa et al., 2004) and disrupts 
Hsp90/IKK complex, thus prevents the phosphorylation of IκB by IKK, and further 
blocks NF-κB activation (D. I. Kim et al., 2011; Perdomo, Santos, & Badinga, 2011; 
Rakib et al., 2013). The down-regulation of NF-κB signaling reduces the proliferation 
of cancer cells and weaken them to be vulnerable to TNF-induced apoptosis (D. I. Kim 
et al., 2011; Park et al., 2007; Perdomo et al., 2011; Rakib et al., 2013). On the other 
hand, t10, c12-CLA isomer works preferentially through apoptosis modulation by 
activation of caspase-3 and caspase-9, induction of p21, p53, and p27, inhibition of 
anti-apoptotic bcl-2, and activation of pro-apoptotic protein Bax (Cho et al., 2006; K. 
P. Kim et al., 2006; S. H. Lee et al., 2006; Ochoa et al., 2004). 
 The anti-inflammatory properties of CLA has been reported both ex vivo in cell 





mechanism of CLA is through cyclooxygenase-2 inhibition and thus reducing 
prostaglandin E2 release (Flowers & Thompson, 2009; Li, Barnes, Butz, Bjorling, & 
Cook, 2005; Y. K. Nakamura & Omaye, 2009; Stachowska et al., 2007). Then by 
activating peroxisome proliferator-activated receptors, CLA could manage to inhibit 
the activation and translocation of NF-κB into nucleus (Borniquel, Jadert, & Lundberg, 
2012; D. I. Kim et al., 2011), and followed by reducing the level of pro-inflammatory 
cytokines formation such as TNF-α (Akahoshi et al., 2004), IL-1β (Albers et al., 2003; 
Tricon et al., 2004), and IL-8 (Jaudszus, Foerster, Kroegel, Wolf, & Jahreis, 2005) 
which are normally activated by NF-κB (Clarke et al., 2010; Song, Sneddon, Heys, & 
Wahle, 2006). Moreover, CLA has also been reported to stimulate the expression levels 
of anti-inflammatory cytokine TFG-β1 (Bassaganya-Riera et al., 2004, 2012) and 
protective immunoglobulins IgA, IgG, and IgM, whereas suppressing IgE production 
(Martinez et al., 2010). On the other side, bacterial pathogenic challenged macrophage 
dendritic cells could rapidly produce and secret IL-12 which acts as the signal for Th 
cells - Th1 (INF-γ, IL-12, and TNF-α) and Th2 (IL-4 and IL-10) (Bassaganya-Riera et 
al., 2003). In vitro and in vivo studies revealed that c9, t11-CLA treatment on murine 
macrophage and dendritic cells suppressed the production of both IL-12 and IL-4 
(Loscher et al., 2005), which indicates that CLA is able to attenuate both Th1 and Th2 





anti-inflammatory effects of CLA will not impair cellular immunity to intracellular 
pathogens or alter resistance to bacterial infection, though the mechanism under it is 
still unknown (Turnock, Cook, Steinberg, & Czuprynski, 2001). 
 The antimicrobial activity of most long-chain saturated and unsaturated fatty 
acids was revealed during years to be dependent on both the bacterial strains and types 
of the fatty acids (Mbandi, Brywig, & Shelef, 2004; S. Y. Shin, Bajpai, Kim, & Kang, 
2007; Zheng et al., 2005). Among those fatty acids, long-chain unsaturated fatty acids 
especially linoleic acid has been well documented to be bactericidal to Staphylococcus 
aureus, Streptococcus pyogenes, and Micrococcus Kristinae (Zheng et al., 2005), 
however no/minimum antimicrobial effect was found to be against Gram-negative 
bacteria such as E. coli and Salmonella, except for Pseudomonas aeruginosa (Dilika, 
Bremner, & Meyer, 2000; C. Q. Sun, O’Connor, & Roberton, 2003). Whereas, CLA 
has also shown considerable promise as an antimicrobial bio-active agent on foodborne 
and pathogenic bacteria for both Gram-positive and Gram-negative, which added value 
for any linoleic acid-containing functional food products as well as CLA-producing 
probiotics. To be specific, Meraz-Torres and Hernandez-Sanchez (2012) reported that 
lower concentration of potassium salt of CLA could slow down the growth rate of both 
Gram-positive bacteria (such as Bacillus cereus, L. monocytogenes, S. aureus, and 





Typhimurium, Vibrio parahemolyticus, Klebsiella pneumoniae, and Proteus mirabilis), 
while higher concentration of potassium salt of CLA could completely inhibit their 
growth. The possible antimicrobial mechanism is through CLA lipid peroxidation at 
both bacterial membrane and cultural medium (Byeon et al., 2009), since CLA in this 
study had been found to be present in the membranes of all tested microorganisms in 
the cultural medium and their disrupted cell membrane surfaces were observed. 
 However, animal and human studies have demonstrated that an estimated daily 
intake of 2.2-4.2 g of CLA may be required to realize these multiple health benefits 
mentioned above (Moloney, Yeow, Mullen, Nolan, & Roche, 2004; Mullen et al., 2007; 
Smedman & Vessby, 2001), but the real consumption of CLA in different countries 
(less than 500 mg) is much lower than this recommended dose (Dhiman, Nam, & Ure, 
2005). Although such health benefits are probiotic strains dependent, a significantly 
higher CLA producing bacterial CFU in fecal is required for the optimal amount of 
CLA production (Gionchetti et al., 2007; Helwig et al., 2006; Larsen et al., 2006; 
Mimura et al., 2004). Therefore, increasing of CLA production by per bacterial cells 






Production of free CLA by bacteria 
Multiple factors including culture media, temperature, oxygen availability, 
period of fermentation, as well as substrate concentration influence the CLA production 
(Pandit, Anand, Kalscheur, & Hassan, 2012). For certain examples, L. acidophilus is 
only able to form CLA in microaerophilia instead of aerophilia conditions (Kishino et 
al., 2011); Yadav et al. (2007) informed that dahi-containing fermentation could 
stimulate the CLA production by L. acidophilus; Lin et al. (2005) demonstrated that 
immobilized L. bulgaricus and L. acidophilus in chitosan and poly-acrylamide matrix 
exhibited higher CLA productivity than in normal cultural condition; Kishino et al. 
(2002) revealed that in nutrient medium supplemented with free linoleic acid inducer, 
the washed cell of L. plantarum was able to express higher level of CLA productivity 
than obtained in growth cultures with extended incubation. Moreover, the isomers 
formed are strain-dependent (Van Nieuwenhove et al., 2011), indicating that several 
strains like L. paracasei and S. thermophilus only form single isomer, whereas two or 
more CLA isomers could be produced by other strains such as L. acidophilus, L. casei, 
and L. plantarum (Table 1-8). 
 LI has been found to present in Lactobacillus by two major forms: either as a 
membrane-bound protein or as a soluble enzyme which allows possible extraction 





Macouzet, Lee, & Robert, 2010; Martin Macouzet et al., 2010). Few studies were 
conducted focusing on the optimal enzymatic conditions for LI. It was suggested that 
the optimal conditions for linoleic acid isomerization by LI in washed cells of multiple 
Lactobacillus are pH 6.5 and 34-37 °C (Kishino et al., 2011; S. O. Lee et al., 2003). 
However for growing culture of Lactobacillus, the optimal temperature condition 
turned out to be between 10 and 22 °C (Hernandez-Mendoza, Lopez-Hernandez, Hill, 
& Garcia, 2009). During past years, putative LI proteins have been characterized and 
sequenced for research (Farmani et al., 2010), which include LI enzymes from 
Bifidobacterium breve, B. dentium, Clostridium sporogenes, L. acidophilus, L. 
plantarum, L. lactis, L. reuteri, Propionibacterium acnes, and Rhodococcus 
erythropolis strains (S. S. Peng et al., 2007). The mechanism for the Lactobacillus 
production of CLA has been demonstrated to involve hydroxyl fatty acids as 
intermediates (Kishino et al., 2011). Furthermore, the production/conversion of CLA 
in Lactobacillus was hypothesized as a multiple-step, and was later revealed that the 
CLA formation is composed of three distinct steps: linoleic acid hydration into 10-
hydroxy-octadecenoic acid, followed by isomerization and dehydration of 10-hydroxy-






Prospective applications in human health and food safety 
In patients which lack the appropriate microbiota, prebiotics cannot selectively 
increase intestinal levels of fatty acids and confer the resulting health benefits. This has 
led to the introduction of synbiotics, ‘mixtures of probiotics and prebiotics that 
beneficially affect the host by improving the survival and implantation of live microbial 
dietary supplements in the GI tract, by selectively stimulating the growth and/or by 
activating the metabolism of one or a limited number of health-promoting bacteria, thus 
improving host welfare’ (G R Gibson & Roberfroid, 1995; Y. Sun & O’Riordan, 2013). 
Briefly, several related studies have suggested that the co-administration of probiotics 
and prebiotics could yield synergistic health benefits, and are more effective than either 
probiotics or prebiotics alone in promoting SCFA and PUFA production and 
establishing and maintaining the correct composition and balance of gut microbiota 
(Adebola et al., 2014; Saulnier et al., 2008), thereby significantly improving the quality 
of life of patients suffering from foodborne illnesses and UC (Fujimori et al., 2009). 
 On the other hand, livestock including chickens, turkeys, swine, cattle, and 
sheep as well as wild birds in and around farm environments are principal reservoirs 
for foodborne bacterial pathogens like Salmonella, EHEC, and C. jejuni (Oliver et al., 
2009). These foodborne pathogens further contaminate produce and meat products 





Considering the limitations PUFAs and SCFAs place on enteric bacterial survival, 
especially certain pathogenic foodborne bacteria, they have the potential to be added 
into food products as preservatives to greatly reduce pathogenic bacterial 
contamination (Carpenter & Broadbent, 2009; Harrison et al., 2013). Moreover, SCFAs 
have been shown to restrict the shedding of pathogenic bacteria, specifically 
Salmonella, in vivo (Filip Van Immerseel et al., 2004; F. Van Immerseel, De Buck, et 
al., 2004; F. Van Immerseel, Fievez, et al., 2004), and are now extensively used as 
animal feed additives in order to control Salmonella colonization in broilers and reduce 
the risk of cross-contamination during animal slaughtering and processing (Cox & 
Pavic, 2010; Defoirdt, Boon, Sorgeloos, Verstraete, & Bossier, 2009; F. T. Jones, 2011; 
Ricke, 2003; Wales, Allen, & Davies, 2010). However, as Van Immerseel et al. (2004) 
pointed out, elimination of foodborne pathogenic bacteria colonization in poultry 
cannot be achieved solely through SCFA and PUFA feed additives. Their use in 
combination with best hygienic practices and cross-contamination-preventing activities 
is necessary to thoroughly minimize the risk of foodborne infections (Y. Sun & 
O’Riordan, 2013). 
 However, excessive levels of SCFAs and PUFAs may also induce adverse 
effects on human health. Dietary carbohydrate mal-absorption and occasional 





in human colon which could notably lower the bowel pH and further induce 
concentration-based injuries (J. Lin, 2004). Evidences include in vivo studies on 
newborn rats and piglets, in which intraluminal administration of 300-600 mM acetic 
acid caused intestinal injuries (Di Lorenzo, Bass, & Krantis, 1995; Jing Lin et al., 2002; 
Nafday et al., 2002). Moreover, it was hypothesized but without direct evidence that 
the over-secretion and accumulation of 200-300 mM SCFAs in bowel of premature 
infants, normally vulnerable and immature, might also induce intestinal mucosal injury 
which finally leading to neonatal necrotizing enterocolitis (Cheu, Brown, & Rowe, 
1989; Jing Lin et al., 2002). However, further study is needed due to the limitation on 
premature infants’ in vivo measurement of local intestinal SCFAs concentration. 
Similarly, daily PUFAs intake of >10% total energy might also induce few side effects 
in metabolic disorders, but systematic studies are necessary for evidence in cholesterol 











Overall Hypothesis and Specific Aims 
 
By over-producing metabolites genetically or with supplement of prebiotic-like 
components, Lactobacillus (L. casei) can significantly reduce the colonization and 
infection of enteric bacterial pathogens (S. Typhimurium and EHEC) while improve 
the gut health. 
 
To investigate the hypothesis, the following aims need to be fulfilled, 
 
Aim 1: Characterization and in vitro evaluation of the functional properties of cocoa 
and peanut on normal microbial flora and enteric bacterial pathogens 
Aim 2: Assessment of the synergistic effects of cocoa/peanut and Lactobacillus on 
enteric pathogenic bacterial growth in vitro and host-pathogen interactions ex vivo 
Aim 3: Overexpression of linoleate isomerase gene in Lactobacillus as well as both in 
vitro and in vivo investigation on its functions in combating enteric pathogenic bacterial 














Clinical symptoms / Diseases Causative bacterial pathogens
Diarrhea, dysentery, and vomiting
Salmonella, Campylobacter, EHEC, Shigella,
Bacillus, Vibrio, Staphylococcus aureus
Arthritis (reactive arthritis and rheumatoid arthritis) Salmonella, Campylobacter, Shigella, Yersinia
Hemorrhagic uremic synrome EHEC, Shigella
Guillain Barre syndrome Campylobacter
Meningitis and encephalitis Listeria

















Beneficial attributes Potential mechanism
Colonization resistance
Competitive exclusion
Growth inhibition by producing organic acids,
baceriocins, and antimicrobial peptides
Growth stimulation by producing
vitamins, SCFAs, and antioxidants
Decrease toxic metabolites production
Enhancement of mucosal barrier functions
Activation of non-specific and antigen-specific defense
Regulation and activation of Th1/Th2 cells
Production of anti-inflammatory cytokines
Reduction of pro-inflammatory cytokines
Resistance to enteric bacterial pathogens
Modulation of gut flora
Modulation of immune system



















(g for 6 g prebiotic intake)
Chicory Root 64.6 9.3
Jerusalem Artichoke 31.5 19





Wheat bran 5 120
Whole Wheat flour 4.8 125
Banana 1 600
Table 1-3. The top-10 prebiotic-containing foods with their prebiotic fiber content












Food sources Major mirobial producer
Alpha-linolenic acid 18:3 (n-3)
Flaxseeds, canola, soybean,
pumpkin, tofu, walnuts
Essential fatty acid - must be aquired through diet
Lower heart disease; lower cholesterol; reduce high
blood pressure; improve asthma
Docosahexaenoic acid 22:6 (n-3)
Salmon, tuna, sardine,shellfish,
human breast milk
Fish gut microbes (Shewanella );
microalgae (Chlorella, Nannochloropsis, etc.)
Slow down Alzheimer's disease; increase efficacy of
chemotherapy; assist infant development; benefit
nervous system; benefit cardiovascular health
Docosapentaenoic acid 22:5 (n-3)
Salmon, menhaden, beef, human
breast milk
Fish gut microbes (Shewanella );
microalgae (Chlorella, Nannochloropsis, etc.)
Slow down Alzheimer's disease; increase efficacy of
chemotherapy; assist infant development; inhibit
thrombosis; benefit wound-healing responses
Eicosapentaenoic acid 20:5 (n-3)
Cod liver, salmon, tuna, sardine,
seaweed, human breast milk
Fish gut microbes (Shewanella,
Pneumatophoru, etc.);
microalgae (Thraustochytrium, Pavlova,  etc.)
Slow down Alzheimer's disease; increase efficacy of
chemotherapy; assist infant development; reduce
depression; alleviate lupus
Arachidonic acid 20:4 (n-6) Peanut Mammalian cells enzymes Assist muscle growth; slow down Alzheimer's disease
Gamma-linolenic acid 18:3 (n-6)
Spirulina, primrose, black
currant, borage, fungal oils
Mammalian cells enzymes
Alleviate allergy; reduce high blood pressure; improve
breast cancer; improve osteoporosis
Linoleic acid 18:2 (n-6)
Olive, cocoa, peanut, canola,
almonds, sesame, corn
Bifidobacterium, Lactobacillus, Lactococcus,
and Streptococcus isomerize linoleic acid
Reduce body fat; improve blood lipids; antioxidant
defense; normalize glucose tolerance; improve
hyperinsulinemia
Oleic acid 18:1 (n-9) Olive Bifidobacterium, Lactobacillus
Reduce cholesterol; reduce high blood pressure;
decrease risk of breast cancer
Table 1-4.  Common PUFAs, their sources, and functions
Major sources



















































compete nutrients with pathogens
Break down indigestible fibers;
produce numerous fatty acids;
synthesize vitamins;
neutralize toxic food ingredients
Uptake unsaturated fatty acids;
accumulate isomerized PUFAs;
produce few SCFAs
Digest reaching dietary fibers;
higher amount of SCFAs produced;
continue isomerizing alpha-linolenic acid,























Ratio of butyrate, acetate, and propionate
Cellulose 38.3 36:9:55
Methyl cellulose 43.1 51:25:24
Fructooligosaccharide 38.6 59:16:25
Glucose 44.0 70:10:20
Hydrolyzed huar gum 54.6 35:29:36
Inulin 44.7 44:25:31
Hydrolyzed inulin 41.4 52:20:28
Psyllium husk 43.6 29:38:33







Ratio of butyrate, acetate, and propionate
Barley hulls 2 62 78:17:5
Cellulose 1 36 72:14:14
Fructooligosaccharide 1 61 74:17:9
Inulin 2 57 63:19:18
Oligofructose 1 50 71:19:10
Pectin 3 71 84:5:11
Resistant starch 5 92 76:17:7







Ratio of butyrate, acetate, and propionate
White rice 33 69 68:26:6
Brown rice 33 63 62:32:6
Oat bran 44 92 59:32:9
Rice bran 36 68 67:25:8
Wheat bran 42 131 60:31:9
Baked beans 45 124 65:30:5
Table 1-6.  Dietary intervention on SCFAs production
a
 Substrates used in vitro  batch-culture fermentation with human faecal microflora
b
 0.5 g of each study substrates were added into 100 mL human faecal homogenate solution
c
 Total concentration of SCFAs was measured with acetate, butyrate, propionate, and isobutyrate
d























c9, t11-CLA t10, c12-CLA t9, t11-CLA
L. acidophilus 20.0 + + +
L. brevis 1.1 + + +
L. bulgaricus 7.6 + + +
L. casei 4.8 + + +
L. curvatus 1.6 + + -
L. gasseri 3.7 + + +
L. helveticus 4.7 + + +
L. paracasei NA + - -
L. plantarum 4.6 + + +
L. reuteri 26.0 + + +
L. rhamnosus 34.0 + + +
L. lactis NA + + -
S. thermophilus 33.0 + - -
Table 1-8. LAB strains with their linoleic acid conversion ratio and converted isomers









Chapter 2: Functional properties of cocoa and peanut on common 




Probiotics are live non-pathogenic microorganisms that could improve gut intestinal 
microbial balance as well as protect the host from infective agents once administered 
in host (Callaway et al., 2003). Major probiotics are essential part for human gut flora 
and often found as resident bacteria in milk and other dairy products. They can be 
divided into 2 main categories - colonizing species, such as Lactobacillus, Lactococcus, 
and Enterococcus, and free floating non-colonizing species including Bacillus and 
Saccharomyces (M. Sharma & Devi, 2014). These beneficial microbes colonizing in 
the gut are able to ameliorate the overall health of humans by restructuring the gut 
microbial balance (Nueno-Palop & Narbad, 2011). The possible characteristics of 
probiotic microorganisms include production of bacteriocins, propionic acid, and 
vitamin B12, and other various effects include increasing the villous length and nutrient 
absorption, immuno-stimulatory activities, and competitive exclusion of pathogenic 
microorganisms (West, Hammarström, & Hernell, 2009). 
Gibson and Roberfroid (1995) first defined the term ‘prebiotics’ as referring to 
‘non-digestible food ingredients which improve host health by selectively stimulating 
the growth and activity of limited numbers of bacteria in the colon’. Nine years later, 
in 2004, they reclassified the term as indicating ‘selectively fermented ingredients that 
allow specific changes both in the composition and/or activity in the GI microflora that 





prebiotics include inulin, lactulose, and oligosaccharides, and their major properties are 
that they are amenable to colonic microflora fermentation while resistant to digestive 
enzyme metabolization in the human gut (Bielecka, Biedrzycka, & Majkowska, 2002b; 
Kolida, Tuohy, & Gibson, 2002b). Moreover, preliminary studies have revealed that 
several bifidogenic prebiotics could provide native microflora with rate-limiting 
nutrients and energy for fermentation, either by increasing levels of SCFAs and PUFAs 
for modulation of intestinal microflora composition or increasing production of 
antimicrobial byproducts as a competitive advantage promoting the exclusion of 
pathogenic bacteria (J. H. Cummings & Macfarlane, 2002; M. Fukuda et al., 2002; 
Videla et al., 2001). 
Cocoa is a rich source of various polyphenols, including flavanols and 
procyanidins, which are free radical cleaning molecules with strongly antioxidant 
activity and anti-inflammatory potential (Bubonja-Sonje et al., 2011; Cai et al., 2004; 
Gu et al., 2006; Pérez-Berezo et al., 2012). The compounds from cocoa also have been 
shown to have numerous health-promoting properties such as reducing blood pressure, 
increasing the formation of endothelial nitric oxide, and promoting vasodilation (Ried 
et al., 2012). Previous reports found that Lactobacillus strains were one of the 
predominating bacterial species of cocoa bean fermentations (Lefeber et al., 2010; 
Papalexandratou et al., 2011), and there is also evidence that cocoa components like 
flavanols, multiple carbohydrates, and dietary fibers that reach the large intestine may 
have prebiotic-like benefits by promoting the growth of select beneficial gut microflora 
(Massot-Cladera et al., 2012; Tzounis et al., 2011). In addition, novel films of 





developed and demonstrated to have an antimicrobial effect against several pathogens 
(Calatayud et al., 2013). 
In 2003, the US FDA approved a qualified health claim that suggests consuming 
1.5 ounces (42 g) of most nuts, including peanuts (approximately 0.5 to 1.0 g of peanut 
skin and 15 to 20 g of peanut flour), as part of a diet low in saturated fat and cholesterol 
may reduce the risk of heart disease. The benefits on reducing cardiovascular diseases 
(Bao et al., 2013; Isanga & Zhang, 2007; J. B. Jones et al., 2014; Ozcan, 2010) with 
daily intake of peanut or other nut products has been suggested to associate with their 
phenolic compound Resveratrol (3,4,5-trihydroxystilbene) (Bubonja-Sonje et al., 2011; 
Wang et al., 2011). Additionally, Resveratrol once reached large intestine may exert 
prebiotic-like benefits in large intestine by promoting the growth of selective beneficial 
gut microflora, especially Lactobacillus (Calatayud et al., 2013; Tzounis et al., 2011). 
It has been tested that the composition of gut microbiota and its functions are 
affected by daily intake of various foods and beverages (Martin et al., 2010), and are 
under attack by foodborne enteric pathogens. Among these pathogens, EHEC, 
Salmonella, and Listeria have drawn the most attention (D. Adams et al., 2017; K. J. 
Cummings et al., 2012; Dussurget, 2008; Teunis et al., 2008). The human enteric 
bacterial pathogens interaction and their infection process is usually initiated by 
intestinal epithelial cell adhesion and following by cell invasion through site-specific 
ligands (Ahn & Biswas, 2014). Infections with these foodborne enteric pathogens and 
their severity are also highly influenced by normal gut microbiota, and the immunity of 
the host. In general, normal microflora colonization in human's gut is effective in 





2005). As a consequence, there is an increasing interest in the use of diet especially 
prebiotics to modulate the composition of the colonic beneficial microflora for health-
promoting effects such as immuno-stimulation and inhibition of pathogen while 
diminishing the negative effects which include carcinogen production and infection 
(Glenn R. Gibson et al., 2004a). 
The aim of this work is to in vitro assessment of the effects of cocoa/peanut on 
probiotics from two folds: first, investigating the promotive effect on growth of 
beneficial bacteria including four strains of Lactobacillus and three resident bacteria in 
milk, and meanwhile detecting bio-active components in cocoa/peanut for explaining 
the noted growth promotion; second, assessing the effect of cocoa/peanut on 
stimulation of bio-active metabolites production by Lactobacillus. The findings of this 
research will provide insight into the beneficial properties of cocoa on human health 
based on gut microbes. 
 
Material and Methods 
Bacterial strain and growth condition. Four Lactobacillus strains, Lactobacillus casei 
(ATCC334), L. rhamnosus (ATCC11443), L. plantarum (ATCC39542) (gift from Dr. 
John A. Lindquist, University of Wisconsin Madison), and L. acidophilus (ATCC4356) 
were used as probiotics in this study. Lactobacillus strains were grown on de Man-
Rogosa-Sharpe (MRS) agar at 37 °C overnight in the presence of 5% CO2 (Forma™ 
Scientific CO2 water jacketed incubator, Thermo Scientific, Massachusetts, USA). 
Three resident bacterial strains including B. subtilis (PIC 620), E. faecalis (PIC 522A), 





this study. B. subtilis, E. faecalis, and S. thermophilus were grown on Braine-Heart-
Infusion (BHI) agar at 37 °C overnight under aerobic conditions (Thermo Scientific 
MAXQ 4450, Thermo Fisher Scientific Inc., Waltham, MA, U.S.A.). Foodborne 
bacterial pathogens Enterohemorrhagic Escherichia coli EDL933 (ATCC700927), 
Salmonella enterica serovar Typhimurium LT2 (ATCC19585), and Listeria 
monocytogenes LM2 (ATCC19115) were used in this study. EHEC, S. Typhimurium, 
and L. monocytogenes were grown on MacConkey agar, Luria-Bertani (LB) agar, and 
BHI agar (EMD Chemicals Inc., Gibbstown, N.J., U.S.A.), respectively, for 18 h at 
37 °C under aerobic conditions (Thermo Scientific MAXQ 4450) (Thermo Fisher 
Scientific Inc., Waltham, Mass., U.S.A.). 
 
Cocoa powder and peanut flour/skin preparation. Commercial, non-alkali treated cocoa 
was purchased at the local supermarket. Cocoa powder was defatted with hexane for 
18 h and the residual hexane was evaporated from the cocoa powder before use. The 
defatted cocoa powder was stored at 4 °C and sterilized 2 h under ultraviolet light 
before experimental use. In shell Jumbo Virginia raw peanut was purchased from a 
local market and shelled by hand to isolate the kernel fractions. Peanut skin was 
removed by hand and the white kernel was ground to form peanut flour. Both peanut 
skin and peanut flour were defatted by 2 extractions with n-hexane (n-hexane: peanut 
portion 10 mL/g) for 12 h at room temperature (25 °C). Peanut flour and peanut skin 
fraction suspensions were prepared in sterilized distilled water (pH adjusted to 8.0 with 





peanut portion was mixed in MRS broth. The cocoa/peanut-MRS solution was used for 
HPLC-MS analysis. 
 
Viability assay of Lactobacillus strains, milk resident bacteria, and foodborne bacterial 
pathogens in presence of cocoa and peanut. L. casei, L. rhamnosus, L. plantarum, and 
L. acidophilus on MRS agar plates were collected in phosphate buffer saline (PBS) and 
the optical density (OD) of the bacterial suspension was adjusted by PBS to an 
absorbance value of 0.2 at 600 nm which contains 107 CFU/mL bacterial cells using a 
LAMBDA BIO/BIO þ spectrophotometer (PerkinElmer, Beaconsfield, UK). A 400 mL 
aliquot of the bacterial suspension was added into either 3.6 mL MRS broth, whole 
milk, or skim milk in the presence or absence of 3% (w/v) cocoa powder in sterilized 
culture tube (Thermo Fisher Scientific Inc.) and incubated for different time points (0, 
24, 48 and 72 h) at 37 °C under aerobic conditions with 5% CO2 (Forma™ Scientific 
CO2 water jacketed incubator). Serial dilutions were performed in PBS after each 
incubation period, followed by plating on MRS agar in triplicate. Bacterial CFUs on 
plates were counted after 24 h incubation and transformed into log values, and results 
were expressed as average number of CFU in log-scale. B. subtilis, E. faecalis, and S. 
thermophilus were grown and plated on BHI agar, and their viability in whole milk was 
investigated following the method described above. L. acidophilus was also recognized 
as well as resident bacteria in milk. Likewise, bacterial suspensions of EHEC, S. 
Typhimurium, and L. monocytogenes in PBS were adjusted to absorbance value of 
0.100 at 600 nm to get 107 CFU/mL. LB broths with and without 3% (w/v) cocoa 





12, 24, 48, and 72 h). After incubation, foodborne pathogens were plated and counted 
on strain-specific agar plates (MacConkey agar for EHEC, Xylose Lysine 
Deoxycholate agar for S. Typhimurium, and Oxford Listeria agar base for L. 
monocytogenes) overnight at 37 °C under aerobic conditions (Thermo Scientific 
MAXQ 4450). 
 
Determination of total phenolic contents in cocoa. The total phenolic content in each 
extract was estimated by Folin-Ciocalteu reagent described previously (Serajus 
Salaheen, Nguyen, Hewes, & Biswas, 2014). Briefly, to construct standard curve, 0, 
0.25, 0.5, 1.0, 1.5, 2.0 mg/mL Gallic acid solutions were prepared for individual 
standard points. Supernatant containing soluble contents in cocoa was collected from 
3% cocoa-water suspension by passing sterile 0.2 mm syringe filter (VWR). 20 mL of 
each Gallic acid solution or 3% cocoa sample supernatant was dissolved in 1.58 mL 
water and mixed with 100 mL Folin-Ciocalteu reagents (MP; CAT NO.195186). 300 
mL of 7.5% Na2CO3 was added to the mixture and incubated at room temperature for 
2 h. The absorbance was measured with spectrophotometer at wavelength of 765 nm. 
The total phenolic content was expressed as gallic acid equivalent (GAE). 
 
Reversed-phase HPLC-tandem mass spectrometry (LC-MS/MS) analysis of 
metabolites. A Thermo Fisher LTQ Orbitrap XL (ThermoFisher Scientific, San Jose, 
CA) instrument coupled with an Agilent 1100 series HPLC (Agilent Technologies, 
Santa Clara, CA) via an electrospray ionization source was used for the analysis of 





well plate autosampler and binary pumping device. Metabolites were separated using 
a Waters Atlantis T3 reversed-phase column (Waters Corp., Milford, MA) with 
2.1×150 mm, 3.0 mm dimensions. Mobile phase A was 0.1% formic acid in water and 
mobile phase B was 0.1% formic acid in acetonitrile, with a flow rate of 300 mL/min. 
A volume of 10 mL was loaded onto the column and separated using a 60 min gradient. 
Mobile phase B started at 0% and reached 95% at 41 min and remained at that level 
until 50 min, before reverting to 0% B at 60 min. The Orbitrap was operated in positive 
ion mode. The source voltage was 3.9 kV, capillary voltage was 29 V, and the tube lens 
voltage was 150 V. The capillary temperature was 275 °C, sheath gas flow was set to 
30 (arb), auxiliary gas was set to 18 (arb), and sweep gas was set to 0. Data were 
acquired using data dependent scanning mode and dynamic exclusion was enabled. 
Fourier Transform Mass Spectrometry (FTMS) resolution of 60,000 with a mass range 
of 70e1100 m/z was used for full scan analysis and the FTMS was used for MS/MS 
data acquisition with a resolution of 7500. The top two most intense ions were acquired 
from scan 1 with a minimum signal of 1000, isolation width of 2, normalized collision 
energy of 35, default charge state of 1, activation Q of 0.250, and an activation time of 
30 min. The samples were evaluated with Thermo Xcalibur software (version 2.1.0) 
and Agilent Mass Profiler Professional (version B.12). Signal peak intensities of 
metabolites from L. casei in cocoa-MRS solution were compared with the peak 
intensities values in MRS broth. Glutamic acids were used and analyzed as control. 
Relative intensity of each component was converted by normalized peak values. Peak 
annotations were made by querying the Human Metabolite Database (HMDB, 






Statistical Analysis. Data were analyzed by the Statistical Analysis System software. 
The one-way analysis of variance following by Tukey's test were used to evaluate the 
treatments and determine the significant differences on single time point among the 
control and the treatments based on significant level of 0.05. 
 
Results 
Comparative growth of L. casei, L. plantarum, and L. rhamnosus in MRS broth with 
and without cocoa powder. The stimulatory effect of cocoa powder on beneficial 
Lactobacillus strains was evaluated in liquid cultures and measured by the plate 
counting method. The effect of cocoa powder on the growth of L. casei, L. rhamnosus, 
and L. plantarum is shown in Figure 2-1. In the presence of 3% cocoa powder, the 
growth of all three Lactobacillus strains significantly increased (0.27 CFU/mL for L. 
casei, 0.61 CFU/ mL for L. rhamnosus, and 0.36 CFU/mL for L. plantarum) in MRS 
broth at 24 h. However, as the living numbers of Lactobacillus in control condition 
decreased after 24 h, cocoa showed different effects depending on the strains. The 
growth of L. casei (Figure 2-1A) and L. rhamnosus (Figure 2-1B) was continuously 
increased after 24 h, whereas growth stimulation of cocoa powder on L. plantarum 
(Figure 2-1C) became insignificant. Among the Lactobacillus strains, L. casei was most 
affected by cocoa powder in MRS broth as it was stimulated by more than 1 log 






Growth stimulation of Lactobacillus strains and various milk resident bacteria in whole 
milk and skim milk supplemented with cocoa powder. The effect of 3% cocoa powder 
in whole milk and skim milk on the growth of three Lactobacillus strains (L. casei, L. 
rhamnosus, and L. plantarum) as well as different resident bacterial strains including 
L. acidophilus, B. subtilis, E. faecalis, and S. thermophilus were investigated. The 
stimulatory effect of cocoa powder on Lactobacillus strains is shown in Figure 2-2. 
Cocoa powder (3%) in both whole milk and skim milk exhibited a significant and 
continuous growth stimulatory effect on all three Lactobacillus strains at 24, 48 and 72 
h time points. We observed a greater than 1 log CFU/mL increase at the 24 h time point 
for all three strains in whole milk. Furthermore, cocoa powder in milk had a longer 
lasting growth stimulating effect (more than 1 log CFU/mL) on L. plantarum (Figure 
2-2C) compared with it in MRS broth (Figure 2-1C). 
The overall effect of 3% cocoa powder on all four resident bacteria is shown in 
Figure 2-3. We found significant and continuous growth stimulatory effect of cocoa in 
whole milk on all these four resident bacterial strains at different time points (24, 48 
and 72 h). Among these bacterial strains, the maximum growth promotions were 
observed for L. acidophilus (Figure 2-3A) which was promoted by 1 log CFU/mL 
within 72 h and E. faecalis (Figure 2-3C) whose growth was also stimulated by 1 log 
CFU/mL within 48 h in the presence of cocoa in milk. 
 
Growth inhibition of EHEC, S. Typhimurium and L. monocytogenes by cocoa powder. 
Antimicrobial activity of cocoa powder against selected foodborne bacterial pathogens 





powder in LB broth on three of the most common foodborne pathogens, EHEC, S. 
Typhimurium, and L. monocytogenes is shown in Figure 2-4. The growth of each 
pathogen was significantly (p < 0.05) reduced during the first 9 h of incubation with 
cocoa powder. With 3 more hours extended incubation, cocoa powder continues to 
exhibit significant inhibitory effect on EHEC (Figure 2-4A). Cocoa reduced the growth 
of EHEC (Figure 2-4A) and S. Typhimurium (Figure 2-4B) by more than 1 log 
CFU/mL during the first 6 h, however after 12 h of incubation, the effect was attenuated. 
Growth of L. monocytogenes was reduced by cocoa powder by 0.3 logs CFU/mL (p < 
0.05) during the first 9 h, however after 9 h this reduction was minimized to be 
neglected (Figure 2-4C). No statistically significant growth promotion was found in 
three pathogens within 72 h. 
 
Comparative growth of L. casei, L. rhamnosus, and L. plantarum in the presence and 
absence of peanut flour and skin extract in MRS broth. Growth conditions of 3 
beneficial Lactobacillus strains were evaluated in MRS broth in the presence and 
absence of 0.5% peanut flour or peanut skin extract. Comparative growth of L. casei, 
L. rhamnosus, and L. plantarum between control and treatments is shown in Figure 2-
5. In the presence of 0.5% peanut flour, out of the 3 strains of Lactobacillus, L. casei 
(Figure 2-5A) and L. rhamnosus (Figure 2-5B) were stimulated at 24, 48, and 72 h time 
points of incubation in MRS broth. Out of these 2 strains, the most intensive stimulatory 
effect was found on L. casei, whose growth was promoted by more than 1 log CFU/mL 
within 72 h. However, peanut flour had no significant effect on the growth of L. 





(Figure 2-5C). In the same study, it was found that L. casei, L. rhamnosus, and L. 
plantarum were significantly inhibited by >2 log CFU/mL at 24, 48, and 72 h time 
points in MRS broth supplemented with 0.5% peanut skin extract (Figure 2-5). 
 
Growth of Lactobacillus strains in milk supplemented with peanut skin extract. In order 
to further investigate the growth inhibitive effect of 0.5% peanut skin extract, the 
growth of 3 beneficial Lactobacillus strains were also examined in whole milk which 
serves as a natural reservoir for Lactobacillus. Time-dependent comparative growth 
performance of L. casei, L. rhamnosus, and L. plantarum in the presence of peanut skin 
extract between controls and treatments are shown in Figure 2-6. Lactobacillus strains 
showed overall better and longer growth in whole milk compared to MRS broth after 
48 h. However, the growth of all 3 strains of Lactobacillus was significantly inhibited 
by 0.5% peanut skin extract in whole milk. The growth of L. casei (Figure 2-6A), L. 
rhamnosus (Figure 2-6B), and L. plantarum (Figure 2-6C) was inhibited by >2 log 
CFU/mL at 24, 48, and 72 h time points in the presence of 0.5% peanut skin extract in 
whole milk, compared to growth in whole milk alone. 
 
Effect of peanut flour or peanut skin extracts on growth of EHEC, S. Typhimurium, 
and L. monocytogenes. The antimicrobial properties of 0.5% peanut flour and 0.5% 
peanut skin extract against selected foodborne bacterial pathogens (EHEC, S. 
Typhimurium, and L. monocytogenes) were evaluated in liquid cultures. Among these 
selected 3 enteric bacterial pathogens, 0.5% peanut flour only showed inhibitory effect 





EHEC in the presence of 0.5% peanut flour was significantly inhibited by a range of 
0.5 to 1 log CFU/mL. However, 0.5% peanut flour exhibited no significant negative 
effect on the growth of S. Typhimurium (Figure 2-7B) or L. monocytogenes (Figure 2-
7C) within 72 h. On the contrary, EHEC (Figure 2-7A) and S. Typhimurium (Figure 2-
7B) were stimulated slightly by 0.5% peanut skin extract within 72 h. Peanut skin 
extract only showed inhibitory effect on L. monocytogenes (Figure 2-7C). 
 
Total phenolic compounds concentration in 3% cocoa. Total phenolic content was 
estimated by using Folin-Ciocalteu reagent, determined from the supernatant part 
obtained from 3% cocoa-water solution, and expressed as mg/mL GAE. Based on 
triplicate measurement, concentration of phenolic compounds in 3% cocoa was 0.848 
± 0.068 mg/mL GAE. 
 
HPLC-MS based analysis of metabolites from L. casei in cocoa solution. After the 
structural match based on HMDB database, total of 350 compounds in 3% cocoa-MRS 
solution, 284 compounds from supernatant of L. casei overnight culture in MRS broth, 
and 284 compounds from supernatant of L. casei overnight culture in MRS broth 
supplemented with 3% cocoa were identified by LC-MS/MS analysis (lists showed in 
supplemental data). Table 2-1 summarizes some of the bio-active metabolites of L. 
casei identified in 3% cocoa solution with their classes, known biological functions, 
and relative intensities. They belong to steroids (Androsterone and Corchorusoside B), 
disaccharides (1-(3-Methylbutanoyl)-6-apiosylglucose, and Methyl cellulose), indoles 





lineolic acid, and Nigellidine), and Glycerophospholipid (LysoPC (18:0)) classes and 
were potential nutrients. Six possible antimicrobial compounds (Epicatechin, Quercetin 
3-galactoside, Rubraflavone D, 20,4-Dihydroxy-40,60-imethoxy-30-prenylchalcone, 
Glicoisoflavanone, and 3-Hydroxyglabrol) which belong to the class of flavonoids were 
also identified. Two compounds (Benzoic acid and Benzonatate) are benzoic acid and 
its derivative, among which Benzoic acid and 3-Hydroxyglabrol have already been 
recognized as antimicrobials. Citrusin E originated from lemon peel were also detected. 
 
Discussion 
Previous reports have demonstrated that phenolic compounds from plant products 
could inhibit the growth of several harmful bacteria such as S. Typhimurium 
(Puupponen-Pimiä et al., 2005) and EHEC (Bubonja-Sonje et al., 2011). Resveratrol, 
one of the known compound of polyphenol, has been shown to extend the doubling 
time of multiple bacterial pathogens including S. Typhimurium, S. Enteritidis, E. coli, 
and so on (C. M. Jung, Heinze, Strakosha, Elkins, & Sutherland, 2009). In our study, 
the growth of the Gram-negative foodborne pathogen EHEC was inhibited by nearly 1 
log CFU/mL within 48 h of incubation in the presence of peanut flour, and the Gram-
positive foodborne pathogen L. monocytogenes was inhibited by more than 1 log 
CFU/mL at 24 h by use of peanut skin extract. Moreover, significant growth inhibition 
against both EHEC and L. monocytogenes was found within 72 h. This study indicates 
that components of peanut flour and peanut skin exhibit both different scopes and 
efficacies of antimicrobial effects depending on bacterial species. However, the growth 





opportunities to survive or multiply in peanut products especially unblanched peanut 
butter. 
We also observed that the growth of L. casei and L. rhamnosus were 
continuously and significantly stimulated up to 72 h by 0.5% peanut flour. This result 
agreed with the previous research of Salaheen et al., (2014), which suggested that the 
production of fatty acids, one growth factor for Lactobacillus, was promoted by water-
soluble peanut flour fractions. However, in our study, no significant stimulatory effect 
on L. plantarum was observed within 72 h incubation in MRS broth supplemented with 
peanut flour. The possible explanation might be based on padA gene, a substrate-
inducible gene responsible for phenolic acid decarboxylase enzyme expression, which 
counteract the promotive effect on this special Lactobacillus (Gury, Barthelmebs, Tran, 
Diviès, & Cavin, 2004). In the same study, we also evaluated the growth of 3 
Lactobacillus strains in both MRS broth and whole milk supplemented with 0.5% 
peanut skin extract. Our data indicated that the growth of all 3 Lactobacillus strains 
was drastically reduced by peanut skin extract within 72 h, no matter whether in broth 
or milk compared with in controls. Based on study in 2005, peanut skins are considered 
as having no adverse effects and would qualify as a GRAS (generally recognized as 
safe) product (Yu, Ahmedna, & Goktepe, 2010). Beside safety, peanut skins extract 
possess even much greater in vitro antioxidant properties than vitamin C and vitamin 
E (Yu et al., 2010). However, no previous study has examined the role of peanut skins 
play on growth of beneficial bacteria. In general, our finding indicates that components 





is needed to know how peanut skin extract and its compounds inhibit the growth of 
Lactobacillus. 
This study also describes the potential role of cocoa in promoting growth of 
probiotics. Previous study on polyphenolic compounds-containing beverages like berry 
juices demonstrated the promotive effect on the growth of probiotic bacteria including 
Lactobacillus (Puupponen-Pimiä et al., 2005; Lacombe et al., 2012; H. Yang et al., 
2014). Similarly, in this study, we observed that the growth of 4 Lactobacillus strains 
and 3 other milk resident bacteria were all generally promoted by cocoa powder. Study 
on the relationship between polyphenol-rich diet and gut microbiota composition 
(Etxeberria et al., 2013; Hervert-Hernández, Pintado, Rotger, & Goñi, 2009; Parkar, 
Stevenson, & Skinner, 2008), and research about cocoa on modulating fecal microbiota 
(Massot-Cladera et al., 2012) give some clues that the presence of polyphenol 
compounds as well as nutritious components like disaccharides and indoles in cocoa 
detected by LC-MS/ MS might be the reason for probiotic bacterial growth stimulation 
in our observation. No significant stimulatory effect on L. plantarum was observed after 
24 h incubation in MRS broth supplemented with cocoa powder. A substrate-inducible 
padA gene in L. plantarum encoding for a phenolic acid decarboxylase enzyme capable 
of converting phenolic compounds into several derivatives (Gury et al., 2004) might be 
one possible explanation for no significant growth stimulation after 24 h in MRS broth 
supplemented with cocoa. Although milk is known to provide more abundant nutrients, 
the reason for different stimulatory abilities of cocoa in MRS broth and milk medium 
warrants further investigation. In the same study, four resident bacteria (L. acidophilus, 





growth promotion in whole milk supplemented with 3% cocoa powder. These results 
supported the idea of using cocoa as a probiotic growth stimulus in milk and dairy 
products, which could benefit human health after consuming. 
Flavonoid compounds of plant origin have gained considerable attention due to 
their functional and nutritional benefits including anti-inflammatory, antimicrobial 
activity and some other beneficial effects (Cooper et al., 2007; Cushnie & Lamb, 2005; 
M. Kim et al., 2010). Cocoa rich in flavonoids were believed to act as antimicrobials 
by depriving substrates required for microbial growth, inhibiting extracellular 
microbial enzymes, or inhibiting oxidative phosphorylation (Kanazawa et al., 2005). 
This study demonstrates the short-time inhibitory effects of cocoa against two Gram-
negative foodborne pathogens (EHEC and S. Typhimurium) and a Gram-positive 
pathogen (L. monocytogenes), which is parallel with previous reports that have already 
indicated the role of flavonoids and phenolic compounds in cocoa as well as other plant 
products in inhibition of the growth of harmful bacteria (Bubonja-Sonje et al., 2011; 
Puupponen-Pimiä et al., 2005; Vargas et al., 2013). However, the evidence in our study 
only suggests that cocoa powder may be active against both Gram-negative and Gram-
positive foodborne pathogens for the first 9 h. In accordant with previous study, the 
minimum inhibitory concentrations (MICs) of blueberry and blackberry pomace 
extract on Campylobacter jejuni are 0.4 and 0.6 mg/mL GAE (Serajus Salaheen, 
Nguyen, et al., 2014). Based on total phenolic content estimated by Folin-Ciocalteu in 
this study, 3% cocoa contains 0.848 ± 0.068 mg/ mL GAE, which is high enough for 
antimicrobial activities. However, attenuated inhibitory ability against bacterial 





provided as extra sources for pathogens with limited carbon sources, which acts as 
growth promoting agents, neutralizing the effect of antimicrobials (including phenolic 
compounds and flavonoids) in cocoa. In addition, in accordance with the potential 
antimicrobial agents in cocoa analyzed by LC-MS/MS in this study, synergistic 
application of flavonoids, benzoic acids and derivatives, and citrus-derivative 
compounds are promising to be combined in order to reduce the level of foodborne 
illness as well as minimizing the wide spread of multidrug resistant bacteria. 
 
Conclusions 
1. Bio-active steroids, indoles, indazoles, and glycerophospholipid ingredients found 
in cocoa/peanut provided extra nutrients on probiotics; antimicrobial components like 
flavonoids, benzoic acids, and citrusin were detected in cocoa/peanut. 
2. Cocoa and peanut flour stimulated the growth of multiple Lactobacillus strains. 
However, peanut skin induced negative effects on growth of Lactobacillus. 













Figure and Table list 
 
Figure 2-1. Effect of cocoa on bacterial growth in MRS broth. L. casei (A), L. 
rhamnosus (B), and L. plantarum (C) strains were grown with 3% cocoa powder in 
MRS broth, and sampled at 0, 24, 48, and 72 h for the growth measurements. Asterisks 






Figure 2-2. Effect of cocoa on bacterial growth in milk. L. casei (A), L. rhamnosus (B), 
and L. plantarum (C) were grown in either whole milk or skim milk with or without 3% 
cocoa powder, and sampled at 0, 24, 48, and 72 h. Asterisks (*) indicate significant 






Figure 2-3. Growth stimulation of Lactobacillus acidophilus (A), Bacillus subtilis (B), 
Enterococcus faecalis (C), and Streptococcus thermophilus (D) in whole milk with or 
without 3% cocoa powder. Cultures were sampled at 0, 24, 48, and 72 h for growth 
measurements. Error bars indicate standard deviation. Asterisks (*) indicate significant 














Figure 2-4. Cocoa inhibits growth of enteric pathogenic bacteria. EHEC (A), S. 
Typhimurium (B), and L. monocytogenes (C) were grown in strain-specific broth with 
or without 3% cocoa powder. Bacterial CFU were counted at 0, 3, 6, 9, 12, 24, 48, and 






Figure 2-5. Growth stimulation by 0.5% peanut flour and inhibition by 0.5% peanut 
skin extract on L. casei (A), L. rhamnosus (B), and L. plantarum (C) in MRS broth at 
0, 24, 48, 72 h. Error bars indicate standard deviation. Different letters within a time 






Figure 2-6. Growth inhibition of L. casei (A), L. rhamnosus (B), and L. plantarum (C) 
in MRS broth, whole milk, and whole milk with 0.5% peanut skin extract at 0, 24, 48, 
72 h. Error bars indicate standard deviation. Different letters within a time point 






Figure 2-7. Growth conditions of EHEC (A), S. Typhimurium (B), and L. 
monocytogenes (C) in LB broth, with 0.5% peanut flour, and with 0.5% peanut skin 
extract at 0, 24, 48, 72 h. Error bars indicate standard deviation. Different letters within 









Compound name Class Biological Functions Relative Intensities*
Epicatechin Flavonoids Not available 0.016
Quercetin 3-
galactoside
Flavonoids Not available 0.066









































Indoles Nutrient supply 1.630
3-Methylene-indolenine Indoles Nutrient supply 1.658
Nigellidine Indazoles Nutrient supply 1.935
Glicoisoflavanone Flavonoids Nutrient supply 7.845






Table 2-1. Some putative bio-active components identified in cocoa/peanut by HPLC-MS





Chapter 3: Synergistic effects of prebiotic-like cocoa/peanut and 
Lactobacillus in control of enteric bacterial pathogens 
 
Introduction 
The Center for Disease Control and Prevention estimated that 48 million illnesses, 
128000 hospitalizations, and 3000 deaths are caused by foodborne pathogens (D. 
Adams et al., 2017). Among bacterial pathogens, EHEC, Salmonella, and L. 
monocytogenes are the leading causes of foodborne illness and deaths in the US (K. J. 
Cummings et al., 2012; Dussurget, 2008; Teunis et al., 2008). Consequently, their 
prevention and growth inhibition are of great concern to public health professionals, 
farmers, and food producers. Antibiotics are commonly used either orally through 
drinking water or as feed additives (M Peng et al., 2014) for control of zoonotic 
pathogen colonization in gut of farm animal including cattle, swine, and chicken 
(Scallan et al., 2011). However, it was demonstrated to worsen the niche for beneficial 
gut microflora (Andersson & Hughes, 2010) and accelerate the drug-resistance in 
human pathogens (DeWaal et al., 2013). Therefore, there is increasing interest in use 
of dietary supplement, especially prebiotics, to modulate the composition of the colonic 
microflora. The promotion of the growth of probiotics by prebiotics including 
prebiotic-like components like cocoa and peanut, in turn, is hypothesized to inhibit or 
even exclude the harmful bacteria like foodborne bacterial pathogens (Glenn R. Gibson, 
Probert, Loo, Rastall, & Roberfroid, 2004b). 
To colonize in the human GI tract, all foodborne pathogens must compete with 





microbiota are colonized (Sullivan & Nord, 2002). Probiotic such as lactic acid bacteria 
(LAB) are known to play crucial roles in maintaining the microbial ecosystem of 
human GI tract by preventing colonization and infection of incoming bacterial 
pathogens (Campana, Federici, Ciandrini, & Baffone, 2012; Maldonado Galdeano & 
Perdigón, 2006; Servin & Coconnier, 2003). Though the molecular basis has not been 
fully understood, possible mechanisms of the protection against pathogens by 
probiotics include stimulating innate and acquired immune response of human 
intestinal cell (Neeser et al., 2000; Reid & Burton, 2002), direct antimicrobial effects 
(Van de Guchte, Ehrlich, & Maguin, 2001), and competition in receptor mediated 
colonization to cell hosts (Sherman, Bennett, Hwang, Sherman, & Bevins, 2005). 
Moreover, (Medellin-Peña et al. (2007) hypothesized that intestinal bacteria in 
different genera may all use quorum sensing as regulatory system for the control of 
virulent genes of foodborne pathogens. They also found that secreted compounds of L. 
acidophilus inhibited the production of AI-2 molecules of EHEC O157 as well as 
altered flagella synthesis and motility of the pathogen. Therefore, it is possible that 
probiotics in the human intestine, particularly in the large intestine, influence the 
virulence gene expression of other non-resident bacteria through their quorum sensing 
system, and thus prevent the pathogenic bacterial infection by affecting or limiting 
bacterial motility, flagella assembly, specific protein synthesis and secretion, and other 
pathogenic mechanisms (Sperandio, Li, & Kaper, 2002). Meanwhile, increased 
interests have been put on investigating the role of probiotic bacteria for maintaining 
human health and personal hygiene, including oral health, GI tract health and vaginal 





2014; Parvez, Malik, Ah Kang, & Kim, 2006; Wannun, Piwat, & Teanpaisan, 2014). 
These health promoting activities by LAB have been proposed to be associated with 
their growth inhibiting effect against human pathogens. 
Recent research on LAB revealed their abilities of multiple antimicrobial 
production (D. Sharma & Singh Saharan, 2014), which suggests the selection of certain 
Lactobacillus strains as promising biological preservatives against foodborne bacterial 
pathogens. Antimicrobial compounds produced by LAB include organic acids, 
hydrogen peroxide, diacetyl, SCFAs, small peptide inhibitors, bacteriocins, and bio-
surfactants, among which bacteriocins have been recognized as the most potent agent 
(Miao et al., 2014; D. Sharma & Singh Saharan, 2014). Nisin for example, produced 
by Lactococcus lactis, has been approved by the US FDA since last decade for food 
preservation and shelf life extension (Collins, Guinane, Cotter, Hill, & Ross, 2012). 
The most common application of L. casei, the resident bacteria in human intestine and 
mouth, is for dairy production such as yogurt, cheese, and ice cream. Recently, an 
extensive study has been focused on the use of L. casei in preventing AAD and 
Clostridium difficile infections (McFarland, 2009). In addition, L. casei has been 
suggested to be effective in alleviating GI pathogenic bacterial infections both in vitro 
and in vivo (Chung & Yousef, 2010; Forestier, De Champs, Vatoux, & Joly, 2001; 
Wong et al., 2014), and there is no evidence of any pathogenic behavior on human and 
animals. 
The most common application of L. casei, the resident bacteria in human 
intestine and mouth, is for dairy production such as yogurt, cheese, and ice cream. 





and Clostridium difficile infections (McFarland, 2009). In addition, L. casei has been 
suggested to be effective in alleviating GI pathogenic bacterial infections both in vitro 
and in vivo (Chung & Yousef, 2010; Forestier et al., 2001; Wong et al., 2014), and there 
is no evidence of any pathogenic behavior on human and animals. Furthermore, our 
previous study also suggested that potential components (disaccharides and indoles) in 
cocoa powder could stimulate the growth of L. casei in both MRS broth and milk media 
(Mengfei Peng, Aryal, Cooper, & Biswas, 2015a). 
Based on the latent beneficial properties reported previously, we aimed to 
examine the combined growth inhibitory effect of L. casei and cocoa on common 
foodborne pathogens and to investigate the capacities of this probiotic strain combined 
with prebiotic-like cocoa/peanut in reducing host cell (INT-407) and pathogen 
interactions at cellular level. In addition, for better understanding of the reduced host 
cell-pathogen interactions, investigation of their role on expression of foodborne 
bacterial virulent genes related to flagellation, motility, and cell-specific binding is 
included as well. 
 
Material and Methods 
Bacterial strains and growth conditions. L. casei (ATCC 334) was grown on MRS agar 
overnight at 37 °C under aerobic condition with 5% CO2 (Thermo Fisher Scientific Inc., 
Waltham, MA, USA). Three foodborne bacterial pathogens Enterohemorrhagic E. coli 
EDL933 (ATCC700927), Salmonella enterica serovar Typhimurium LT2 





MacConkey agar, LB agar, and BHI agar (EMD Chemicals Inc., Gibbstown, NJ, USA), 
respectively, overnight at 37 °C under aerobic conditions (Thermo Fisher Scientific). 
 
Cocoa powder and peanut flour/skin preparation. Commercial, non-alkali treated cocoa 
was purchased at the local supermarket. Cocoa powder was defatted with hexane for 
18 h and the residual hexane was evaporated from the cocoa powder before use. The 
defatted cocoa powder was stored at 4 °C and sterilized 2 h under ultraviolet light 
before experimental use. In shell Jumbo Virginia raw peanut was purchased from a 
local market and shelled by hand to isolate the kernel fractions. Peanut skin was 
removed by hand and the white kernel was ground to form peanut flour. Both peanut 
skin and peanut flour were defatted by 2 extractions with n-hexane (n-hexane: peanut 
portion 10 mL/g) for 12 h at room temperature (25 °C). Peanut flour and peanut skin 
fraction suspensions were prepared in sterilized distilled water (pH adjusted to 8.0 with 
1 N NaOH), mixed well and sterilized with UV irradiation for 2 h. Cocoa powder or 
peanut portion was mixed in MRS broth. The cocoa/peanut-MRS solution was used for 
HPLC-MS analysis. 
 
Cell lines and culture conditions. Human intestinal epithelium cell line (INT-407 CCL-
6) was purchased from American Type Culture Collection and cultured following the 
method described by Peng, Bitsko and Biswas (2015) with slight modification. Briefly, 
cells were grown at standard condition (37 °C, 5% CO2, 95% humidity) in Dulbecco’s 
modified Eagle medium (DMEM; HyClone Laboratories Inc., Logan, UT, USA) 





cultured cells were seeded at approximately 2 × 105 cells/mL into 24-well tissue culture 
plates (BD Falcon, Franklin Lakes, NJ, USA) to reach 80-90% confluence monolayer 
at standard condition. The post-confluent INT-407 epithelial cell monolayers were 
rinsed with PBS and stabilized in antibiotic-free DMEM for 1 h prior to the invasion 
assay. 
 
Mixed culture of L. casei with foodborne pathogens. L. casei, EHEC EDL933, S. 
Typhimurium LT2, and L. monocytogenes LM2 bacterial cells were collected from 
overnight agar plate culture. A volume of 400 L L. casei bacterial suspension containing 
107 CFU/mL was mix-cultured with same amount of EHEC EDL933, S. Typhimurium 
LT2, or L. monocytogenes LM2, respectively, in 3.6 mL LB/MRS (1:1, v/v) broth in 
the presence or absence of 3% cocoa powder at 37 °C under aerobic condition. Serial 
dilutions were performed in PBS, followed by plating on MRS agar (L. casei), 
MacConkey agar (EHEC EDL933), Xylose Lysine Deoxycholate (XLD) agar (S. 
Typhimurium LT2), and Oxford Listeria agar base (L. monocytogenes LM2) at 0, 12, 
24, 36, and 48 h time points. 
 
Cell free culture supernatant (CFCS) of L. casei on growth of foodborne pathogens. 
Fresh overnight (18 h) liquid cultures of L. casei in MRS with or without 3% cocoa 
were centrifuged at 4000 × g for 20 min. CFCSs were collected and filtered by sterile 
syringe 0.2 μm filter (VWR). Filtered CFCS from L. casei (CFCS1) and filtered CFCS 
from cocoa supplemented L. casei (CFCS2) were collected and stored at 4 °C. A cell 





or L. monocytogenes LM2 was inoculated in separate culture tubes with 3.6 mL 
LB/MRS broth (1:1, v/v), LB/MRS broth (1:1, v/v) with 3% (w/v) cocoa powder, 
LB/CFCS1 (1:1, v/v), or LB/CFCS2 (1:1, v/v), respectively and cultured at 37 °C under 
aerobic condition. Serial dilutions were performed in PBS, followed by plating on 
specific agars mentioned above for different pathogens at 0, 4, 8, 24, and 48 h time 
points. 
 
CFCS sensitivity to pH, heat, and enzymes. The pH of CFCS was adjusted from 4.87 
either to 1.0, 2.0, 3.0, and 4.0 with 10 M HCl or to 5.0, 6.0, 7.0, 8.0, 9.0, and 10.0 with 
10 M NaOH measured by FiveEasy™ pH meter (Mettler Toledo, Columbia, MD, 
USA). After overnight incubation at 4 °C, all pH was adjusted back to 4.87 for further 
assay. Thermal treatment of CFCS was conducted by incubating CFCS at 40, 60, 80, 
or 100 °C in a water bath (Isotemp, Thermo Fisher Scientific) for 30 min, and then 
cooled down at room temperature (25 °C) for further assay. Enzymatic treatments on 
CFCS were conducted at original pH value (4.87) by using of catalase (25 °C), 
proteinase K (50 °C), and/or trypsin (25 °C) (Sigma-Aldrich) at a final enzyme 
concentration of 1 mg/mL. EHEC EDL933 was used as indicator strain for multiple 
antimicrobial activity tests. The MIC was evaluated using broth micro-dilution method 
described previously (Nkanwen, Gatsing, Ngamga, Fodouop, & Tane, 2009). Briefly, 
CFCS ranging from 1:1 to 1:128 dilutions in LB broth were used as medium for growth 
of bacteria. An aliquot of 2 μL of bacterial suspension containing approximately 107 
CFU/mL was added into 198 μL medium in 96-well plate (Greiner Bio-One Inc., 





MIC was determined as the lowest dilution of CFCS that prevented visible growth of 
EHEC EDL933 compared with control, and it was recorded in the form of arbitrary 
unit per mL (AU/mL). 
 
Cell adhesion and invasion assay. We performed the adherence and invasion assays 
following the methods described previously by Peng, Bitsko and Biswas (2015) with 
some modification. Briefly, the INT407 cells grown in 24-well plate with 800 μL 
DMEM containing 10% FBS were pre-treated with 100 μL DMEM (control), 3% cocoa, 
2 × 106 CFU/mL L. casei, CFCS1, or CFCS2 separately for 1 h, with each treatment in 
triplicate. A 100 μL aliquot of EHEC EDL933, S. Typhimurium LT2, or L. 
monocytogenes LM2 with multiplicity of infection (MOI) of about 10 (2 × 106 CFU/mL) 
were inoculated into triplicate wells. Infected cells were incubated at standard condition 
for 2 h and washed three times with DMEM containing 10% FBS. The monolayers 
were lysed by 0.1% Triton X-100 for 15 min, serial diluted, and plated on specific agars 
for adhesive bacterial CFU counting. Cell invasive activity was measured by further 1 
h incubation of the washed monolayers in DMEM containing 10% FBS and 100 g/mL 
gentamicin followed by three-times washing, Triton X-100 lysis, serial dilution, and 
plating on specific agars. 
 
Evaluation of hydrophobicity of foodborne pathogens treated with CFCSs. Cell surface 
hydrophobicity was determined in accordance with the methods described previously 
(Ahn, Almario, Salaheen, & Biswas, 2014; Serajus Salaheen, Nguyen, et al., 2014) with 





monocytogenes LM2 was cultured overnight (18 h) in 5 mL LB broth and treated with 
equal volume (5 mL) of LB broth, MRS broth, CFCS1, and CFCS2 separately for 4 h 
at 37 °C under aerobic condition. Cells were collected and resuspended in pH 7.4 PBS 
to adjust the OD to 0.5 (Ht0) under 570 nm wavelength. One volume cell suspension 
was mixed with 2 volumes of n-hexadecane (Sigma-Aldrich), vigorously vortexed, and 
incubated at room temperature for 5 min. The aqueous phase was collected and the OD 
(Ht5) was measured at 570 nm by microplate reader (Multiskan FC, Thermo Scientific 
Inc., Odessa, TX, USA). The hydrophobicity value was calculated by the equation: 
Hydrophobicity (%) = (1 − Ht5/Ht0) × 100. 
 
RNA extraction and cDNA synthesis. The bacterial cell suspensions were rinsed three 
times with 5 mL ice-cold PBS. The cell pellets were lysed with 1 mL TRIzol reagent 
(Life Technologies Co., Carlsbad, CA, USA) for 5 min at room temperature. The cell 
lysates were mixed with 200 µL chloroform, vortexed vigorously, and then kept at room 
temperature for 3 min. After centrifugation at 13,000 × g for 15 min at 4 °C, the aqueous 
phase was collected and gently mixed with 500 µL of isopropanol, allowed to stand for 
10 min at room temperature, and then centrifuged at 13,000 × g for 15 min at 4 °C. The 
gel-like RNA pellet was washed with 1 mL 75% ethanol, vortexed 10 s, centrifuged at 
7000 × g for 5 min at 4 °C, and then air-dried in bio-safety cabinet for 10 min to remove 
the remaining ethanol. The RNA pellet was dissolved in 50 µL RNase-free water and 
quantified using a NanoDrop spectrophotometer (Thermo Fisher Scientific). Amount 
of 1 g of extracted RNA was mixed with 1 μL of RTS DNase and 5 µL of DNase buffer 





to remove genomic DNA. Then 5 μL RTS DNase Removal Resin was added and 
resuspended every 1 min up to 10 min to remove DNase. Supernatant containing RNA 
was transferred after 13,000 × g centrifugation for 1 min. The synthesis of cDNA was 
performed according to the qScript cDNA SuperMix protocol (Quanta Biosciences, 
Gaithersburg, MD, USA). The extracted RNA (1 µg) was mixed with qScript cDNA 
SuperMix (containing optimized concentrations of MgCl2, deoxyribonucleotide 
triphosphates, qScript reverse transcriptase, and RNase inhibitor protein). The reaction 
mixture was incubated subsequently at 25 °C for 5 min, 42 °C for 30 min, and 85 °C 
for 5 min. 
 
Quantitative RT-PCR assay. The PCR reaction mixture containing 10 µL of PerfeCTa 
SYBR Green FastMix, 2 µL of each primer (100 nM), 2 µL of cDNA (10 ng), and 4 
µL of RNase-free water were amplified using an Eco Real-Time PCR system (Illumine, 
San Diego, CA, USA) with 30 s denaturation at 95 °C, followed by 40 cycles of 95 °C 
for 5 s, 55 °C for 15 s, and 72 °C for 10 s. The custom-synthesized oligonucleotide 
primers (Erofins MWG Operon, Huntsville, AL, USA) for EHEC EDL933, S. 
Typhimurium LT2, and L. monocytogenes LM2 are summarized in Table 3-1. The 
relative transcription levels of target genes were estimated by the comparative fold 
change. The CT values of target genes in treated bacterial cells were compared to those 
in untreated bacterial cells and normalized to the housekeeping gene. 
 
Statistical Analysis. Data were analyzed by the Statistical Analysis System software. 





was used to evaluate the treatments and determine the significant differences among 
control and treatments based on significant level of 0.05. 
 
Results 
Competitively exclusion of foodborne pathogens in mixed culture. To determine the 
effect of probiotic and its byproducts on the growth of enteric bacterial pathogens, we 
co-cultured EHEC EDL933, S. Typhimurium LT2, or L. monocytogenes LM2 with L. 
casei in medium to support the growth of both bacteria. In this co-cultured or mixed 
culture condition, the growth of L. casei was only promoted slightly at a negligible 
level (p < 0.05) (Figure 3-1). In the same study, we found the growth of each of these 
bacterial pathogens drastically inhibited in the presence of L. casei (Figure 3-1). Two 
pathogens EHEC EDL933 and S. Typhimurium LT2 were completely excluded from 
the cultural medium by L. casei at 48 and 36 h, respectively (Figure 3-1A and B). 
Growth of L. monocytogenes LM2 was also reduced by 5.26 log CFU/mL at 48 h 
(Figure 3-1C). 
 
Distinct effects of peanut flour and peanut skin extract on growth of EHEC, S. 
Typhimurium, and L. monocytogenes in the mixed culture with L. casei. Growth 
conditions of these foodborne pathogens were determined in mixed culture with L. 
casei in the presence and absence of 0.5% peanut flour or 0.5% peanut skin extract. We 
found that EHEC (Figure 3-2A) and S. Typhimurium (Figure 3-2B) were completely 
excluded (below the limit of detection) from the medium by L. casei after 48 h. In the 





logs after 48 h of incubation in mixed culture with L. casei. In mixed culture with L. 
casei in the presence of 0.5% peanut flour, the same inhibitory patterns on the growth 
of these enteric bacterial pathogens were found, but peanut flour, by stimulating growth 
of L. casei, assisted in quickly reducing more EHEC (>0.5 log CFU/mL at 24 h) and S. 
Typhimurium (>1.0 log CFU/mL at 24 h). In contrast, in the presence of 0.5% peanut 
skin extract, L. casei with same amount of inocula only showed reduced inhibitory 
effects on growth of EHEC (Figure 3-2A) and S. Typhimurium (Figure 3-2B), whereas 
L. monocytogenes (Figure 3-2C) was completely excluded (below the limit of detection) 
after 48 h of incubation. 
 
Effect of CFCS on growth inhibition of enteric bacterial pathogens. Both CFCS1 and 
CFCS2 showed growth inhibitory effects on EHEC EDL933, S. Typhimurium LT2, 
and L. monocytogenes LM2 in a dose-dependent manner based on the amount of L. 
casei cells inoculated for collecting CFCSs. CFCS1 (pH = 4.87) and CFCS2 (pH = 
5.24), obtained from overnight culture started with the initial inocula of 106 CFU/mL 
(OD 0.1) and ended with 2 × 109 CFU/mL (CFCS1) and 1010 CFU/mL (CFCS2) final 
concentration of L. casei overnight inoculation, reduced 3.27 and 4.73 log CFU/mL 
EHEC EDL933 (Figure 3-3A), 4.31 and 5.12 log CFU/mL S. Typhimurium LT2 
(Figure 3-3B), 3.16 and 4.33 log CFU/mL L. monocytogenes LM2 (Figure 3-3C), 
respectively, at 48 h, compared with control in LB/MRS (1:1, v/v). In the same study, 
CFCS1 (pH = 4.61) and CFCS2 (pH = 5.12), collected from the overnight culture 
started with initial inocula of 107 CFU/mL (OD 1.0) and ended with 5 × 109 CFU/mL 





antimicrobial effects on the growth of all three enteric foodborne bacterial pathogens 
and both CFCS1 and CFCS2 were able to exclude all three foodborne pathogens within 
48 h (Figure 3-3). However, 3% cocoa only exhibited significant inhibitory effect on 
growth of EHEC EDL933 and S. Typhimurium LT2 within short time period (0.82 log 
CFU/mL EHEC reduction at 4 h, 0.70 log CFU/mL EHEC EDL933 reduction at 8 h, 
and 0.70 log CFU/mL S. Typhimurium at 4 h). 
 
Characterization of CFCS antimicrobial activity. The effects of pH, heat, and enzyme 
treatments on antimicrobial activity of CFCS are summarized in Table 3-2. Original 
collected CFCS with pH value of 4.87 at room temperature (25 °C) (control) exhibited 
strong (>50 AU/mL) antimicrobial activity on EHEC. HCl treatment on CFCS 
maintained its antimicrobial activity, whereas NaOH treatment reduced the 
antimicrobial activity of CFCS. CFCS showed moderate (>5 AU/mL) antimicrobial 
activity when first adjusted to pH from 6.0 to 8.0 for incubation and then converted 
back to pH 4.87, whereas no antimicrobial property was detected when pH value first 
adjusted higher than 9.0. CFCS remained its strong (>50 AU/mL) antimicrobial activity 
with 30 min incubation at both 40 and 60 °C. However, when the thermal treatment 
increased to 80 and 100 °C, antimicrobial activity of CFCS was reduced to moderate 
(>5 AU/mL). Moreover, three kinds of enzymatic treatments (catalase, proteinase K, 
and trypsin) on CFCS all decreased its antimicrobial activity but remained within 
detectable level (>5 AU/mL). Combined enzymatic treatments of catalase and 






Alteration of bacterial cell surface hydrophobicity. In the presence of 3% cocoa, 
CFCS1, and CFCS2, the cell surface hydrophobicity values of EHEC EDL933, S. 
Typhimurium LT2, and L. monocytogenes LM2 were decreased significantly (Table 3-
3). In comparison with control, L. monocytogenes LM2 cells treated with 3% cocoa 
significantly reduced the cell surface hydrophobicity value by 28.50%, whereas no 
significant change in EHEC EDL933 and S. Typhimurium LT2 was observed. In the 
same study, EHEC EDL933, S. Typhimurium LT2, and L. monocytogenes LM2 cells 
treated with CFCS1 showed significant reduction of cell surface hydrophobicity by 
55.63, 52.06, and 55.72% folds, respectively; similarly, EHEC EDL933, S. 
Typhimurium LT2, and L. monocytogenes LM2 cells with CFCS2 treatment decreased 
the hydrophobicity values much effectively by 79.62, 74.30, and 78.37% folds, 
respectively. 
 
Reduction in pathogen-host cell interactions. Pre-treatment with 3% cocoa, L. casei 
cells, CFCS1, and CFCS2 reduced the pathogenic cell adhesive and invasive activities 
of three enteric bacterial pathogens (Figure 3-4). In this study, we observed that 3% 
cocoa reduced the adherence and invasive abilities of EHEC EDL933 by 77.58 and 
97.23%, S. Typhimurium LT2 by 93.41 and 100%, and L. monocytogenes LM2 by 
37.41 and 100%, respectively. In the same study, we found that pre-treatment with L. 
casei cells could also competitively inhibit the pathogen-host cell interactions. For 
EHEC EDL933, S. Typhimurium LT2, and L. monocytogenes LM2, 62.12, 68.51, and 
58.53% of cell-adhesive activities as well as 77.50, 93.97, and 79.85% of cell-invasive 





three foodborne pathogens (56.40% for EHEC EDL933, 85.28% for S. Typhimurium 
LT2, and 24.11% for L. monocytogenes LM2) and invasion abilities of S. Typhimurium 
LT2 (92.25%) and L. monocytogenes LM2 (95.86%). Furthermore, CFCS2 showed 
more intensive effect compared with CFCS1, in which adhesion abilities of EHEC 
EDL933, S. Typhimurium LT2, and L. monocytogenes LM2 were reduced by 80.81, 
97.35, and 30.47%, respectively. We also found that in the presence CFCS2, invasion 
abilities of EHEC EDL933, S. Typhimurium LT2 and L. monocytogenes LM2 were 
reduced by 98.98, 100, and 100%, respectively. 
Pretreatment with peanut fractions or in the presence of L. casei reduced 
significantly the adhesion to and invasion into INT-407 cells by these enteric bacterial 
pathogens (Figure 3-5). We observed that pretreatment with 0.5% peanut flour 
significantly (p < 0.05) reduced the adherence ability of EHEC, S. Typhimurium, and 
L. monocytogenes to INT-407 cells by 89.9%, 86.5%, and 40.3%, respectively. 
Likewise, 0.5% peanut skin extract also significantly (p < 0.05) reduced the adhesion 
abilities of these 3 foodborne pathogens by 90.1%, 84.7%, and 54.9%, respectively. 
Pre-incubation of L. casei showed attenuated inhibitive effects, which reduced the 
adhesive level of EHEC, S. Typhimurium, and L. monocytogenes by 51.5%, 66.7%, 
and 61.0%, respectively. However, the combine effect, pretreated with L. casei and 0.5% 
peanut flour, further enhanced the inhibitive capability on pathogens’ adhesion ability 
up to 94.2% for EHEC, 97.2% for S. Typhimurium, and 83.8% for L. monocytogenes. 
When compared with single effect of L. casei, the combined effect of L. casei and 
pretreatment of 0.5% peanut skin extract did not inhibit more cell adhesive activity at 





peanut flour or 0.5% peanut skin extract showed significant reduction (96.8% to 98.6%) 
in invasion ability by these foodborne pathogens (Figure 5D, 5E, and 5F). We also 
found that combined effect of pretreatment with L. casei and 0.5% peanut flour or 0.5% 
peanut skin extract enhanced the inhibitory effect of these pathogens by 100% (below 
the limit of detection) for EHEC, 93.9% for S. Typhimurium, and 83.4% for L. 
monocytogenes. 
 
Effects on virulent gene expression. To further investigate the effects of 3% cocoa, L. 
casei CFCS1, and L. casei CFCS2 on each of these enteric bacterial pathogens (EHEC, 
S. Typhimurium, or L. monocytogenes) and host intestinal epithelial INT-407 cell 
interactions, the relative expression levels of major virulent genes related to attachment 
and invasion were determined using qRT-PCR (Figure 3-6). 
Fold-change of EHEC EDL933 virulence genes were shown in Figure 3-6A. In 
the presence of 3% cocoa, CFCS1, and CFCS2 significantly reduced the relative 
expression level of eaeA gene by 1.68, 1.79, and 4.57-fold, respectively. In the same 
study, relative expression level of fliC gene of EHEC EDL933 were up-regulated by 3% 
cocoa (6.89-fold), CFCS1 (7.95-fold), and CFCS2 (8.25-fold). Whereas compared with 
control, the relative ex-pression level of tir gene in EHEC EDL933 showed no 
significant fold change when treated by cocoa or CFCSs. 
For S. Typhimurium LT2 (Figure 3-6B), in the presence of 3% cocoa, CFCS1, 
and CFCS2, significant down-regulation of the relative expression level of nmpC gene 
by 3.31, 100.75, and 28.57-fold, respectively, was found. Meanwhile, fliC gene was 





respectively. When compared with control, expression level of fliD gene was only 
increased by CFCS1 (1.97-fold) and CFCS2 (4.38-fold), whereas expression level of 
motB gene was increased by 3% cocoa (1.61-fold) and CFCS2 (4.68-fold), respectively. 
Fold-change of L. monocytogenes LM2 virulence genes were shown in Figure 
3-6C. The expression level of fbp gene was reduced significantly by 3% cocoa (1.49-
fold), CFCS1 (3.73-fold), and CFCS2 (6.13-fold). Meanwhile treatment of 3% cocoa, 
CFCS1, and CFCS2 also significantly up-regulated the relative expression level of flaA 
gene of L. monocytogenes LM2 by 1.61, 2.97, and 5.24-fold, respectively. Additionally, 
the expression level of iap gene in L. monocytogenes LM2 was also decreased by 




Probiotics can be found in various different foods as supplement, and they are believed 
to play very important roles in regulation of proper intestinal function, digestion by 
balancing intestinal microflora, and disease progressions including growth inhibition 
of bacterial pathogens to various degrees (Anas, Jamal Eddine, & Mebrouk, 2008; 
Coman et al., 2014; Rodríguez et al., 2012). In consistence with previous studies, we 
observed the antimicrobial property of L. casei against EHEC EDL933, S. 
Typhimurium LT2, and L. monocytogenes LM2 in mixed cultures. In order to test our 
hypothesis that the antimicrobial activity of L. casei comes from its produced 
metabolites or byproducts, we further investigated the effects of CFCS collected from 





with former researchers (Coconnier, Liévin, Bernet-Camard, Hudault, & Servin, 1997), 
we found that CFCS of L. casei inhibited the growth of EHEC EDL933, S. 
Typhimurium LT2, and L. monocytogenes LM2 strains. Additionally, we observed that 
3% supplemented medium could stimulate the growth and increase the amount of 
byproducts of L. casei (Mengfei Peng, Aryal, Cooper, & Biswas, 2015b) and 3% cocoa 
containing CFCS exhibited stronger inhibitory effects on multiple foodborne bacterial 
pathogens. This study also indicated that the intensive antimicrobial effects of CFCSs 
depended on the amount of metabolites/byproducts L. casei produced overnight in the 
medium. 
To characterize the CFCS’s activity, CFCS of L. casei with pH, temperature, 
and enzymatic treatments on growth of EHEC was also examined. We detected 
attenuated antimicrobial property of CFCS at high pH treatment condition, which 
revealed the crucial role of the ionic state of lactic acids produced and secreted by L. 
casei in exclusion of foodborne pathogens in acidic conditions (Gyawali & Ibrahim, 
2012; Serajus Salaheen, White, et al., 2014). Discounted antimicrobial activity of 
CFCS processed by high temperature (80 and 100 °C) as well as enzyme (catalase, 
proteinase K, or trypsin) treatments indicated that in spite of lactic acids, hydrogen 
peroxide and antimicrobial polypeptides in CFCS also contribute to antimicrobial 
activity (Atassi & Servin, 2010; Wannun et al., 2014; Xu et al., 2008). Simultaneously, 
combined enzymatic treatments with catalase + proteinase K, catalase + trypsin, and 
catalase + proteinase K + trypsin showed the minimum or no antimicrobial activity. 
With HPLC-MS/MS analysis, we also detected few potential bio-active metabolites 





which further proved the synergistic antimicrobial effects of hydrogen peroxide and 
antimicrobial polypeptides in CFCS. 
Combined with L. casei and peanut flour showed a drastically inhibitory effect 
against 3 major foodborne bacterial pathogens. Two possible explanations for this 
might be that compounds in peanut flour either induced the number of L. casei or the 
antimicrobial metabolites production by L. casei, both of which contribute to the 
competitive exclusion of foodborne pathogens. As antimicrobial resistance among 
foodborne pathogens especially Salmonella, L. monocytogenes, and E. coli growing 
rapidly recently, FDA has paid close attention on this emergent issue. This study has 
investigated the potential of combining probiotics and prebiotics in inhibiting 
foodborne pathogens. Our findings may suggest replacing the chemical antimicrobial 
use with bio-competitive inhibitors and natural growth promotive components such as 
peanut flour, as an alternative to minimize the spread of multidrug resistance bacteria 
as well as it may ensure food safety for human. The combinational use of L. casei and 
peanut skin extract only showed strong inhibition on growth of L. monocytogenes. The 
antimicrobial effect of peanut skin extract itself on L. monocytogenes might be one 
explanation of this, as a result of which, though the amount as well as the inhibitive 
effect of L. casei in the mixed culture were attenuated by peanut skin extract, L. 
monocytogenes still was not able to survive in the supplemented mixed culture. 
In the same study, we also found that L. casei, peanut flour, and peanut skin 
extract can reduce foodborne pathogens colonization on human intestinal cells. In 
general, the enteric bacterial pathogens’ infection processes usually initiate from 





specific ligands. However, normal microflora colonization in gut competitively 
prevents foreign bacterial pathogens from attachment. Both Lactobacillus and 
enteropathogens are known to express cell surface proteins and displays carbohydrate-
binding specificities on human intestinal cells (Neeser et al., 2000). In order to attach 
and colonize host’s gut, foodborne pathogens have to compete with normal gut 
microflora, as a consequence of which, we hypothesize that pretreatment of L. casei 
reduce the adhesive and invasive activities of pathogens by occupying the intestinal 
cell surface receptors. In addition, bio-active components in peanuts such as phenolic 
acids and flavonoids might inhibit the colonization of pathogens by reducing their 
flagellin and adhesin level. Simultaneously, the increased activities of cell attachment 
by L. casei in supplement with peanut flour may explain why combinational 
pretreatment with L. casei and peanut flour could exhibit much stronger adhesion and 
invasion inhibitive effect on 3 pathogens. 
To investigate the role of L. casei cells in co-culture condition and CFCSs on 
pathogen-host INT-407 cell interactions, we examined their inhibitory effects on cell 
adhesive and invasive activities, cell surface hydrophobicity, and cell attachment-
related gene expression of EHEC EDL933, S. Typhimurium LT2, and L. 
monocytogenes LM2 strains. Both pre-treatment of L. casei cells and CFCSs 
significantly reduced the cell adhesion and invasion abilities of three pathogens, which 
is in agreement with previous studies on anti-adherence properties of Lactobacillus 
strains against multiple bacterial pathogens (Bendali F, Hebraud M, & Sadoun D, 2014; 






By sharing similar carbohydrate-binding specificities displayed by cell surface 
proteins, L. casei is hypothesized to decrease the adhesive and invasive activities of 
pathogens by pre-occupying the surface receptors on INT407 cells (Neeser et al., 2000; 
Serajus Salaheen, White, et al., 2014). Furthermore, antioxidant containing products 
like cocoa is known to block the level of host cell-pathogen interactions especially 
bacterial invasion abilities by inhibiting inflammatory responses in intestinal epithelial 
cells (M. Kim et al., 2010; Mengfei Peng, Aryal, et al., 2015b). In this study, CFCS2 
combined the capabilities of both CFCS1 and antioxidants-rich cocoa and exhibited the 
most intensive properties on limiting pathogen-cell interactions. Additionally, Saran et 
al. (2012) demonstrated the positive correlation between bacterial cell surface 
hydrophobicity and cell attachment activities. Therefore, the noticeable reduction in 
cell surface hydrophobicity of three foodborne pathogens with CFCS treatments could 
be another identical indicator of their attenuated adhesion activities on human GI cells 
in this study. 
We assessed the relative expression levels of multiple virulence genes of EHEC 
EDL933, S. Typhimurium LT2, and L. monocytogenes LM2 strains, which are 
summarized in Table 3-1. Based on our findings, with the exception of tir (EHEC 
intimin translocation) gene, all genes for specific cell attachment and infection 
including eaeA (EHEC intimin adherence protein synthesis), fbp (L. monocytogenes 
fibronectin-binding-protein synthesis), and iap (L. monocytogenes invasion-associated 
protein synthesis) were negatively affected by CFCSs. The significant down-
regulations of these genes, in supporting previous studies (Dowd, Killinger-Mann, 





provide us an explanation for the reduced cell adhesion and invasion abilities. A 
significant increase (4-8 folds) in relative expression of all flagellin synthesis and 
bacterial motility associated genes (fliC, fliD, flaA, and motB) were detected when the 
bacterial cells were pretreated with CFCS2. Generally, flagella ensure bacterial motility 
and are involved in their initial interaction with intestinal cells of the host (La Ragione, 
Cooley, Velge, Jepson, & Woodward, 2003). It is likely that the observed up-regulation 
of flagella/ motility associated genes would be correlated with emergent flagellin 
synthesis and flagella production in response to induced stress in the presence of 
multiple antimicrobial components (peroxide, polypeptides, phenolic compounds, 
flavonoids and many other) containing CFCS2. This result agrees with previous study 
that under stressed condition, survival strategy such as up-regulating flagellar 
biosynthesis and motility will be induced by bacterial pathogens (Bradley, Beach, de 
Koning, Pratt, & Osuna, 2007; Serajus Salaheen, Nguyen, et al., 2014). The mechanism 
behind up-regulation of flagella/ motility associated genes remains unknown, but these 
differentially transcribed genes contribute to the pathogenesis of foodborne pathogens, 
especially bacterial motility and initial host cell attachment, as response to the 
attenuated specific cell surface binding activities. Finally, it is of note that significant 
down-regulation of nmpC gene (encodes Salmonella outer membrane-associated 
protein) is associated with bacterial membrane disruption and increased permeability. 
 
Conclusions 
1. Combining of cocoa/peanut and L. casei competitively excluded EHEC and S. 





2. CFCS from L. casei supplemented with cocoa/peanut altered the enteric pathogenic 
bacterial cell surface hydrophobicity, disrupted their host-pathogen interactions, and 
down-regulated their virulence gene expressions. 
3. Antimicrobial properties of CFCS from L. casei was attributed from multiple 
metabolites including hydrogen peroxide, organic acids, and polypeptides. 






















Figure and Table list 
 
Figure 3-1. Comparison in growth conditions of both L. casei and enteric pathogens including EHEC (A), S. Typhimurium (B), and L. 
monocytogenes (C) between single and mixed culture at 0, 12, 24, 36, and 48 h. Error bars indicate standard deviation from parallel 
trials. Asterisks (*) at each time point indicate the significant growth in mixed culture when compared with single culture as a control 






Figure 3-2. Comparative growth conditions of EHEC (A), S. Typhimurium (B), and L. monocytogenes (C) alone, in mix-culture with L. 
casei, and in mix-culture in the presence of 0.5% peanut flour or with 0.5% peanut skin extract at 0, 24, 48, 72 h. Error bars indicate 
standard deviation from parallel trials. Different letters within a time point indicate significant difference between control and treatment 






Figure 3-3. Inhibitory effects of CFCSs from L. casei on growth of EHEC (A), S. 
Typhimurium (B), and L. monocytogenes (C) at 0, 4, 8, 24, and 48 h. Error bars indicate 
standard deviation from parallel trials. Bars with different letters (a through d) at single 






Figure 3-4. Cell adhesion (A, C, and E) and invasion (B, D, and F) levels of EHEC (A 
and B), S. Typhimurium (C and D), and L. monocytogenes (E and F) to INT407 cells 
with pre-treatment of 3% cocoa, L. casei bacterial cells, and CFCSs of L. casei. A 
constant MOI=10 is applied in each sub-figure. Error bars indicate standard deviation 
from parallel trials. Bars with different letters (a through d) within each pathogen are 









Figure 3-5. Reduction of adhesive activities of EHEC (A), S. Typhimurium (B), and L. 
monocytogenes (C) as well as invasive activities of EHEC (D), S. Typhimurium (E), 
and L. monocytogenes (F) on INT-407 cells by pretreatment with 0.5% peanut flour, 
0.5% peanut skin extract, L. casei, 0.5% peanut flour plus L. casei, and 0.5% peanut 
skin extract plus L. casei. Error bars indicate standard deviation from parallel trials. 
Different letters within a time point indicate significant difference between control and 







Figure 3-6. Relative expression of multiple virulence genes from EHEC (A), S. 
Typhimurium (B), and L. monocytogenes (C) when treated with 3% cocoa and CFCSs 
from L. casei. The relative transcription levels of target genes are shown in the form of 
comparative fold change with gene expression in control being 1. Error bars indicate 
standard deviation from parallel trials. Bars with different letters (a through d) are 





























































































































++: Antimicrobial activity >50 AU/mL.
+: Antimicrobial activity >5 AU/mL.
−: Non-detected antimicrobial activity.














































Values with different letters (a–d) within an individual column are significantly different at p < 0.05.
*
 Data in the table represent ‘mean ± standard deviation’ of triplicate.
Bacteria
Treatment







Compound name Class Biological Functions Fold change
*
Citric acid
Tricarboxylic Acids and 
Derivatives




Lineolic Acids and 
Derivatives





Pyrrolidones Not available 28.36
2-Methylglutaric acid Branched Fatty Acids
Membrane integrity/stability; Fuel or energy 
source; Cell signaling
24.06
Leucinic acid Branched Fatty Acids




Alpha Amino Acids and 
Derivatives







Cinnamyl alcohol Phenylpropenes Not available 1.25
Zalcitabine
Pyrimidine Nucleosides and 
Analogues








 Fold change of each compound is calculated based on ratio of relative intensity values





Chapter 4: Combating enteric pathogenic bacterial infections 
with linoleic acids overexpressed Lactobacillus casei 
 
Introduction 
Human enteric microbial infections are principally characterized by diarrhea with or 
without other complications/consequences which causes 4 to 6 million deaths annually 
worldwide and possess huge economic burden (Christou, 2011; Viswanathan, Hodges, 
& Hecht, 2009). The dominant causative agents of enteric bacterial diseases include 
Salmonella, EHEC, Campylobacter, Listeria monocytogenes and Shigella (Forsythe, 
2016; Huang et al., 2016; Mor-Mur & Yuste, 2010; Viswanathan et al., 2009). These 
enteric bacterial pathogens are typically acquired through contaminated foods and 
water, therefore daily risk associated with foodborne diseases for everyone living in 
this planet. According to the estimation of the Center for Disease Control and 
Prevention, in the US alone, 48 million illnesses (approximately 1 in 6 Americans), 
more than one hundred thousand hospitalizations, and thousands of death are caused 
by foodborne infections each year (D. Adams et al., 2015, 2017; D. A. Adams et al., 
2016; Hoffmann et al., 2012). The most predominant causative foodborne infectious 
agents, Salmonella and EHEC are colonized in farm animal gut as a part of normal 
flora in swine, poultry, and cattle.  
Poultry and cattle are the most common reservoirs for Salmonella , whereas 
EHEC mostly are shed in cattle and their products can be cross-contaminated directly 
or fruits and vegetables acquire these pathogens through water and/or soil contaminated 





practices are enforced (García, Fox, & Besser, 2010; Mengfei Peng et al., 2016). The 
serious health concerns and enormous economic loss precipitated by enteric bacterial 
infections forced both scientists, and consumers to seek approaches defeating the 
pathogens by improving the host defense. 
The majority of human gut epithelial surfaces are colonized by a tremendous 
number of microorganisms which are known as normal gut microflora and their role is 
crucial in forming a complex ecosystem with huge microbial diversity (Tlaskalová-
Hogenová et al., 2011). Though viruses, fungi, and protozoans are also colonized along 
with predominant bacterial flora, and they build up a microbial genetic repertoire being 
approximately 100 times greater than the number cells that of human host (Fujimura et 
al., 2010). According to recent reports, human distal gastrointestinal (GI) tract houses 
more than 1000 distinct bacterial species and the total number was estimated to be 
larger than 1014 CFU/gm of fecal material. Bacteroidetes, Firmicutes, Proteobacteria, 
and Actinobacteria are the prevalent phyla in human microbiota (Guarner & 
Malagelada, 2003; Shreiner, Kao, & Young, 2015; Vedantam & Hecht, 2003). In 
normal situation, most of the commensal bacteria colonize and survive symbiotically, 
whereas, under certain conditions such as immunodeficiency, malnutrition, and 
antibiotic-treatment causing dysbiosis, commensal bacteria can also induce pathology 
and diseases (Segal & Blaser, 2014; Wexler, 2007). For instance, taking broad-spectrum 
antibiotics or any other detrimental effect may cause dysbiosis of gut ecosystem that 
lead the irritating bowel, reducing the number of beneficial bacteria, and increase the 
number of opportunistic pathogens and further weaken the host defense and/or induce 





microflora and/or their produced metabolites, a very limited number of enteric bacterial 
pathogens and/or opportunistic pathogens can take over the gut ecosystem. In such 
situation, procommensal strategies by application of probiotics, and/or prebiotics, or 
synbiotics can be considered as priority in prevention and therapy of foodborne 
bacterial pathogen-induced enteric illness. With such promising scheme, it allows an 
establishment of the enteric microbial ecosystem by introducing native or genetically 
engineered beneficial probiotics without deleterious effects on human commensal gut 
bacteria (Mengfei Peng & Biswas, 2017). 
The enormous microflora, specifically probiotics or beneficial bacteria, in the 
host GI tract ferment or metabolize undigested dietary components which reaches the 
small and large intestine, and generates/releases a tremendous treasury of secondary 
metabolites (byproducts), most of which have been associated with multiple health-
beneficial effects (Flint et al., 2012; Marcobal et al., 2013). These metabolites from 
probiotics generally include bio-active polypeptides with antimicrobial and immune-
modulatory properties as well as vitamin B which is essential for human growth, 
metabolism, and reproduction (Stanton et al., 2005). Whereas, the major byproducts 
are lipid molecules like fatty acids various in chemical structure from SCFAs to PUFAs 
(Louis et al., 2014; Serini et al., 2009). The mixed concentration of by-produced lipid 
molecules in human colon is approximately 50-150 mM, and these beneficial lipid 
molecules are active and involved in modulation of host’s immune responses (Louis et 
al., 2014). 
Linoleic acid is one of the most crucial beneficial metabolites produced from 





Ntzani, Bika, Kostapanos, & Elisaf, 2012). The mixture of positional and geometric 
isomers of linoleic acid (C18:2, c9, c12), as conjugated linoleic acids (CLA), 
distinguishes themselves from other fatty acids because of its wide range of benefits on 
human health including anti-obesity, anti-carcinogenesis, anti-inflammation, and anti-
pathogenic activity (Benjamin & Spener, 2009; H. Y. Lee et al., 2006; O’Shea et al., 
2012; Bo Yang et al., 2015). Dairy and human/animal intestinal originated bacteria 
including LAB and bifidobacteria were demonstrated to produce CLA during their 
metabolism (Alonso, Cuesta, & Gilliland, 2003b; Y. J. Kim & Liu, 2002; Tung Y. Lin, 
2000; Ogawa et al., 2001; Soo et al., 2008). Among these bacteria, L. acidophilus, L. 
casei, L. plantarum, L. rhamnosus, Lactococcus lactis, and Streptococcus thermophilus 
have been revealed as CLA productive bacteria (Van Nieuwenhove et al., 2011), 
however their CLA productivity is various and usually limited by multiple factors 
including temperature, oxygen availability, substrate concentration etc. (Pandit et al., 
2012). A growing number of researches are recently focusing on stimulating the 
productivities of linoleic acids and CLA from microbial sources especially probiotics 
both in human intestine and industry production level (Mengfei Peng & Biswas, 2017).  
Through our previous research, we have observed relatively intense 
antimicrobial activities in L. casei against enteric bacterial pathogens such as 
Salmonella enterica serovar Typhimurium (ST) and EHEC (Mengfei Peng, Reichmann, 
et al., 2015). However, the linoleic acid productivity (conversion ratio) remains relative 
low as 4.8%. On the contrary, although L. rhamnosus possesses the highest CLA 
conversion ratio among all active Lactobacillus strains, its anti-pathogen capability is 





the mcra (myosin-cross-reactive antigen gene), encoding LI, from L. rhamnosus GG 
into L. casei, and aimed to examine the role of this novel probiotic in prevention and 
control of enteric bacterial infections both in vitro and in vivo on BALB/cJ mice model. 
 
Materials and Methods 
Bacterial strain and growth conditions. Probiotic strains Lactobacillus casei ATCC 334 
(LC-WT) and L. rhamnosus GG ATCC 53103 were purchased from American Type 
Culture Collection (ATCC, VA, USA). Lactobacillus strains were grown on MRS 
(EMD Chemicals Inc., Gibbstown, NJ, USA) agar at 37°C for 24 h in the presence of 
5% CO2 (Forma™ Scientific CO2 water jacketed incubator, Thermo Fisher Scientific, 
Waltham, MA, USA). Enteric bacterial pathogens Salmonella enterica serovar 
Typhimurium (ATCC 14028) (ST) and enterohemorrhagic Escherichia coli EDL933 
(ATCC 700927) (EHEC) were grown on LB agar (EMD Chemicals Inc., Gibbstown, 
NJ, USA) for 18 h at 37°C under aerobic conditions (Thermo Scientific, Thermo Fisher 
Scientific, Waltham, MA, USA). 
 
Cell lines and culture conditions. Human intestinal epithelium cells (INT407, ATCC 
CCL-6) were purchased from ATCC and cultured at standard condition (37°C, 5% CO2, 
95% humidity) in DMEM) supplemented with 10% FBS and 100 g/mL gentamicin 
(HyClone Laboratories Inc., Logan, UT, USA). The cultured cells were seeded at 
approximately 2×105 cells/mL/well into 24-well tissue culture plates (BD Falcon, 
Franklin Lakes, NJ, USA) to reach 80-90% confluence monolayer at standard condition 





rinsed with PBS and stabilized in antibiotic-free DMEM for 1 h prior to the invasion 
assay. 
Human macrophage cell line (U937, ATCC CRL3253) was purchased from 
ATCC and grown at standard condition in RPMI-1640 Medium supplemented with 10% 
FBS and 100 g/mL gentamicin. An aliquot of 6 mL cell suspension containing 1×106 
cells will be transferred into 25 cm2 flask (Greiner Bio-One, Monroe, NC, USA) and 
cultured at standard condition for 24-30 h. After time, the cell monolayer was washed 
for three times with RPIMI for further bacterial infection. 
 
Mice model and animal care. The 3-week-old BALB/cJ Mice (around 8-10 g) were 
purchased from the Jackson Laboratory (Bar Harbor, ME USA) and reared in static 
micro-isolating cages with cellulose Bio-Performance bedding and bio-huts as 
environmental enrichment. Teklad standard rodent diet and regular tap water were 
provided for mice feeding and drinking. A total of 90 mice (45 male and 45 female) 
were used for each trial experiment. Specifically, following completely randomized 
design, 90 mice were randomly assigned to 9 groups, thus 10 mice per group; two cages 
of the unit were assigned to each group, thus a total of 5 mice per cage. 
Mice cages were changed weekly, and each individual mouse was weighed and 
monitored for health examination daily. At the end of the second, third, and fourth week, 
3, 3, and 4 mice from each group were euthanized respectively with CO2 inhalation in 






Over-expression of myosin-cross-reactive antigen gene (mcra) in L. casei for 
developing LC-CLA. Plasmid pJET and E. coli DH5α were purchased from Thermo 
Fisher Scientific (Waltham, MA, USA), pDS132 and E. coli β2155 were donated by 
Dr. Fidelma Boyd (Delaware University, Newark, DE, USA), and pMSP3535 were 
purchased from Addgene (Cambridge, MA, USA). LC-WT and L. rhamnosus GG 
(ATCC 53103) were harvested from overnight culture in MRS broth, followed by three 
times sub-culture on MRS agar plate at 37°C for 24 h in the presence of 5% CO2 
incubator. 
The entire cloning design was summarized in Figure 1. Briefly, the 1750 bp 
mcra from L. rhamnosus GG was PCR amplified and ligated into pJET vector through 
blunt-end cloning. Aliquot of 250 μL E. coli DH5α bacterial suspension in cold 50 mM 
CaCl2 was mixed with 10 μL ligated product (pJET-mcra) for 10 min incubation on ice, 
followed by 50 s incubation at 42°C in water bath. After further 2 min incubation on 
ice, 250 μL LB broth was added into bacteria-plasmid mixture for 10 min incubation 
at room temperature followed by selection on LB agar with 100 μg/mL ampicillin for 
transformation. The E. coli DH5α-expressed mcra was double-excised from pJET-
mcra with BamHI and XbaI and then ligated into pMSP3535 vector at 16°C overnight. 
Following the same condition, pMSP3535-mcra was further transformed into E. coli 
DH5α and mixed with LC-WT at ratios of 1:1, 1:5, and 1:10 (donor cells: recipient 
cells) for bacterial mating. The L. casei-pMSP3535 was harvested through consecutive 
sub-culture and selection on MRS agars containing 300 µg/mL erythromycin at 37°C 







Removal of antibiotic-resistance marker and mcra chromosomal recombination. The 
pMSP3535-mcra was isolated using Plasmid Mini Kit (Qiagen, Germantown, MD, 
USA). The gene sequence of mcra linked with transcription promoter Pnis was 
amplified by PCR using pMSP3535-mcra as the template. The upstream homologous 
arm upp1 (208 bp) and downstream homologous arm upp2 (211 bp) concatenated with 
Xba1 and Sac1 linkers were also PCR amplified using LC-WT genomic DNA as the 
template. Ligation of upp1-mcra-upp2 was performed by PCR programmed for 40 
cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 60 s. After pJET blunt-end cloning, 
pJET-upp1-mcra-upp2 and pDS132 were double-digestion with Xba1 and Sac1, 
followed by sticky-end ligation for overnight at 16°C. The pDS132-upp1-mcra-upp2 
was then transformed into E. coli β2155 following the same method described above 
but with 0.3 mM DAP selection. The transformed E. coli β2155 was mixed with 
overnight cultured LC-WT at ratio of 1:1, 1:5, and 1:10 (donor cells: recipient cells) 
for bacterial mating. Aliquot of 1 mL of the mixed bacterial suspension was spread on 
MRS agar plate with 0.3 mM DAP, followed by 5 h incubation at 37°C under micro-
aerophilic condition. The L. casei-pDS132 was harvested through sub-culture and 
selection on MRS agar with 30 μg/mL chloramphenicol. Individual bacterial colony 
was consecutively sub-cultured in fresh MRS broth and selected on MRS agar 
containing 100 μg/mL 5-fluorouracil (5-FU) for upp1-mcra-upp2 chromosomal 
homologous recombination. Finally, the mcra chromosomal recombinant L. casei 






In vitro mixed culture of L. casei with enteric bacterial pathogens. Bacterial cells from 
overnight agar plates were collected in 10 mL PBS using 10 µL sterile disposable loops. 
Each concentrated bacterial suspension was adjusted using PBS and measured by 
LAMBDA BIO/BIO+ spectrophotometer (PerkinElmer, Beaconsfield, UK) for 
adjusting the bacterial concentration to approximately 7 log CFU/mL. Aliquots of 400 
µL adjusted L. casei and S. Typhimurium or EHEC suspension were added to sterilized 
test tubes containing 3.2 mL DMEM with 10% FBS and then incubated at 37 °C for 
different time points (0, 2, 4, 8, 24, 48, and 72 h). After incubation, serial dilutions were 
performed in PBS, and then plated on agar plates (MRS agar for L. casei, LB agar for 
S. Typhimurium and EHEC) in triplicate, followed by incubation for 18 h at 37 °C for 
growth. Bacterial CFUs were counted afterwards and results were expressed in unit of 
bacterial log CFU/mL as the average number from triplicate assays. 
 
Isolation of CFCSs from L. casei. The fresh overnight (18 h) liquid cultures of L. casei 
ATCC 334 and L. casei-CLA in MRS were centrifuged at 4000 × g for 15 min. CFCSs 
were collected and then passed through 0.2 μm sterile syringe filter (VWR, PA, USA) 
for removal of bacterial cells. The filtered CFCSs were then collected and stored at 
4 °C for further in vitro antimicrobial and anti-inflammatory investigations. 
 
Evaluation of physicochemical properties of S. Typhimurium and EHEC. To determine 
the cell surface hydrophobicity of S. Typhimurium and EHEC, the enteric bacterial cells 
were grown in the presence or absence of CFCS from either L. casei-CLA or L. casei 





OD adjustment into 0.5 (Ht0) at wavelength at 570 nm. The adjusted bacterial 
suspension was mixed with 1 mL of n-hexadecane and incubated for 5 min at room 
temperature. The OD (Ht5) of aqueous phase from the mixture was measured at 570 
nm using microplate reader (Multiskan FC, Thermo Fisher Scientific Inc., Waltham, 
MA, USA). The hydrophobicity values were calculated based on the following 
equation: Hydrophobicity (%) = (1 - Ht5/Ht0) × 100. 
 The interactions between bacteria cell surfaces were determined by the auto-
aggregation assay. The bacterial cells cultured in the presence or absence of L. casei 
CFCSs at 37 ˚C for 18 h were centrifuged at 3,000 g for 20 min, and then the bacteria 
were diluted with PBS (pH 7.2) for OD adjustment to 0.5 (At0) at 570 nm. The bacterial 
suspensions (3 mL each) were incubated at 37 °C for 2 h. The OD of upper suspensions 
were further measured at 570 nm (At2) using Multiskan microplate reader (Ahn et al., 
2014). The ability of bacterial cells to aggregate was estimated based on following 
equation: Auto-aggregation (%) = (1- At2/ At0) × 100. 
 Enteric bacterial cell injury induced by L. casei CFCSs was evaluated according 
to the overlay method. Briefly, the control and CFCSs-treated S. Typhimurium/EHEC 
bacterial cells cultured at 37 °C for 18 h were serially (1:10) diluted with PBS (pH 7.2), 
followed by plating on Trypticase soy (TSA) agar and XLD- or MacConkey-overlaid 
TSA agar, respectively, and then they were incubated at 37 °C for 24h. The 
antimicrobial-induced bacterial cell injury rate was estimated by the difference between 
the bacterial cell CFU numbers obtained from TSA and XLD agar or MacConkey agar 






Bacterial biofilm formation. Both S. Typhimurium and EHEC were inoculated at 
approximately 5 × 105 CFU/mL in 6-well plates (Corning, NY, USA) containing 22 × 
22 mm2 glass slides and LB broth in the absence or presence of L. casei CFCSs in 
triplicate for 24, 48, and 72 h incubation at 37 °C without shaking. At each time point, 
the glass slides were rinsed with PBS for five times and bacterial cells were recovered 
from the glass slide surface using sterile cell scraper (VWR, PA, USA). The biofilmed 
bacterial cells were scrapped from glass slides and then serially diluted for plating on 
LB agar for enumeration. 
 
Enteric bacterial adhesion and invasion activities on human intestinal cells. The 
INT407 cells grown in 24-well plate with 800 µL DMEM were pretreated with 100 µL 
DMEM (control), L. casei CFCSs, or 2×108 CFUs L. casei bacterial cells, separately 
for 1 h, with each treatment in triplicate. A 100 µL aliquot of S. Typhimurium or EHEC 
with MOI=100 (2×108 CFUs) was inoculated into triplicate wells. Afterwards, the 
infected cells were incubated at standard condition for another 2 h, and then followed 
by three times washing with DMEM. The cell monolayers were lysed with 0.1% Triton 
X-100 for 15 min, serial diluted, and plated on specific agars (MRS agar for L. casei, 
Xylose Lysine Deoxycholate agar for S. Typhimurium, MacConkey agar for EHEC) to 
estimate the adhesive bacterial CFU. To measure bacterial cell invasive activity, 
DMEM washed cell monolayers after 2 h bacterial infection was incubated in DMEM 
containing 10% FBS supplemented with 250 µg/mL gentamicin for 1 h, then followed 
by three times DMEM washing, Triton X-100 lysis, serial dilution, and eventually 






Simulation of enteric bacterial inflammation in human macrophage cells. Enteric 
bacterial pathogen S. Typhimurium that provoke inflammation in human gut intestine 
was cultured on LB agar plate for 18 h. A 100 µL aliquot of bacterial suspension, 
containing approximately 1×108 CFU (MOI=100) was inoculated into triplicate 25 cm2 
flasks containing U937 cell monolayer. In the test flasks, 500 µL overnight (18 h) 
CFCSs from L. casei in DMEM with 10% FBS were added during S. Typhimurium 
infection period. The infected monolayers will be incubated for 24 h at standard 
condition, followed three times washing with ice-cold PBS for RNA extraction. 
 
RNA extraction and cDNA synthesis. Extraction of bacterial cells, human macrophage 
cell line, and mice spleen RNA was carried out using TRIzol® Reagent (Life 
Technologies Co., Carlsbad, CA, USA). Briefly, host cell pellets or mice spleen 
smashed pieces were lysed with 1 mL TRIzol for 5 min at room temperature. The cell 
or tissue lysates were mixed with 200 µL chloroform with 30 sec vigorous vortexes. 
After 3 min condensation at room temperature, the mixtures were centrifuged at 14,000 
× g at 4 °C for 15 min. Then the aqueous phase was collected and gently mixed with 
500 L of isopropanol for 10 min standing at room temperature and centrifugation at 
14,000 × g at 4 °C for 15 min. The gel-like RNA pellet was washed with 1 mL 75% 
ethanol, vortexed 10 s, centrifuged at 7000 × g at 4 °C for 5 min, air-dried in bio-safety 
cabinet for 10 min, and dissolved in 50 µL RNase-free water. The RNA concentration 
was quantified with a NanoDrop spectrophotometer (Thermo Fisher Scientific Inc., 





DNase and 5 µL of DNase buffer (MO BOI Laboratories, Inc., Carlsbad, CA, USA) 
and incubated at 37 °C for 20 min; 5 µL RTS DNase Removal Resin was added and re-
suspended every 1 min up to 10 min. After 1 min 14,000 × g centrifugation, the 
supernatant containing RNA was transferred and kept at -20 °C for cDNA reverse 
transcription. 
The cDNA synthesis will be performed according to the protocol of qScript 
cDNA SuperMix. The eluted RNA (1 µg) will be mixed with 4 µL of 5X qScript cDNA 
SuperMix containing optimized concentration of MgCl2, dNTPs, RNase inhibitor 
protein, qScript reverse transcriptase, random primers, oligo (dT) primer, and 
stabilizers and then incubated at 25 °C for 5 min, 42 °C for 30 min, and 85 °C for 5 
min. 
 
Quantitative RT-PCR for evaluation of gene expressions. The PCR reaction mixture 
containing 10 µL PerfeCTa SYBR Green Fast Mix (Quanta Biosciences, Beverly, MA, 
USA), 2 µL of each 100 nM primer (listed in Table 4-1, 4-2, and 4-4), 2 µL of cDNA 
(10 ng), and 4 µL of RNase-free water was amplified using an Eco Real-Time PCR 
system with 30 sec denaturation at 95 °C, followed by 40 cycles of 95 °C for 5 sec, 
55 °C for 15 sec, and 72 °C for 10 sec. All the relative transcription levels of target 
genes were estimated by comparative fold change. The CT values of genes were 
normalized to the housekeeping gene, and the relative expression levels of target genes 
were calculated by the comparative method (Livak & Schmittgen, 2001). Quantitative 






In vivo probiotic colonization and enteric bacterial challenge. Overnight culture of L. 
casei bacterial cells from MRS broth were 1:50 diluted in fresh 5 mL MRS broth for 3-
4 h further growth. The exponential phase bacterial cells were harvested following 
centrifugation at 3,000 × g for 15 min, PBS washing, and resuspension in 1.0 mL PBS. 
A final concentration of 1011 CFU/mL was adjusted with PBS. The design of in vivo 
trial was summarized in Table 3-3. Approximately 109 CFU L. casei bacterial cells were 
maintained daily in mice water bottle containing regular tap water for group B and C. 
Aliquot of 100 µL L. casei ATCC 334 and L. casei-CLA suspensions were fed to mice 
in group B and C respectively, by oral gavage using fluid dispensing syringe (BD, 
Franklin Lakes, NJ, USA) at morning of Day 6 and 7. Mice in group A was 
orogastrically fed with 100 µL PBS and served as control. 
Overnight culture of S. Typhimurium and EHEC bacterial cells from LB broth 
were 1:50 diluted in fresh 5 mL MRS broth for 3-4 h further growth. The exponential 
phase bacterial cells were harvested following centrifugation at 3,000 × g for 15 min, 
PBS washing, and resuspension in 1.0 mL PBS. A final concentration of 108 CFU/mL 
was adjusted with PBS. At Day 7 afternoon, Aliquot of 100 µL S. Typhimurium or 
EHEC suspension was fed to mice in groups 2 or 3 respectively, with oral gavage, and 
the mice were reared thereafter for another 3 weeks. Mice in group 1 was orogastrically 
fed with 100 µL PBS and served as control. 
 
Mice sample collection and processing. In order to estimate the bacterial fecal shedding, 
fecal samples were collected from each mouse in sterile Whirl-Pak bags using sterile 





specific agar plates (MRS agar for L. casei, XLT-4 agar for S. Typhimurium, 
MacConkey agar for EHEC). 
In order to investigate the bacterial colonization in mice gut intestine, ilium, 
jejunum, and cecum from each euthanized mouse were separated and harvested. Then 
the ilium, jejunum, and cecal fluids were serial diluted with PBS, followed by plating 
on specific agar plates (MRS agar for L. casei, XLT-4 agar for S. Typhimurium, 
MacConkey agar for EHEC). 
Mice spleen was harvested and kept in RNA Later for further RNA extraction, 
cDNA reverse transcription, and inflammation-related gene expression level analysis; 
Mice kidney, ilium, jejunum, and cecum were collected, washed with PBS, and 
preserved in 4% formaldehyde for further histopathology study. 
 
Statistical analysis. All the data were analyzed by the Statistical Analysis System 
software. The one-way analysis of variance followed by Tukey's test was applied to 
determine the significant differences of bacterial counts, physicochemical values, and 
virulent gene expression levels among the control and treatments based on a significant 
level of 0.05. 
 
Results 
Phenotypical characterization of LC-CLA. In comparison with LC-WT, LC-CLA 
maintained an analogous growth/survival rate, improved the adhesion ability on human 
intestinal cells in vitro and in vivo colonization capability in mice gut (Figure 2). Due 





(Table 5). To be specific, primarily, LC-CLA showed slower growth (around 0.3-0.4 
log CFU/mL less) compare to the LC-WT during exponential phase, first 24 h of 
inoculation, but after 24 h, LC-CLA showed higher survival ability (around 0.1-0.3 log 
CFU/mL more) during stationary and death phase, up to 96 h. 
In addition, 0.8 and 1.5 log CFU/mL more LC-CLA attached to INT-407 cells 
both at 4 and 24 h of incubation, showing significant differences comparing to the 
adhesion ability of LC-WT. Furthermore, based on the duplicated mice trials, LC-CLA 
remarkably improved their colonization ability in mice cecum, jejunum, and ileum with 
7-day-administration. The colonization amount of LC-CLA was found to be 1.0, 0.7, 
and 0.5 log CFU/g higher in cecal fluids, 0.6, 0.6, and 0.5 log CFU/g higher in jejunum 
fluids, and 0.1, 0.1, and 0.3 log CFU/g higher in ileum fluids than the LC-WT, at 2nd, 
3rd, and 4th weeks respectively. Finally comparing with LC-WT, the genitival 
engineered strain, of LC-CLA induced 7.2-fold up-regulation on mcra (LI gene) mRNA 
level expression identified by qPCR; with HPLC-MS/MS analysis, we also detected 
4.5-fold increment in relative total linoleic acids per 1 mL overnight cultural 
supernatant as well as 21.1-fold boost in relative total linoleic acids per bacterial cell. 
 
Competitive exclusion of enteric bacterial pathogens. Probiotic L. casei strains and 
enteric bacterial pathogens ST and EHEC were grown in mixed-cultured condition in 
vitro to investigate their survival ability through competition between them in both 
short (4 and 8 h) and long (up to 72 h) period. The competitive inhibitory abilities of 
both LC-WT and LC-CLA against ST and EHEC were shown in Figure 3. With both 





enteric bacterial pathogens, showing 0.8 and 2.0 log CFU/mL ST and EHEC, 
respectively, more reduction at 4 h, 1.3 and 2.3 log CFU/mL ST and EHEC, 
respectively, more reduction at 8 h comparing with LC-WT. Overall, LC-CLA 
competitively exclude ST at 72 h, in comparison with 8.3 and 2.5 log CFU/mL survival 
ST for control and wild type LC; similarly, EHEC were also eliminated by LC-CLA at 
48 h, at which time point, 8.9 and 4.4 log CFU/mL EHEC were still detected in the 
cultural media. 
 
Metabolites from LC-CLA in combating against enteric bacterial pathogens. Overnight 
CFCSs from both LC-WT (CFCS1) and LC-CLA (CFCS2), in terms of initial inocula 
of 106 CFU/mL overnight probiotic culture, were collected for examination the 
antimicrobial activities of their secreted byproducts. Comparing with control, both 
CFCSs from L. casei inhibited the growth of ST and EHEC, however, CFCS2 showed 
more intensive effects (Figure 4). To be specific, CFCS2 reduced 1.3 and 2.0 log 
CFU/mL more ST as well as 1.9 and 2.3 log CFU/mL more EHEC in the early stage at 
4 and 8 h, when compared with CFCS1. The inhibitory activity of CFCS1 attenuated 
after 24 h, 3.2, 4.5, and 5.2 log CFU/mL ST and 4.2, 5.0, and 5.1 log CFU/mL EHEC 
were observed at 24, 48, and 72 h, respectively. Even, metabolites from LC-CLA 
exhibited a stable antimicrobial activity after 24 h, whereas CFCS2 were capable of 







Alterations in physicochemical properties of enteric bacterial pathogens. The entire 
metabolites from both LC-WT and LC-CLA alters multiple physicochemical properties 
of both ST and EHEC (Table 6). For example, CFCS1 decreased 7.2% and 3.2% 
bacterial surface hydrophobicity of ST and EHEC, respectively, whereas CFCS2 
exhibited more profound effectiveness in significantly lowering hydrophobicity of both 
pathogens 11.7% for ST and 10.2% for EHEC). Following the same trend, metabolites 
from LC-CLA significantly reduced 9.5% and 3.8% bacterial auto-aggregation 
activities of ST and EHEC, respectively, which displayed more effective alterations 
compared with metabolites from wild type LC-WT (6.1% for ST and 1.6% for EHEC). 
Similarly, 30.9% and 38.3% injured ST and EHEC bacterial cells were observed with 
treatment of CFCS1, whereas CFCS2 significantly increased the injured cells of ST 
(11.9%) and EHEC (12.5%). 
 
Effect on biofilm formation by ST and EHEC. The biofilm formation ability of ST and 
EHEC in absence or presence of CFCSs from LC-WT and LC-CLA has been presented 
in Figure 5. At 24, 48, and 72 h incubation under the inhibitory pressure of LC-CLA 
secreted metabolites in CFCS2, the biofilm formation of ST was significantly repressed 
by 1.4, 1.0, and 1.0 log CFU/mL respectively. Whereas CFCS1 from LC-WT exhibited 
less inhibitory effects and failed to decrease the ST biofilm formation significantly after 
72 h of incubation. The biofilm formation ability of EHEC was significantly restrained 
by 1.9 log CFU/mL at 24 h treatment with CFCS2 from LC-CLA. At 48 and 72 h, both 
CFCS1 and CFCS2 exhibited significant reduction on EHEC biofilm formation by 1.0 






Disruption on host-ST/EHEC interactions. The host cell-ST or EHEC interactions were 
evaluated based on their adhesion to and invasion into human intestinal (INT-407) cells, 
and the results were shown in Figure 6. Wild type LC-WT pre-colonization before 
adding enteric bacterial pathogens significantly reduced the cell adhesive and invasive 
abilities of ST by 1.8 and 1.3 log CFU/mL, respectively. In the same experiment, cells 
were pretreated with LC-WT reduced the adherence and invasion abilities of EHEC by 
0.7 and 1.1 log CFU/mL, respectively. With much effective performance was observed 
when INT-407 cells were allowed to pre-colonize with LC-CLA. The adhesive and 
invasive activities of ST were suppressed by 2.4 and 2.2 log CFU/mL, counting around 
99.58% and 99.34% reductions separately, by LC-CLA. Similarly, LC-CLA also 
reduced EHEC host cell adhesion and invasion capabilities by 2.0 and 2.9 log CFU/mL, 
which equaled to 99.10 and 99.88% reductions separately. 
Correspondingly, the pre-treatments of ST and EHEC with L. casei CFCSs 
displayed significant effects on their interactions/infections with INT-407 cells. 
Specifically, metabolites in CFCS1 from LC-WT, CFCS1 restricted the adherence 
activities of both ST and EHEC on INT-407 cells by 1.8 and 0.9 log CFU/mL, 
respectively. CFCS1 also significantly reduced the invasive activities of ST and EHEC 
by 1.2 and 1.0 log CFU/mL separately in comparison with control infections. Whereas, 
CFCS2 from LC-CLA by interfering with ST and EHEC much intensively, depressed 
2.4 log CFU/mL (99.66% reduction) ST and 1.8 log CFU/mL (98.53% reduction) 
EHEC adhesion, as well as 2.1 log CFU/mL (99.15%) ST and 2.5 log CFU/mL (99.70%) 






Down-regulation on expression of bacterial virulence genes. The relative expression 
levels of multiple ST/EHEC virulence genes were found to be significantly down-
regulated with CFCSs from both LC-WT and LC-CLA based on qPCR analysis, among 
which, the suppressive effects from CFCS2 were detected to be more intensive than 
CFCS1 (Figure 7). For ST, CFCS2 from LC-CLA notably down-regulated the 
expression of transcriptional regulator genes hilA, hilC, hilD, and invF by 3.2, 2.8, 3.9, 
and 5.1 folds respectively. Similarly, the expression levels of effector genes invA, invG, 
invH, and prgK were also significantly suppressed by CFCS2. Whereas insignificant 
fold-changes were detected in relative gene expression levels of invC, prgH, prgI, and 
sipA. 
For EHEC, 8 virulence genes were investigated in this study, among which only 
effector gene tir kept conservative under the pressure of both CFCSs treatment. CFCS2 
effectively down-regulated the expression levels of regulator gene ler as well as other 
effector genes including eaeA, espA, espB, and espD by 2.8, 3.6, 7.3, 6.9, and 7.1 folds 
respectively. 
 
Anti-inflammatory effects of LC-CLA in vitro. Metabolites secreted by L. casei strains 
managed to induce anti-inflammatory effects on human macrophage cells by down-
regulating pro-inflammatory cytokine genes and up-regulating anti-inflammatory 
cytokine genes (Figure 8). In details, CFCS1 from LC-WT suppressed the expression 
levels of IL-1β, CXCL-8 (IL-8), IL-12, and TNF-α genes by 3.3, 3.0, 3.0, and 4.8 folds 





genes by 4.4 and 2.5 folds separately. Whereas negligible difference was found on IL-
6 and IL-23 gene expressions. On the other side, CFCS2 containing metabolites 
released from LC-CLA impressively amplified the anti-inflammatory activities, by 
which relative expression levels of pro-inflammatory cytokine IL-1β, IL-8, IL-12, IL-
23, and TNF-α genes were all significantly down-regulated by 7.7, 5.2, 6.0, 1.6, and 
6.7 folds respectively; relative expression levels of anti-inflammatory cytokine IL-10 
and TGF-β genes were significantly up-regulated by 8.0 and 5.9 folds. 
 
Improvement of mice weight from enteric bacterial infections. The weight of each mice 
was monitored every day for the purpose of investigating if probiotics preventive 
administration could rescue mice from weight loss due to ST/EHEC infection (Figure 
9). Within the entire 4-week rearing, a total of 12 mice in control group, 7 mice in group 
with LC-WT treatment, and 1 mouse in group with LC-CLA treatment were sacrificed 
due to their health abnormality induced by ST infection. These sacrificed individuals 
included 8 mice from control and 5 mice from LC-WT treatment found self-death due 
to ST challenge, but none from LC-CLA treatment, which provided us the ST survival 
rates as 60% in control group, 75% in LC-WT group, and 100% in LC-CLA group. The 
death of the mice was generally accompanied with extreme (>20%) weight loss to 
approximately 8-10 g. 
In details, the 3-week-old mice started from an average of 10-12 g weight at 0 
d and reached approximately 14-16 g for the first week’s rearing, during which, either 
LC-WT or LC-CLA consumption contributed around 1-2 g more weight gain compared 





of mice in control group (14.64 g at the day of ST challenge) was found to suspend 
showing 14.65 g at 1st post-infection week, and it was even diminished to 14.36 g and 
13.47 g at 2nd and 3rd post-infection weeks separately. However, LC-CLA 
administration assisted mice in continuous averaged weight gain, in spite of the 
negative effect induced by ST infection, from 16.21 g at the day of challenge to 16.88, 
17.02, and 19.12 g at the 1st, 2nd, and 3rd post-infection weeks. LC-WT exhibited mild 
effects by maintaining the averaged mice body weight during the first two weeks of ST 
infection and raising around 1.5 g weight at the 3rd post-infection week. 
At the other hand, we failed to observe any negative effects including average 
weight loss induced by EHEC infection. Whereas, the oral administration of LC-CLA, 
influencing much effectively than LC-WT which declined to induce any significant 
average weight gain in comparison with control over the same period, benefited the 
mice in their weight earnings by promoting 1.1 and 1.4 g averaged weight increasing 
at the 2nd and 3rd post-infection weeks. 
 
Reduction on gut colonization of enteric bacterial pathogens. Either LC-WT or LC-
CLA was orally administrated to mice in order to examine the preventive effects of 
probiotics on enteric bacterial infection. According to the colonization data collected 
from two individual trials, both L. casei pre-treatments significantly reduced the 
follow-up ST gut-intestinal infecting/colonizing levels, whereas LC-CLA fought back 
on ST much remarkably (Figure 10). To specify, 1.0, 0.9, and 1.2 log CFU/g less ST 
presence in cecum fluids with LC-WT prevention at 14, 21, and 28 d (1st, 2nd, and 3rd 





much intensively, reduced 2.0, 2.0, and 2.5 log CFU/g ST cecum-colonization at 14, 
21, and 28 d. 
For ST colonization on jejunum and ileum, LC-WT and LC-CLA pre-
administration managed to lower 1.0 and 2.3 log CFU ST per gram jejunum fluids at 
1st week post-infection, 0.9 and 2.5 log CFU/g on 2nd week post-infection, and 1.3 and 
3.7 log CFU/g on 3rd week post-infection. Following a comparable way, LC-WT and 
LC-CLA pre-administration also abated 1.7 and 2.2 log CFU ST per gram ileum fluids 
at 1st week post-infection, 0.9 and 1.9 log CFU/g on 2nd week post-infection, and 1.2 
and 3.4 log CFU/g on 3rd week post-infection. 
The significant reduction on ST gut intestinal colonization was also presented 
by the difference of ST fecal shedding among groups. On the subsequent after ST 
challenge on ST-free mice (the 8th day), both groups with probiotic administration 
induced significant 0.8 to 1.1 log CFU ST less per gram feces, though the reductions 
attenuated to be unsubstantial at the 9th day. However, notably major effectiveness 
started to appear in LC-CLA group after 1st week post-infection, at which 1.3 log 
CFU/g less ST was recovered from mice feces. In the subsequent two weeks, 1.1 and 
2.1 log CFU/g ST reduction on fecal shedding were observed, which is much 
significantly effective/preventive compared with LC-WT led to less than 0.6 log CFU/g 
ST reduction. 
On the other hand, for EHEC gut intestinal colonization, LC-WT administration 
barely influenced the EHEC in a considerable level, whereas LC-CLA pre-treatment 
presented an influential outcome (Figure 11). In particular, LC-CLA administration was 





1.6, 1.8, and 2.7 log CFU/g EHEC jejunum-colonization, and 2.8, 1.8 and 2.1 log 
CFU/g EHEC ileum-colonization at the 1st, 2nd, and 3rd week post-infection time point. 
Meanwhile, consequential decreased EHEC fecal shedding was detected in LC-CLA 
treatment group as well, given that insignificant reductions (0.1 to 0.5 CFU EHEC less 
per gram feces) were found only during the first two days after EHEC challenge on 
EHEC-free mice (the 8th and 9th day). The LC-CLA administration substantially 
lowered 0.9, 1.9, and 2.2 CFU/g EHEC fecal shedding at the 1st, 2nd, and 3rd post-
infection weeks in comparison with control. 
 
Regulation of mice splenic inflammatory cytokine genes. The manipulation of splenic 
inflammatory cytokine gene expressions during 3-week ST infection as well as 1-week 
probiotic pre-administration was summarized in Table 7. Specifically, ST infection 
induced remarkably up-regulation on relative expression level of splenic pro-
inflammatory cytokine genes, for example, 7.4-9.6 log folds raise of INF-γ gene, 6.1-
7.9 log folds raise of IL-1β gene, 3.5-5.7 log folds raise of TNF-α gene, 1.5-2.4 log 
folds raise of IL-6 gene, etc. The relative expression level of anti-inflammatory 
cytokine IL-10 gene was notably reduced by 2.0-3.2 log folds. Whereas, LC-CLA pre-
treatment managed to mitigate the boost in inflammatory cytokine genes over-
expression. For instance, LC-CLA significantly decreased 4.9-9.1, 3.4-6.6, and 1.5-3.5 
log folds expressions of INF-γ, IL-1β, and TNF-α genes in comparison with situations 
of ST infection. Simultaneously, LC-CLA also assisted in promoting the expression of 
IL-10 and TGF-β genes by 3.9-5.1 and 2.5-3.5 log folds. On the contrary, LC-WT 





only INF-γ and IL-1β genes were found to be consistently down-regulated at each time 
point of measurement (14th, 21st, and 28th days) at a statistically significant level 
(p<0.05). As for IL-10 and TGF-β genes, LC-WT up-regulated their mRNA expression 
levels by 1.2-1.7 and 0.5-1.8 log folds compared with control, displaying a more 
moderate effect than LC-CLA. 
 
Discussion 
Probiotics, prebiotics, or a combination of the two as synbiotics have emerged as a 
promising alternative treatment for enteric bacterial infections (Hardy, Harris, Lyon, 
Beal, & Foey, 2013; Pandey, Naik, & Vakil, 2015; Mengfei Peng & Biswas, 2017; 
Mengfei Peng, Reichmann, et al., 2015; Vyas & Ranganathan, 2012). To improve and 
maintain host’s gut health, the beneficial effects of probiotic depend largely upon the 
total quantity and type of functional metabolites they could produce. In recent studies, 
we found that several prebiotic-like components in cocoa and peanut facilitated L. casei 
in producing more linoleic acids and outcompeting major foodborne bacterial 
pathogens, including ST and EHEC (Mengfei Peng, Aryal, et al., 2015a; Mengfei Peng, 
Bitsko, et al., 2015; Serajus Salaheen, White, et al., 2014). On the basis of these 
evidences, we have overexpressed the mcra encoding LI in natural L. casei and verify 
the ability of LC-CLA in combating against enteric bacterial infection both in vitro and 
in murine model. 
The myosin-cross-reactive antigens present across a wide range of taxa 
including Lactobacillus, not only take responsibility in linoleic acids construction and 





also have been revealed to contribute in bacterial stress-tolerance, blood-survival, and 
host cell adherence (Y. Y. Chen, Liang, Curtis, & Gänzle, 2016; O’Flaherty & 
Klaenhammer, 2010; Volkov et al., 2010). In this study accordantly, the mcra 
overexpressed LC-CLA was found with prominently higher production of total linoleic 
acids, fitter growth pattern though not statistically significant, and remarkably 
improved intestinal colonization both in vitro and in vivo especially in mice cecum and 
jejunum. Though assisting in development of healthy gut microflora and maintenance 
of cardiovascular health, peanut, cocoa, or other prebiotic-like functional foods are not 
impeccable for application in long term or in specific populations due to their 
restrictions on the cost, inducing allergy, and limited bio-availability (Badrie, Bekele, 
Sikora, & Sikora, 2015; Feeney et al., 2016; Hasler, 2002). Therefore, the genetically 
engineered probiotic in our research, being self-sufficient, stands out in supply of 
increased bio-active byproducts devoid of any prebiotic. 
As previously discussed by Peng, Reichmann and Biswas (2015), Lactobacillus 
by releasing antimicrobial components like organic acids, hydrogen peroxide, and 
poly-peptides, outcompete pathogenic bacteria in shorter period. Here in this study, LC-
CLA exhibited even stronger effects against ST and EHEC than by LC-WT in mix-
culture competitive exclusion, CFCS extensive growth elimination, as well as inducing 
bacterial cell injury. The outcomes are in accordance with findings on anti-pathogenic 
activities in CLA (Bhattacharya, Banu, Rahman, Causey, & Fernandes, 2006; 
Hontecillas et al., 2002; L.S. Meraz-Torres & H. Hernandez-Sanchez, 2012). However, 
we also surprisingly observed enhanced effects of LC-CLA in alteration ST/EHEC 





linoleic acids in LC-CLA might take responsibility in these alterations, since they were 
suggested to interact with cytoplasmic membrane of bacterial pathogens and further 
disrupt phospholipid or extracellular polysaccharides (Mengfei Peng & Biswas, 2017), 
both of which are crucial factors for bacterial physicochemical properties as well as 
biofilm development (Renner & Weibel, 2011; Vu, Chen, Crawford, & Ivanova, 2009). 
Specific virulence genes of ST/EHEC involved in T3SS were significantly 
down-regulated by the secreted metabolites from LC-CLA. These genes include 
invasion regulator genes and effector genes especially eaeA that functions in EHEC 
A/E and invH encoding ST invasion lipoprotein. In fact, several research groups have 
reported the dose-dependent activities of PUFAs in regulation of Salmonella and E. coli 
(Cardenal-Muñoz & Ramos-Morales, 2011; S. Nakamura et al., 2012), however, the 
conclusion remains to be ambiguous and bearing little relativeness with bacterial 
infections (Mengfei Peng & Biswas, 2017). The repressed invasive genes and the 
disrupted bacterial physicochemical properties by LC-CLA, served as identical 
indicators, both further supported in the in vitro reduction of ST/EHEC-host cell 
adhesive and invasive activities. Through competitive occupying INT-407 cell surface 
receptor-like molecules (Bernet, Brassart, Neeser, & Servin, 1994; Matsuo, Miyoshi, 
Okada, & Satoh, 2012; Mengfei Peng, Reichmann, et al., 2015), together with enhanced 
linoleic acid regulatory effects on bacterial pathogenesis (Belury, 2002b; Hontecillas et 
al., 2002; Bo Yang et al., 2017), LC-CLA stands out with double inhibitory actions 
against enteric bacterial pathogens. 
The preventive effectiveness of PUFAs against pathogenic bacterial 





model (Garner et al., 2009; Snel, Born, & van der Meer, 2010). Whereas the current 
study, by applying novel probiotic strain with targeted genetical modification, 
systematically and in-depth investigated the double effects of both Lactobacillus and 
CLA on murine gut health. According to our results, 1-week consecutive consumption 
of LC-CLA (including 5-day ingestion through drinking water and 2-day orogastrically 
feeding) efficiently prevented/mitigated the following Salmonella infection. Although 
probiotic administration through water might generate variance of bio-availability in 
mice gut, it is worth mentioning that early-staged oral probiotic gavage was performed 
at only 6th and 7th days instead of through the entire 1st week to avoid potential induced 
injury in 3-week-old mouse esophagus. The bacterial fecal shedding serves as a key 
indicator about the gut intestinal colonization (S. M. Lee et al., 2013), correspondingly 
we observed reduced ST/EHEC in both fecal content and intestinal fluids. Though 
similar studies conducted based on EHEC were not systematic and completed, 
Salmonella colonization was claimed to be restricted by functional fatty acids oral 
supplements in vivo (Snel et al., 2010; Sunkara et al., 2011; Sunkara, Jiang, & Zhang, 
2012; Willamil, Creus, Francisco Pérez, Mateu, & Martín-Orúe, 2011), in which the 
virulence gene factors of Salmonella were suggested to be manipulated (Hung et al., 
2013; Y. Sun & O’Riordan, 2013). 
On the other hand, probiotic itself was addressed to both directly through 
physical repellence and indirectly through host’s immune stimulation mediate 
colonization resistance against intestinal pathogens (Amalaradjou & Bhunia, 2012; 
Buffie & Pamer, 2013; Dicks & Botes, 2010; He, McLean, Guo, Lux, & Shi, 2014; 





mentioned above supported our in vivo findings in which either wild type or genetically 
engineered L. casei remarkably diminished ST/EHEC colonization in cecum, jejunum, 
and ileum, while LC-CLA displayed more intensive reductions considering the 
extraneous effects implemented by its over-promoted CLA production (Mengfei Peng 
& Biswas, 2017). 
Finally, extensive anti-inflammatory effects of LC-CLA were presented both ex 
vivo on human macrophage cells and in vivo on murine splenic cells. In accordance 
with previous studies on linoleic acids (Akahoshi et al., 2004; Albers et al., 2003; 
Tricon et al., 2004), we also detected the reducing levels of pro-inflammatory cytokines 
including INF-γ, TNF-α, IL-1β, and IL-12 in this study. Moreover, we identified the 
up-regulation of anti-inflammatory cytokine IL-10 and TGF-β genes as well, the two 
cytokines of which were believed to induce inhibition on Th cells activation (L Gorelik, 
Constant, & Flavell, 2002; Leonid Gorelik & Flavell, 2002; Hsieh et al., 2012). The 
activated macrophage cells bearing bacterial pathogen challenges normally produce 
and release IL-12 for activation of Th1 cells and further induces INF-γ, TNF-α, and IL-
12 production (Bassaganya-Riera et al., 2003; Dong & Flavell, 2001; Kidd, 2003; 
Romagnani, 1999), which exactly explained the significantly elevated expressions of 
INF-γ, TNF-α, and IL-12 genes with ST infections. LC-CLA in secreting auxiliary 
amounts of CLA, ameliorated the ST infection-induced gut inflammatory responses by 
suppressing Th1 cells through reducing IL-12 and pathogenic Th17 cells through 
reducing IL-1β (Acosta-Rodriguez, Napolitani, Lanzavecchia, & Sallusto, 2007; Cosmi, 
Maggi, Santarlasci, Liotta, & Annunziato, 2014; Monteleone, Pallone, & Monteleone, 





cytokine/myokine was revealed to be both pro-inflammatory and anti-inflammatory 
properties in inflammation and infection responses (Hunter & Jones, 2015; Scheller, 
Chalaris, Schmidt-Arras, & Rose-John, 2011; Yao et al., 2014). In the foremost place, 
the anti-inflammatory activities of linoleic acids have not been documented to impair 
any gut immunity against enteric bacterial pathogen infections (Mengfei Peng & 
Biswas, 2017; Turnock et al., 2001). 
Findings from this study herald a new era wherein non-traditional therapeutics 
become the first line in defense against enteric bacterial pathogens in all age groups 
without causing morbidity to the gut microflora. LC-CLA with linoleate isomerase 
gene over-expression managed to colonize efficiently on mice gut intestine and secret 
larger amounts of linoleic acids. In this way by combating against ST and EHEC, the 
preventive probiotic strain competitively excluded their growth in vitro, altered their 
physicochemical properties as well as biofilm formation, reduced their colonization 
and infection on gut intestine in vivo, and attenuated the inflammatory process induced 
by enteric bacterial pathogens. The development and implement of such novel, cost-
effective, and simple-to-use genetically engineered probiotic being independent from 
prebiotics or prebiotic-like functional food ingredients is promising in open the new 
avenue in prevention and treatment of GI infections and enteric diseases where 
antibiotics were failed to be prescribed without causing negative consequences. 
 
Conclusions 
1. LC-CLA overexpressed the mcra gene with linoleate isomerase activity and over-





2. LC-CLA attached/colonized gut intestinal cells efficiently than LC-WT. 
3. Enteric bacterial pathogens were competitively excluded much efficiently by LC-
CLA. 
4. The physicochemical properties, biofilm formation, host-pathogen interactions, and 
virulence gene expression of enteric bacterial pathogens were altered/disrupted by 
metabolites from LC-CLA especially linoleic acids. 
5. The treatment/administration of LC-CLA prevented enteric pathogenic bacterial 
colonization and infection to a significant level as well as maintained the overall health 
condition in infected mice. 
6. Metabolites particularly linoleic acids secreted from LC-CLA induced anti-
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Figure 4-2. Phenotypic characterization of LC-CLA. The growth condition over 96 h 
(A), ex vivo adherence on human intestinal cells at 4 and 24 h (B), and in vivo 
colonization on mice cecum (C), jejunum (D), and ileum (E) were examined and 
compared between wild type L. casei and LC-CLA. Error bars indicate standard 
deviation from parallel trials. Letters (‘a’ and ‘b’) indicate significantly different on 












Figure 4-3. Competitive exclusion of enteric bacterial pathogens by LC-CLA. 
Comparative growth of S. Typhimurium (A) and EHEC (B) in single-culture or mix-
culture with wild type L. casei or LC-CLA over 72 h was evaluated. Error bars indicate 















Figure 4-4. Antimicrobial activities of LC-CLA metabolites on enteric bacterial 
pathogens. Inhibitory effects of CFCSs from wild type L. casei or LC-CLA were 
detected on growth of S. Typhimurium (A) and EHEC (B) over 72 h. Error bars indicate 
standard deviation from parallel trials. Different letters (‘a’ through ‘c’) at single time 













Figure 4-5. Reduction on enteric pathogenic bacterial biofilm formation by LC-CLA. 
Comparative biofilm formation of S. Typhimurium (A) and EHEC (B) under pressure 
of CFCS from either wild type L. casei or LC-CLA over 72 h was investigated. Error 














Figure 4-6. LC-CLA in interfering with enteric bacterial pathogen-cell interactions. 
Human intestinal cell adhesive and invasive activities of S. Typhimurium (A) and 
EHEC (B) with pre-treatment of either L. casei bacterial cells or CFCSs from L. casei 
were examined. A constant MOI=100 was applied in each sub-figure. Error bars 
indicate standard deviation from parallel trials. Different letters ‘A’ to ‘C’ or ‘a’ to ‘c’ 
within each bacterial pathogen are significantly different for cell adhesion or invasion 













Figure 4-7. LC-CLA in suppression of enteric bacterial virulence genes. The relative 
expression of T3SS-related virulence genes from S. Typhimurium (A) and EHEC (B) 
under pressure of CFCSs from L. casei was investigated. The relative transcription 
levels are in the form of comparative fold change with control being 1.0. Error bars 
indicate standard deviation from parallel trials. Asterisks (*) indicate the significant 






Figure 4-8. Anti-inflammatory effects of LC-CLA on human macrophage cells. The 
relative expression of macrophage (anti-)inflammatory cytokine genes with treatment 
of CFCSs from L. casei was investigated. The relative transcription levels are in the 
form of comparative fold change with control being 1.0. Error bars indicate standard 
deviation from parallel trials. Asterisks (*) indicate the significant difference in 












Figure 4-9. Preventive effects of LC-CLA against enteric pathogenic bacterial infections on weight loss. The weight of each mice in 
control groups (A and D), wild type L. casei administrated groups (B and E), and LC-CLA administrated groups (C and F) was measured 
and compared. The wild type L. casei and LC-CLA were administrated from D1 to D7. S. Typhimurium (A, B, and C) and EHEC (D, 







Figure 4-10. LC-CLA in reduction of S. Typhimurium colonization on mice gut. The 
in vivo colonization of S. Typhimurium on mice cecum (A), jejunum (B), and ileum (C) 
and the fecal shedding of S. Typhimurium (D) with or without L. casei preventive 
administration were examined. Error bars indicate standard deviation from parallel 
trials. Letters (‘a’ through ‘c’) indicate significantly different on S. Typhimurium gut 












Figure 4-11. LC-CLA in reduction of EHEC colonization on mice gut. The in vivo 
colonization of EHEC on mice cecum (A), jejunum (B), and ileum (C) and the fecal 
shedding of EHEC (D) with or without L. casei preventive administration were 
examined. Error bars indicate standard deviation from parallel trials. Letters (‘a’ 
through ‘c’) indicate significantly different on EHEC gut colonization or fecal shedding 










































































































































































PBS LC (wt) LC-CLA PBS ST EHEC
A1 10 + - - + - -
B1 10 - + - + - -
C1 10 - - + + - -
A2 10 + - - - + -
B2 10 - + - - + -
C2 10 - - + - + -
A3 10 + - - - - +
B3 10 - + - - - +
C3 10 - - + - - +
Group (#) Mice (n)
Probiotic Treatment
(daily during 1st week)
Pathogen challenge
(beginning of 2nd week)





























TGF-β Anti-inflammatory cytokine gene
Table 4-4. Primers for RT-qPCR analysis of mice splenic cytokine genes
GADPH House keeping gene
IL-1β Inflammatory cytokine gene
IL-6 Pro-/Anti-inflammatory cytokine gene
IL-10 Anti-inflammatory cytokine gene
IL-17 Pro-inflammatory cytokine gene
CXCL-8 Inflmmatory chemokine gene
TNFα Inflammatory cytokine gene
IFNγ Pro-inflammatory cytokine gene

























Wild type 1.00 1.00 1.00
LC-CLA mcra over-expressed 7.15 4.48 21.06
Table 4-5. Expression level of mcra  and production of linoleic acids






















































 Means with different letters (a-c) in individual column are significantly different at p<0.05
Injured bacterial cells (%)
Table 4-6. Physicochemical properties of ST and EHEC with CFCS treatments
Treatment



















1. Cocoa and peanut contains steroids, indoles, indazoles, and glycerophospholipid 
ingredients in support of probiotics, and they contain antimicrobial components like 
flavonoids, benzoic acids, and citrusin as well. 
2. Cocoa and peanut flour stimulated the growth of multiple Lactobacillus strains. 
However, they induced only short time period-reduction on enteric bacterial pathogens. 
3. Combining of cocoa/peanut and L. casei competitively excluded EHEC and S. 
Typhimurium in mixed-culture condition. 
4. Metabolites from L. casei supplemented with cocoa/peanut altered the enteric 
pathogenic bacterial cell surface hydrophobicity, disrupted their host-pathogen 
interactions, and down-regulated their virulence gene expressions. 
5. Antimicrobial properties of L. casei was attributed from multiple metabolites 
including hydrogen peroxide, organic acids, polypeptides, etc. 
6. Cocoa/Peanut stimulated the production of linoleic acids by Lactobacillus. 
7. LC-CLA overexpressed the mcra gene with linoleate isomerase activity, over-
produced linoleic acids, and attached/colonized gut intestinal cells efficiently than LC-
WT. 
8. Metabolites from LC-CLA, especially linoleic acids, efficiently eliminated enteric 
bacterial pathogens, altered their physicochemical properties, reduced their biofilm 






9. The preventive administration of LC-CLA reduced enteric pathogenic bacterial 
colonization and infection by a significant level as well as maintained the overall health 
condition on infected mice. 
10. Metabolites particularly linoleic acids secreted from LC-CLA induced anti-
























1. Histopathological analysis on mice kidney and cecum with enteric pathogenic 
bacterial infections and LC-CLA prevention. 
2. Fatty acids composition analysis on mice liver and blood. 
3. Gut microbiome profile in mice model with LC-CLA administration. 
4. Preventive/Therapeutic studies of LC-CLA based on clinical trials. 
5. Extensive cost-benefit survey on practical applicability of LC-CLA in food market 





















Probiotics Live non-pathogenic microorganisms that are administered in 
order to improve gut intestinal microbial balance as well as 
protect the host from infective agents. 
 
Prebiotics Selectively functional ingredients that allow specific changes 
both in the composition and/or activity in the gut intestinal 
microflora that confer benefits upon host well-being and health. 
 
Synbiotics Mixtures of probiotics and prebiotics that beneficially affect the 
host by improving the survival and implantation of live microbial 
dietary supplements in the gut intestinal tract, by selectively 
stimulating the growth and/or by activating the metabolism of 
one or a limited number of health-promoting bacteria, thus 
improving host welfare. 
 
Functional food Foods with existing or supplemental ingredients which provides 
additional functions on disease prevention and health promotion, 
e.g., prebiotic-like food components or specially formulated food 
nutrients. 
 
Microbiota The collective microbial including bacteria, virus, and archaea 
community which inhabits specific environments, e.g., mice 
cecal microbiota or human skin microbiota. 
 
Microbiome The collective microbial genomic contents which provide 
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